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Abstract  
Streptococcus pneumoniae or pneumococcus is included among major human 
pathogens and is responsible for a number of diseases including life-threatening 
conditions such as pneumonia, meningitis and sepsis.  Though pneumococcal 
vaccines are available, they provide limited coverage against infections as 
pneumococcus shows extensive variation, which also allows escape from 
vaccines and antibiotic resistance. It is armed with several virulence factors 
including capsule, surface proteins, enzymes and toxins, which are variably 
expressed and altogether determine pneumococcal virulence.   
 
The aim of this project was to study pneumococcal genetic variation and its 
effect on virulence, with a focus on pneumococcal capsule, which is considered 
the major determinant of virulence and is involved in interaction with host 
immune system.  It is the target for current vaccines and at least 93 
pneumococcal serotypes are known, which differ in pathogenicity. 
 
To study the effect of capsule on the pneumococcal virulence, capsule-switch 
mutants were constructed in three genetic backgrounds; TIGR4 (serotype 4, 
virulent), 403 (serotype 4, avirulent) and D39 (serotype 2, virulent) and were 
studied for variation in their in vivo and in vitro characteristics.  These mutants 
were compared with their parent strains and other mutants for effects of 
capsule switching on their growth, formation of capsular polysaccharide, 
capsular thickness, chain formation and virulence in murine models of infection 
using MF1 mice.  Significant differences were observed in behaviour of parent 
and mutant strains. 
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To develop a broader insight into pneumococcal virulence, avirulent derivative 
of strain TIGR4, 403 was genome sequenced and compared with TIGR4 for 
genetic mutations.  To study differences in gene expression both the strains 
were also compared using microarrays.  Genome analysis revealed only few 
mutations in strain 403 but microarray experiments showed 288 genes to be 
expressed differently in strain 403. 
 
Strain 403 was also tested as live attenuated vaccine to see if it could provide 
protection against the same and different serotypes, as it can be used as a 
vehicle for delivery of different polysaccharides to the host body along with the 
whole set of pneumococcal antigenome. Vaccine trials of 403 were not very 
fruitful as it failed to provide any protection through intranasal route though 
partial protection was observed in mice vaccinated intraperitoneally with 
significant differences in levels of bacteraemia, survival, weight and 
temperature losses on challenging with homologous strain.    
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1  Introduction: 
Streptococcus pneumoniae, commonly known as pneumococcus, is a facultative 
anaerobe that is gram-positive and grows in pairs and short chains. It is 
considered among major human pathogens and is responsible for several diseases 
including life-threatening conditions such as meningitis, pneumonia and sepsis 
(O'Brien et al., 2009).  Pneumococcal diseases cause considerable financial loss 
to the society and mainly affect children, the elderly and immunocompromised 
patients.  It is a highly transformable bacterium, which shows extensive 
variation and plasticity of its genome (Golubchik et al., 2012; Croucher et al., 
2011). 
  
Though pneumococcal research has completed more than hundred years and it 
has played a major role in the development of our insight into nature of genetic 
material, genetic transformation, infectious diseases and development of 
antibiotic resistance, pneumococcal diseases still cause significant morbidity and 
mortality around the world (O'Brien et al., 2009; Black et al., 2003; Austrian, 
1981).  The high transformability of pneumococcus has resulted in evolution of 
antibiotic-resistant strains that can mutate and avoid effects of vaccines 
(Brueggemann et al., 2007; Cartwright, 2002).    
 
1.1 Classification of pneumococcus: 
S. pneumoniae is closely related to Streptococcus mitis and Streptococcus oralis 
which reside in nasopharyngeal niches, though it can be differentiated from 
them on the basis of sensitivity to optochin, solubility in bile and specific anti-
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pneumococcal antibodies (Kilian et al., 2008; Whatmore et al., 2000). It has 
been classified into at least 93 serotypes on the basis of capsular structure and 
Quellung reactions, which can be visualized as capsular swelling and bacterial 
agglutination  when specific antibodies are used against homologous capsular 
components (Calix & Nahm, 2010; Park et al., 2007; Pai et al., 2006; 
Henrichsen, 1999). These serotypes vary in their distribution and virulence (Calix 
& Nahm, 2010; Park et al., 2007).  Since serotyping with anti-sera is expensive 
and cross-reactivity occurs, cheaper and more specific methods based on 
molecular techniques have been developed to type pneumococci with accuracy 
(Siira et al., 2012; Pai et al., 2006; Lawrence et al., 2003).  Though it has been 
an extremely useful tool for pneumococcal characterization, it has its limitations 
and provides only a broader classification scheme, which has encouraged the 
development of better molecular characterization techniques for the study of 
pneumococcal molecular epidemiology and ecology.  One of them is multi-locus 
sequence typing (MLST), which was described by Enright and Spratt (Enright & 
Spratt, 1998).  It allows genetic identification of isolates by the matching of 
internal sequence of seven housekeeping gene loci, which are: 
i. Glucose kinase (gki) 
ii. Shikimate dehydrogenase (aroE) 
iii. Glucose-6-phosphate dehydrogenase (gdh),  
iv. Signal peptidase I (spi) 
v. Transketolase (recP) 
vi. D-alanine-D-alanine ligase (ddl)  
vii. Xanthine phosphoribosyltransferase (xpt).   
Each allele is assigned a unique number after matching with sequences in online 
MLST database.  This unique number is then compared to those for other isolates 
in the database and each isolate is assigned a specific sequence type (ST).  As a 
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result isolates with all seven identical alleles of these 7 housekeeping gene loci 
share the same ST.  It is a powerful technique for online molecular 
characterization of bacterial isolates and provides an electronic portable method 
of comparison of evolutionary relationship of different species (Enright & Spratt, 
1999).  It has added a substantial amount of information about pneumococcal 
taxonomy and population dynamics.  Utilizing information obtained from MLST, 
it was reported that not only a variety of STs are present in each serotype, but 
also some STs are found in more than one serotype, indicating that pneumococci 
can switch their capsule type by acquiring  capsules of different serotypes from 
other strains (Pai et al., 2006; Mcgee et al., 2001; Coffey et al., 1998a; Coffey 
et al., 1996; Coffey et al., 1991; Munoz et al., 1991).  It was also reported that 
certain serotypes and STs were more related to invasive disease as compared to 
others (Hanage et al., 2005).  
     
This diversity in the pneumococcal genome, shown by molecular 
characterization has been explained by Distributed Genome Hypothesis (DGH), 
which proposes that pneumococci share a supragenome that enables them to 
shuffle their genetic contents in response to environmental stimuli (Hiller et al., 
2007).  Pneumococcus acquires new genetic material by different methods 
including horizontal gene transfer, the environment or from bacteriophages 
(Thomas et al., 2005).  This transfer not only takes place within the species but 
can also involve different bacteria residing in the same niche (Hakenbeck et al., 
1999).  Besides having a core genome, they possess additional genes, which may 
be strain specific.  These genes code for virulence factors that can be expressed 
in variable manner according to conditions of host environment (Hiller et al., 
2007). 
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As a result of this extensive variation in pneumococcal genome, despite all 
classification schemes, exact characterization of S. pneumoniae strains is only 
possible through whole genome sequencing, as strains that share the same 
serotype and ST not only vary in spectrum of symptoms they produce, but also 
differ in host selection (Forbes et al., 2008; Sjostrom et al., 2006).  As a part of 
this project we sequenced the complete genome of an avirulent type 4 strain 
and compared it with previously published TIGR4 genome to study genes 
involved in pathogenicity of serotype 4 pneumococci. 
 
1.2 Carriage dynamics of pneumococcus:   
S. pneumoniae is among predominant colonizers of human nasopharynx. 
Pneumococcal carriage rates have been reported to be different among various 
studies and populations (Bogaert et al., 2004) and carriage prevalence is quite 
high in developing countries as compared to developed ones, which results in 
higher exposure to different strains (Scott, 2007).  Colonization may begin very 
early in life and up to 95% of healthy individuals can be colonized in the first 
three years, who can carry up to four different serotypes simultaneously (Obaro 
& Adegbola, 2002).  This nasopharyngeal colonization may begin as soon as the 
very first day after birth, though duration of carriage may vary and can decline 
with increasing age (Gray et al., 1979).  It may be related to a number of risk 
factors such as use of antibiotics, smoking, asthma, ethnicity, over-crowding and 
proximity of adults with children (Bogaert et al., 2004).  
 
S. pneumoniae is accompanied by Neisseria, Haemophilus, Staphylococcus and 
other Streptococcus species in the nasopharynx (Bogaert et al., 2004), which 
creates a highly competitive environment for bacterial growth.  Pneumococcus 
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has developed certain features, which provides a competitive advantage over 
other colonizers of nasopharynx such as neuraminidase and hydrogen peroxide 
production, which inhibits their growth (Bogaert et al., 2004; Shakhnovich et al., 
2002; Pericone et al., 2002; Pericone et al., 2000). Though pneumococcal 
colonization is an important event in disease development, it also protects 
against occupation of nasopharyngeal spaces by other pathogens, reducing their 
chance of causing invasive diseases (Bogaert et al., 2004).   
 
1.3 Pneumococcal diseases and their burden: 
S. pneumoniae causes a number of diseases ranging from life-threatening 
pneumonia, meningitis and septicemia to painful otitis media and sinusitis 
(Cartwright, 2002).  These diseases not only cause great economic burden on the 
society but also cause considerable mortality around the world, especially in 
developing countries (Black et al., 2003).  According to World Health 
Organization (WHO) estimates of 2005, pneumococcal diseases kill 1.6 million 
humans annually, while the worst affected are children as their yearly mortality 
count due to pneumococcal diseases is about 0.7–1 million (WHO, 2008) and 
these diseases have an estimated death toll of approximately 11% (8–12%) of all 
deaths in non-HIV positive children less than 6 years of age (O'Brien et al., 
2009).  Another commonly affected group is the elderly, whose susceptibility to 
contract pneumococcal diseases increases due to decreasing immunity and 
antibody counts with increasing age (Simell et al., 2008). Chances of getting 
disease also increase in presence of co-morbidities, such as cardiac or renal 
disease, especially in hospitalized patients, where there is a very high rate of 
mortality among patients acquiring pneumococcal infections nosocomially.  
Influenza has also been shown to increase pneumococcal disease (Bogaert et al., 
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2004; McCullers & Rehg, 2002) resulting in higher mortality during epidemics and 
pandemics (Brundage & Shanks, 2008).  
 
1.3.1 Pneumonia and bacteraemia: 
S.  pneumoniae is the most common cause of infectious pneumonia acquired in 
the community and is responsible for up to 35% of cases in adults (Moine et al., 
1995).  It claims approximately 20% of all childhood deaths, chiefly in developing 
countries (Black et al., 2003).  It is characterized by inflammation of lung 
parenchyma accompanied by consolidation and exudation of alveolar spaces, 
which obstructs optimum gaseous exchange between lungs and bloodstream (van 
der Poll & Opal, 2009).   
 
A number of factors predispose an individual to pneumococcal pneumonia such 
as extremes of age, pulmonary, cardiac, hepatic or neurological disease, 
smoking, cancer, HIV, diabetes, alcohol abuse, recent hospitalization and 
previous pneumonia (Cardozo et al., 2008).  Pneumonia may lead to bacteraemia 
resulting in sepsis and death (Laterre et al., 2005), though bacteraemia 
occurring independently is not uncommon  (Myers & Gervaix, 2007; Kaplan et 
al., 1998).   
 
 
1.3.2 Meningitis: 
Inflammation of protective membranes of brain and spinal cord along with 
infection of cerebrospinal fluid (CSF) as a result of pneumococcal infection is 
called pneumococcal meningitis (Mook-Kanamori et al., 2011).  It is a serious and 
life threatening condition, characterized by a range of symptoms including 
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headaches, stiffening of the neck, seizures and coma, which may lead to death.  
Mortality ranges from 16-37%, with residual neurological sequel in 32-50% 
(Kastenbauer & Pfister, 2003; Durand et al., 1993).  Meningitis is generally 
preceded by initial pneumococcal infection elsewhere, in about 30% of cases by 
acute otitis media and in about 18% by pneumonia (Ostergaard et al., 2005), 
though pneumococci also have the ability to invade and infect central nervous 
system directly through olfactory neurons (Van Ginkel et al., 2003).   
 
1.3.3 Acute otitis media (AOM) 
Acute otitis media is (AOM) the commonest but relatively benign pneumococcal 
infection of middle ear cavity (Mahadevan et al., 2012; Monasta et al., 2012; 
Hausdorff et al., 2002). It is a cause of great economic burden on the society 
and in the US alone, costs about $5 billion per annum (Bondy et al., 2000).  
 
1.3.4 Other pneumococcal infections: 
Pneumococci are also responsible for some other infections which are relatively 
less common.  These infections include a number of relatively benign clinical 
problems, which are discussed in the following paragraphs. 
 
Infection and inflammation of conjunctiva, the transparent membranous 
covering of eye, is called conjunctivitis.  Conjunctivitis is generally caused by 
non-typable pneumococci (Williamson et al., 2008; Porat et al., 2006), which 
mainly occurs as outbreaks (Martin et al., 2003) though sporadic cases have been 
reported (Porat et al., 2006).  
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Pneumococci can also cause inflammation of internal layer of heart, called 
endocarditis, which may involve heart valves and inter-ventricular septum.  It 
may occur between 0.8-3.4% of patients having pneumococcal bacteraemia 
(Lindberg & Fangel, 1999).  Though it is not very common the outcome may be 
fatal  in up to 40-50% cases despite appropriate antibiotic therapy (Bruyn et al., 
1990). 
 
Pneumococcal infections can also lead to collection of pus in brain (cerebral 
abscesses) or lungs (empyema), which are quite uncommon but generally result 
in high morbidity and mortality (Carpenter et al., 2007; Eastham et al., 2004; 
Gransden et al., 1985).   
 
The problem of pneumococcal diseases is complicated because of the emergence 
of antibiotic resistant strains and their intercontinental spread (Jacobs, 2008; 
Van Bambeke et al., 2007; Jacobs, 2004) which might limit our choice of 
antibiotics in future.  
 
1.4 Pneumococcal virulence factors: 
Streptococcus pneumoniae is equipped with a large armamentarium of virulence 
factors, which are important for successful host colonization and subsequent 
invasive disease.  These will be discussed in following sections. 
 
1.4.1 Capsule: 
The capsule is a polysaccharide covering of the pneumococcal cell and is of 
prime importance as it is considered a major determinant of virulence.  It not 
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only helps to evade opsonins, inhibits complement activity and protects the 
pneumococcus from phagocytosis but also helps them avoid mucosal clearance 
by electrostatic repulsion (Melin et al., 2010; Henriques-Normark & Normark, 
2010; Nelson et al., 2007).  It is a complex structure and contains multiple 
sugars, in form of a sugar backbone containing side chains.  The backbone 
depends upon type, number and ring-size of monosaccharides, type and 
orientation of linkages, which are repeated numerous times to form structure of 
capsular polysaccharide (CPS).  Most commonly occurring monosaccharides 
include α or β-D-glucose, D-galactose, L-rhamnose and N-acetyl-α or β-D-
glucosamine (Bentley et al., 2006). 
  
The capsular locus is an extremely variable region and sequencing performed on 
90 serotypes by Bentley and co-workers has revealed its genetic diversity and 
shown that the capsular genes are almost always found between genes dexB and 
aliA and vary in size between 10 and 30 kb. Analysis of cps loci also shows 
presence of several different forms of each of important enzyme classes related 
to capsule synthesis.  Annotated proteins were also assembled into homology 
groups and various groups were observed including polysaccharide polymerases, 
flippases and a large number of transferases, responsible for variable expression 
of different components of capsule.  A large number of mobile elements was 
also noted (Bentley et al., 2006).  Analysis has also shown that the 5′ end 
contains some conserved genes (cpsA, cpsB, cpsC, cpsD and cpsE), related to 
processing, regulation and export of constituent sugars of capsular 
polysaccharide and and these sugars may have a role in attachment of 
polysaccharide to bacterial cell wall (Eberhardt et al., 2012). 
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Pneumococcus is capable of switching capsular type by horizontal gene transfer, 
which also allows it to escape from vaccines that are directed at particular 
capsular types (Coffey et al., 1998a). This has resulted in evolution of 
pneumococcal isolates of particular STs with several different serotypes (Coffey 
et al., 1999; Coffey et al., 1998b; Munoz et al., 1991),  though capsule switching 
can also result in decreased virulence (Kelly et al., 1994).   Different serotypes 
differ in their capacity to cause disease, and although we know that there are at 
least 93 serotypes, only 20% of these cause the majority of pneumococcal 
diseases (Hausdorff et al., 2000a; Hausdorff et al., 2000b).  
 
The highly conserved arrangement of cps genes amongst all strains helps 
naturally transformable pneumococcus to switch serotype through recombination 
(Brueggemann et al., 2007).  This genetic process can be imitated and otherwise 
isogenic capsule switch mutants can be constructed in the laboratory using 
various techniques (Sung et al., 2001; Kelly et al., 1994).  These mutants can be 
used as an experimental tool to study effect of capsule switching on virulence 
and other biological properties.    
 
In this project, capsule switch mutants were constructed in serotype 4 and 
serotype 2 genetic backgrounds.  These mutants were isogenic except capsular 
type and were used for studying variation in pneumococcal biology in relation to 
polysaccharide capsule. 
 
Pneumococci are also capable of altering their capsule expression in response to 
the environment, which results in phase variation.  Decreased expression results 
in a transparent phenotype, which is mainly adapted for colonization and is more 
transformable (Weiser & Kapoor, 1999).  Opaque colonies have higher level of 
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capsular expression and are more suitable for survival in blood and are more 
resistant to phagocytosis (Bruckner et al., 2004; Obaro & Adegbola, 2002; Weiser 
et al., 1994).  The transition between these phenotypes is considered an 
important factor that is related to change from carriage to invasive phenotype 
(Hammerschmidt et al., 2005). It has been reported that pneumococcal strains 
isolated from blood of infected animals had significantly increased levels of 
capsular mRNA as compared to those growing in vitro (Ogunniyi et al., 2002).  It 
was also observed that metabolically cheaper capsule types tend to be thicker 
and thus more likely to offer resistance against host immune response, which 
might lead to persistence in nasopharynx and subsequent infection (Weinberger 
et al., 2009).   
 
The pneumococcal capsule is very important from an immunological point of 
view as it enables the body to identify invading organisms and mount an 
appropriate immune response.  It is the main target for present polysaccharide 
and conjugate polysaccharide vaccines, which have been developed against 
several serotypes.   
 
We have also constructed capsule switch mutants of avirulent serotype 4 strain 
403 to study and compare effects of capsular switching on bacterial growth. 
 
1.4.2 Pneumococcal surface protein C (PspC) 
PspC is a highly variable choline binding surface protein, also called CbpA, PbcA, 
SpsA and Hic (Iannelli et al., 2002).  PspC proteins have  several functions, which 
include binding complement factors C3, factor H and  secretory portion of IgA 
(Dave et al., 2001; Janulczyk et al., 2000).  It also affects bacterial adherence 
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to pulmonary epithelium, colonization of nasopharyngeal tissue and invasion 
(Rosenow et al., 1997).  
 
The contribution of PspC in pneumococcal virulence can vary among different 
strains (Kerr et al., 2006).  It was reported that there is some variation in role of 
PspC among different strains as a PspC knock out in type 2, 3,19F and 4 had 
different effects on virulence in different serotypes (Kerr et al., 2006).  It was 
an interesting finding that no significant difference was observed in the survival 
rate of mice infected with type 2, 3 and 19F wild type and PspC-deficient 
mutants respectively, while survival time significantly increased in case of type 
4 mutants (Kerr et al., 2006).   It has been considered as a candidate for 
inclusion in protein-based vaccines.   
 
1.4.3 Pneumolysin: 
Pneumolysin is an important pore-forming toxin. It has a major role in 
pneumococcal pathogenesis (Mitchell & Andrew, 1997; Andrew et al., 1997) as it 
causes host cell lysis in many tissues (Hirst et al., 2003; Zysk et al., 2001; Zysk 
et al., 2000; Mohammed et al., 1999; Feldman et al., 1990).  It also targets the 
immune system in various ways and induces neutrophil necrosis (Zysk et al., 
2000), inhibits dendritic cell maturation and induces their apoptosis (Littmann et 
al., 2009).  It inhibits degranulation of monocytes and stimulates release of IL-1β 
and TNF-α to prevent pneumococcal clearance (Houldsworth et al., 1994; 
Nandoskar et al., 1986)  and inhibits lymphocyte response to infection. It can 
also activate complement through classical pathway without involvement of 
specific antibodies  (Mitchell et al., 1991; Paton et al., 1984).  It is well 
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conserved (Kadioglu et al., 2008) and is considered as a vaccine candidate for 
protein-based vaccines of the next generation. 
 
1.4.4 Pneumococcal surface protein A (PspA) 
PspA is another choline binding protein associated with virulence of 
pneumococcus and another candidate for protein based vaccines (Arulanandam 
et al., 2001).  PspA is also highly variable and is coded by mosaic genes, which 
have undergone extensive recombination (Heeg et al., 2007; Mollerach et al., 
2004).  It is considered to inhibit uptake of bacteria by phagocytosis (McDaniel et 
al., 1987) and prevents deposition of complement and its activation (Ren et al., 
2003).  It also interacts with lactoferrin and protects bacteria from 
apolactoferrin mediated killing (Shaper et al., 2004; Hammerschmidt et al., 
1999). 
 
These virulence factors with other important determinants of virulence are 
summarized in Table 1.1. 
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Table 1.1.Summary of pneumococcal virulence factors.  
  
Virulence Factor Description 
 
Capsular polysaccharide At least 93 serotypes (Calix & Nahm, 2010; Park et al., 2007)  and many non-typable strains (Park et al., 2012). 
 Resists complement, protects pneumococcus from phagocytosis (Melin et al., 2010; Hyams et al., 2010a; Hyams et al., 2010b). 
 Resists killing of phagocytosed bacteria (Peppoloni et al., 2010). 
 Influence growth in vitro  (Hathaway et al., 2012). 
 Helps to avoid mucosal clearance by electrostatic repulsion and helps in colonization (Nelson et al., 2007). 
 Important for development of immunity (Cohen et al., 2012). 
  
Cell wall and its components Made up of peptidoglycans and teicholic acids (Bui et al., 2012) though chemical structure may vary among strains (Draing et al., 2006). 
 Provides anchorage to the capsule (Eberhardt et al., 2012) . 
  
PspC (CbpA) Highly variable (Iannelli et al., 2002). 
 Binds factor H (Dave et al., 2001), which is a regulator of complement and has a role in adherence (Agarwal et al., 2010). 
 Effect varies with strain (Kerr et al., 2006) 
 Down-regulates classical pathway (Dieudonne-Vatran et al., 2009).  
  
Choline binding proteins B,C,D,E,F,G CbpD, CbpG, CbpE have role in colonization (Gosink et al., 2000). 
 Role in biofilm formation (Moscoso et al., 2006).  
 Role in adhesion (Rosenow et al., 1997). 
 CbpF Inhibits LytC and regulates pneumococcal autolysis (Molina et al., 2009).  
 CbpD is responsible for fratricide (Eldholm et al., 2009). 
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Pneumolysin Interacts with complement  (Yuste et al., 2005; Mitchell et al., 1991; Paton et al., 1984) . 
 Cause  cell damage and destroys ciliary activity  (Zysk et al., 2000; Mohammed et al., 1999; Mitchell & Andrew, 1997; Feldman et al., 1990). 
  
Autolysins 
 
Role in biofilm formation (Moscoso et al., 2006). 
 Cell wall degradation and remodeling, chain splitting(Las Rivas et al., 2002).  
region of cells (De Las Rivas et al., 2002) 
LytA and LytC are responsible for fratricide (Eldholm et al., 2009).  
 LytB and LytC , have role in colonization (Gosink et al., 2000). 
 Lyt A is responsible for autolysis (Weiser et al., 1996). 
  
Hyaluronidase Increases epithelial damage caused by pneumolysin (Feldman et al., 2007).   
  
Neuraminidases Exoglycosidase that desialates host protective proteins (Dalia et al., 2010; Burnaugh et al., 2008; King et al., 2006). 
 Presence may vary among the strains (Pettigrew et al., 2006). 
 Also protects against colonization with other bacteria (Shakhnovich et al., 2002). 
 Facilitates biofilm formation (Soong et al., 2006). 
 Assists in invasion of neuroendothelium (Uchiyama et al., 2009).  
  
Hydrogen peroxide Causes epithelial damage and ciliary slowing (Feldman et al., 2002). 
 Inhibits other nasopharyngeal colonizers (Pericone et al., 2000). 
  
Pneumococcal surface protein A Highly variable (Heeg et al., 2007; Hollingshead et al., 2000). 
 Inhibition of complement activation (Tu et al., 1999) and deposition (Yuste et al., 2005). 
 Binds human apolactotoferring and lactoferrin and protects against phagocytosis (Shaper et al., 2004; Hakansson et al., 2001). 
  
Pneumococcal surface adhesin A 
Clp P 
Highly variable (Berry & Paton, 1996).  
 Protects against oxidative stress (Johnston et al., 2004). 
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Pneumococcal histidine triad proteins  
PhtA 
PhtB 
PhtE 
PhtA, PhtB and PhtD are required for lung infection (Hava & Camilli, 2002). 
Virulence 
 Inhibit complement (Ogunniyi et al., 2009). 
  
Pili Host cell adhesion (Barocchi et al., 2006). 
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1.5 Immunity against pneumococcus: 
Host defenses against pneumococcus utilize both arms of immune system and 
cell mediated and humoral mechanisms work in co-ordination for  development 
of immune response against the organism (Paterson & Orihuela, 2010; Malley, 
2010).  The roles of cell mediated and humoral mechanisms are briefly discussed 
below:  
 
1.5.1 Cellular Immunity: 
Neutrophils are phagocytic cells, which are the first responders to bacterial 
invasion.  As soon as pneumococcus is phagocytosed by neutrophils, lysosomes 
fuse with phagosome and convert it into phagolysosome, which mediates 
bacterial killing by oxidative and non-oxidative mechanisms (Standish & Weiser, 
2009; Klebanoff, 2005).  Neutrophils also kill bacteria extracellularly by 
releasing DNA, histones, and other proteins forming neutrophilic extracellular 
traps (NETs), which can bind bacteria and are bactericidal (Mori et al., 2012; 
Wartha et al., 2007; Urban et al., 2006).  They play a significant role in 
controlling pneumococcal infections as their impaired recruitment have been 
reported to result in severe pneumococcal pneumonia in mice (Nakasone et al., 
2007; Sun et al., 2007)  
 
Another group of phagocytic cells, which provide immunity against pneumococci 
are alveolar macrophages that engulf opsonized bacteria (Jonsson et al., 1985), 
release proinflammatory  cytokines and express various receptors that play a 
vital role in development of immunity (Koppe et al., 2012; Paterson & Orihuela, 
2010; Koppel et al., 2008).  Importance of their role can be understood by the 
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reports that the incidence of pneumonia was found to be higher in patients with 
impaired macrophage activity because of smoking cigarettes (Phipps et al., 
2010).  It was also shown that macrophage dysfunction leads to higher mortality 
in animal models (Arredouani et al., 2006; Arredouani et al., 2004), while their 
depletion reduces survival (Traeger et al., 2009).    
 
Adaptive immune response is mediated by T lymphocytes, which interact with 
dendritic cells and produce cellular immunity against pneumococci (Palucka & 
Banchereau, 2002).  These T lymphocytes are of three main types, helper T cells 
(TH), cytotoxic T cells (Tc) and regulatory T (TR) cells. Helper T cells are divided 
into three subtypes known as TH1, TH2 and TH17, which develop from naïve TH 
cells into one of these subtypes depending upon cytokine environment.  TH1 are 
produced mainly in response to viruses and intracellular bacteria that stimulate 
macrophages or natural killer (NK) cells and promote cellular immunity, which 
has been shown to provide protection in humans. TH2 mediated response is 
directed against toxins, allergens and parasites.  It acts by induction of 
cytokines, which promote production of antibodies by B cells and release of 
inflammatory mediators by mast cells.  These cells produce IFNγ, which 
contributes towards the development of immunity against pneumococci and 
other bacteria.  TH17 response develops under the influence of a number of 
extracellular and intracellular bacteria and fungi.  It mainly controls the balance 
between humoral and cell mediated immune responses and forms a bridge 
between these two by monocyte, macrophage and neutrophil recruitment.  They 
also have a role in production of anti-bacterial peptides by epithelial cells 
(Malley, 2010; Peck & Mellins, 2010; Zhang et al., 2009).   
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1.5.2 Humoral immunity and B lymphocytes  
B lymphocytes are nonphagocytic cells which are responsible for development of 
humoral responses against pneumococcal antigens (Moens et al., 2008).  These 
responses are very important for protection against pneumococcal diseases, as 
has been shown by successful utilization of capsular polysaccharide based 
vaccines and demonstration of protective antibodies against capsule and other 
antigens (Lipsitch et al., 2005).  Some of these responses are antigen dependent 
as capsular polysaccharide stimulates differentiated B cells independent of T 
cells, which results in failure of induction in young children (Casal & Tarrago, 
2003). In contrast, immune response against proteins is T cell dependent and 
stimulated B cells can develop into plasma cells and generate memory cells, 
resulting in antibody production, which has been reported in case of a wide 
range of pneumococcal  proteins (Giefing et al., 2008; Ogunniyi et al., 2007; 
Jomaa et al., 2006; Brown et al., 2001; Briles et al., 2000).  These antibodies 
have a significant contribution in development of immune response against 
pneumococci as they perform opsonization (Plotkin, 2008) and complement 
activation (Baxendale et al., 2008; Brown et al., 2002).  Patients with disorders 
related to antibody production have been reported to have increased 
susceptibility to pneumococcal infections (Phipps et al., 2010; Yuste et al., 
2008).    
 
1.5.3 Role of complement: 
The complement system is an antimicrobial system that consists of numerous 
serum and membrane proteins, which participate in host defence by acting as 
opsonins, bactericidal and chemoattractive agents.  These proteins remain 
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present in blood in inactive form and can be activated by a number of factors. 
There are three pathways that activate complement called classical, alternative 
and mannose-binding lectin pathways (Walport, 2001a; Walport, 2001b).  Several 
pneumococcal proteins such as PspA, pneumolysin and phtD interact with 
complement and interfere with its function. Regardless of the activated 
pathway, the end result of complement activation is deposition of C3 convertase 
on pathogen surface, leading to breakdown of C3 into C3a and b, which finally 
leads to cleavage of C5 that draws neutrophils and macrophages (Hawlisch & 
Kohl, 2006).  Further assembly of component proteins and their insertion on the 
pathogen membrane results in its perforation, resulting in an influx of water and 
solutes into the cell causing bacterial cell lysis (Walport, 2001a).  Phagocytosis 
of S. pneumoniae has also been reported to be complement dependent (Yuste et 
al., 2008), which is mainly activated by classical pathway in case of 
pneumococcal infection (Brown et al., 2002).  The importance of the 
complement system and classical pathway has been described in a number of 
studies and it was observed that patients with dysfunctional complement have 
an increased tendency to develop pneumococcal disease (Yuste et al., 2008; 
Brown et al., 2002; Roy et al., 2002)., while the classical pathway was reported 
to be the most important in murine models of pneumococcal infections (Brown 
et al., 2002).   
 
1.6 Pneumococcal vaccines: 
Vaccines have been used for pneumococcal disease control for a very long time. 
Current vaccines against pneumococci employ capsular polysaccharide (CPS), 
which induces serotype-specific antibodies to activate and fix complement and 
induce opsonisation and phagocytosis by host phagocytes (Plotkin, 2008).  There 
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are two main vaccination strategies against pneumococcal infections, which are 
the use of purified CPS based pneumococcal capsular polysaccharide (PPV) and 
pneumococcal conjugate vaccines (PCV) that are prepared by conjugating CPS to 
immunogenic carrier proteins (Artz et al., 2003).  
 
PPV and PCV have certain drawbacks and certain advantages over each other.  
PCV, unlike PPV is known to reduce carriage as well as invasive pneumococcal 
disease (IPD) by included serotypes (O'Brien & Dagan, 2003; Obaro & Adegbola, 
2002).  The PPV23 vaccine serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 
12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F covers for most of (>90%) 
of IPD in developed world.  Multivalent vaccines were found to be providing 
protection in about 80% of cases against invasive disease by serotypes, which are 
included in vaccine (Austrian, 1981).  A major limitation of PPV23 is that it is 
only effective in children older than two years of age and adults, as children 
younger than two are unable to mount an appropriate immune response to a 
polysaccharide vaccine because of insufficient development of immune 
mechanisms. 
 
PCV7 is used in the prevention of invasive disease in children younger than two 
years.  It consists of capsular polysaccharide from serotypes 4, 6B, 9V, 14, 18C, 
19F, and 23F combined with detoxified diptheria toxin (CRM147).  This 
conjugation results in a T-cell mediated response.  Introduction of PCV7 in 
vaccination program in the US in 2000 resulted in significant reduction in rate of 
incidence of pneumococcal diseases within a few years (Benninger, 2008; 
Fletcher & Fritzell, 2007; Mahon et al., 2006), even in HIV positive infants 
(Klugman et al., 2003) and elderly over 65 due to development of herd immunity 
(Mcbean et al., 2005).  
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A major problem with these vaccines is serotype replacement, which allows 
pneumococci to gradually escape the effects of vaccines by replacing capsular 
genes included in vaccines with those of uncovered serotypes (Brueggemann et 
al., 2007).  These bacteria can acquire a different type of capsule to escape 
vaccine-effects and continue to cause disease as has been observed with 
multidrug resistant clone 23F (Croucher et al., 2009; Coffey et al., 1998b; Munoz 
et al., 1991) whose variants have been found expressing different capsular types 
such as 19F, 14, 19A, 9N, 3 and serogroup 6 (Mcgee et al., 2001). Similar 
capsular switching have been reported for serotype 14 and 19A variants (Coffey 
et al., 1999; Coffey et al., 1998a; Coffey et al., 1998b).  These variants arise 
from capsular switching among different strains due to recombinational events 
in capsular biosynthesis cps operon (Coffey et al., 1999; Coffey et al., 1998a; 
Coffey et al., 1998b).  These changes in the capsule change the serotypes 
carried in the nasopharynx, which results in transmission of serotypes not 
included in the vaccine and rise in pneumococcal infections in the community 
(Brueggemann et al., 2007; Spratt & Greenwood, 2000).  
 
This phenomenon has been reported from around the globe as in Alaska native 
children, a 96% decrease in vaccine serotypes was noted from 2004, which was 
also accompanied by a 141% increase in non-vaccine serotypes, mainly due to 
infection by 19A (Singleton et al., 2007).  
 
There are serious concerns that limited coverage by these vaccines could result 
in spread of non-vaccine serotypes, which would render these vaccines 
ineffective in populations.  
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A much better strategy would be to introduce vaccines that can provide serotype 
independent protection.  Such vaccines may be protein based, so that they can 
prevent pneumococcal disease independent of serotype.  
 
The use of protein-antigens, which are conserved across serotypes, could offer 
serotype-independent protection in all age groups for vaccines of the future.  
Surface exposed proteins are used to generate protective response and 
opsonophagocytosis of bacteria to clear them from host tissues though 
cytoplasmic proteins are more conserved (Ogunniyi et al., 2007; Jomaa et al., 
2006; Brown et al., 2001).  
 
Another possibility is of use of live attenuated vaccines.  Use of strains 
containing deletions of  major determinants of virulence has been noted to offer 
significant protection in mice and capsule deleted strains were able to generate 
serotype independent immunity (Roche et al., 2007). 
 
Whole-cell killed vaccines have also been tested and unencapsulated killed 
intranasal pneumococcal vaccine using cholera toxin as adjuvant was found to be 
highly effective in preventing colonization and also conferred protection against 
infection through other routes (Malley et al., 2004). A similar vaccine using an 
aluminium derived adjuvant, when given as injection induced both cell mediated 
and humoral immunity with a 30-fold higher antibody response as compared to 
previous approach (Malley & Anderson, 2012)  
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1.7 Aims of the project: 
Aims of this project were to investigate:  
1. The effect of capsular variation on pneumococcal biology. 
 
For this purpose otherwise isogenic mutants were constructed in three 
strains TIGR4, D39 and 403 expressing various serotypes, and were 
compared for variation in in vitro and in vivo characteristics.     
 
2. The genomic diversity in closely related strains of Streptococcus 
pneumoniae in order to understand the affects of mutations on 
phenotype.  
 
Non virulent type 4 strain 403 was genome sequenced and compared for 
differences with previously sequenced virulent serotype 4 strain TIGR4.  
Microarray analysis was also performed to study variation of gene 
expression among the two strains.   
 
3. The possibility of clinical application of capsule switching phenomenon.  
 
Avirulent strain 403 was also tested as a live attenuated vaccine without 
using any adjuvant. It was planned that its capsule switch mutants would 
also be tested as vaccines as a combination of live attenuated and whole 
cell killed vaccine.  Since 403 could not provide sufficient protection on 
its own, the capsule switch mutants were not tested as live attenuated 
vaccine.  
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2 Materials and methods: 
2.1 Bacterial strains: 
To study the effect of capsule switching on different genetic backgrounds, 
different bacterial strains were selected as recipient and donors of capsule 
genes on the basis of difference of their virulence and capsular polysaccharide 
structure.  
2.1.1 Wild type (WT) and capsule knock out bacterial strains: 
Three strains serotype 4 strain TIGR4, serotype 2 strain D39 and serotype 4 strain 
403 with different virulence and capsular structure were used in this study as 
the recepients of capsule genes.  Among these, TIGR4 is the most virulent, D39 
has intermediate virulence and 403 is an avirulent strain. 
Highly virulent serotype 8 strain ATCC6308, virulent serotype 3 strain OXC141 
and D39 were used as capsule donors.  Bioluminescent virulent serotype 3 strain 
A66.1 Xen10 was used for challenging mice vaccinated with 403. 
These strains and their capsule knock out mutants are summarized in Table 2.1. 
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Table 2.1  Wild-type and capsule knock out strains used in this study: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strain Serotype Description 
TIGR4 Serotype 4 Wild type virulent strain 
403 Serotype 4 Avirulent strain derived from TIGR4 
D39 Serotype 2 Wild type virulent strain 
OXC141 Serotype 3 Wild type virulent strain 
ATCC6308 Serotype 8 Wild type highly virulent strain 
TIGR4j (P1672) 
 
 
_ Capsule knock-out TIGR4 
403j _ Capsule knock-out 403 
D39j _ Capsule knock-out D39 
A66.1 Xen10 Serotype 3 Virulent, Bioluminescent  
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2.1.2 Capsule switch strains: 
S. pneumoniae strains were modified using Janus technique so that they remain 
isogenic except for capsule locus (Trzcinski et al., 2003; Sung et al., 2001).  This 
technique has the advantage of double selection as it allows selection for 
incorporation of the cassette accompanied by the capsule knock out as well as 
the loss of Janus cassette resulting from capsule replacement (Trzcinski et al., 
2003; Sung et al., 2001).   It is a bicistronic cassette, which allows selection for 
its acquisition as well as removal and contains kanamycin resistance gene aphIII 
and streptomycin sensitivity gene rpsL as shown in Fig 2.1.   
 
Figure 2.1.  Schematic diagram of Janus cassette containing kanamycin resistance gene 
aphIII and gene rpsL conferring sensitivity to streptomycin.    Cassette is ligated with genes 
dexB and aliA, which flank capsular locus in S. pneumoniae. Figure constructed using CLC 
Genomics workbench(CLC Bio, Denmark) 
 
Using the Janus method, bacteria are first transformed with rpsL gene, which 
confers recessive streptomycin resistance in target bacteria as shown in Fig 2.2 
A.  When these bacteria are transformed with dominant allele rpsLR+, present in 
Janus cassette along with Kanamycin resistance cassette, they become sensitive 
to streptomycin and can be selected for kanamycin resistance.  Once this 
cassette is replaced, transformants can be selected for redevelopment of 
resistance to streptomycin and loss of kanamycin resistance (Sung et al., 2001) 
as shown in Fig 2.2 B and C. 
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Figure 2.2.  Mechanism of Janus transformation. (A)  Streptomycin sensitive wild type 
bacteria can be transformed with rpsL cassette conferring streptomycin resistance.  (B) 
Janus cassette flanked with identical genes can be used to replace the target gene, which 
also confers kanamycin resistance and streptomycin sensitivity.  (C)  Replacement of Janus 
cassette by another gene confers streptomycin sensitivity and kanamycin resistance.  
(Modified from Sung et al 2001) 
 
 
403, TIGR4 and D39 capsule genetic loci were replaced with this cassette, which 
was then replaced with different type of capsules as explained in Section 3.1.   
Switching of capsule genes was confirmed by Quellung reaction to check 
capsular serotype and correct positioning of capsule locus was confirmed by PCR 
with forward primers designed against specific genes present in respective 
serotypes and reverse primer against aliA, which is common flanking gene in all 
serotypes as shown in Fig 2.3.  
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Figure 2.3. Schematic diagram showing method of primer design for confirmation of correct 
placement of capsule locus.  TTM05 is forward primer designed against dexB while cps2AR 
is reverse primer designed inside capsule locus.  TTM06 is reverse primer designed against 
aliA gene while the forward primer is serotype specific, used to confirm correct serotype 
and its proper placement in recipient genome.  
 
Mutant capsule switch strains are summarized in Table 2.2. 
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Table 2.2. Capsular switch mutants strain. 
  
Strains Description 
 
TIGR4
2
 (TIGR4
2
3x)* Otherwise isogenic TIGR4 expressing serotype 2 capsule 
TIGR4
3
 (TIGR4
3
3x)* Otherwise isogenic TIGR4 expressing serotype 3 capsule 
TIGR4
8
 (TIGR4
8
3x)* Otherwise isogenic TIGR4 expressing serotype 8 capsule 
TIGR4
4
 (P1702) Otherwise isogenic TIGR4 retransformed with serotype 4 capsule 
 403
2
 (403
2
3x)* Otherwise isogenic 403 expressing serotype 2 capsule 
403
3
(403
3
3x)* Otherwise isogenic 403 expressing serotype 3 capsule 
403
8
(403
8
3x)* Otherwise isogenic 403 expressing serotype 8 capsule 
D39
8
(D39
8
3x)* D39 expressing serotype 8 capsule 
  
       *All 3x strains are three times back crossed strains. 
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2.2 Growth conditions: 
Pneumococcal strains were statically grown from a single colony in Brain Heart 
Infusion (BHI) broth (Oxoid, UK) at 37 C to mid log phase (OD600nm 0.6) and 
stored at -80 C in 1ml aliquots in BHI containing 15% glycerol (Sigma-Aldrich, UK) 
or in form of bead stocks (Pro-Lab Diagnostics, UK).  Strain purity was verified by 
streaking the culture on Blood Agar Base (BAB) (Oxoid, UK) supplemented with 
5% horse blood (E&O Laboratories, UK) on the next day and optochin sensitivity 
was confirmed (Mast diagnostics, UK).  Antibiotic concentrations used in 
selective media were 500 μg/ml kanamycin (Sigma-Aldrich, UK), 300 μg/ml 
streptomycin (Sigma-Aldrich, UK), 3 μg/ml chloramphenicol (Sigma-Aldrich, UK) 
and 1 μg/ml erythromycin (Sigma-Aldrich, UK).  
2.3 Preparation of pneumococcal genomic DNA: 
Strains were grown statically overnight at 37oC in 20ml BHI, and culture was 
centrifuged at 4000 x g at 4oC for 15 min to pellet the cells.  A BAB plate was 
aseptically streaked with culture to confirm purity and identity using an 
optochin disc (Mast diagnostics, UK) before centrifugation. The pellet was then 
resuspended in 1ml lysis buffer (10mM Tris, 100mM EDTA, 0.5% SDS) and 
incubated for an hour at 37oC.  Proteinase K (Invitrogen, UK) was added to attain 
a concentration of 20μg/ml and was incubated for three hrs at 50oC.  RNase A 
(Invitrogen, UK) was then added to a final concentration of 20μg/ml, and 
samples were incubated for half hour at 37oC.  Each sample was mixed gently 
with equal volume of phenol:chloroform:isoamyl alcohol (25:24:1) (Sigma-
Aldrich, UK) and centrifuged at 12,000 x g for 3 min.  Upper phase was separated 
and placed into a fresh tube of 1.5ml.  0.2 volumes of 10M ammonium acetate 
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(Sigma-Aldrich, UK) and 600μl analytical reagent grade absolute ethanol (Fisher 
Scientific, UK,) were added to samples and mixed gently.  Tubes were 
centrifuged at 12,000 x g for half an hour to form a DNA pellet.  Supernatant was 
decanted and pellet was dried in air for half an hour to remove any remaining 
ethanol and later suspended in 300μl PCR water and incubated at 65oC for 10 
min, with intermittent mixing.  The quality of DNA was assessed by running the 
DNA on 0.7% agarose gel with SYBR® Safe DNA Gel Stain (Life technologies, UK) 
and visualization using a Bio-Rad® Gel doc system (Bio-Rad, UK).   DNA was 
quantified using a Nanodrop ND-1000 spectrophotometer (Agilent Technologies, 
UK) 
Samples were then stored at 4oC if to be used shortly or -20 oC for long term 
storage. 
2.4 Transformation conditions: 
Bacteria were statically grown to OD600 0.1 in BHI containing 0.1 mM CaCl2.  
Competence was induced in TIGR4, 403 and their mutants by using 100ng/ml 
competence-stimulating peptide 2 (csp-2) while in D39 and its derivatives using 
100ng/ml csp-1. Bacteria were incubated 15 min at 37 oC.  One μg/ml DNA was 
used in transformation steps both for chromosomal DNA and purified PCR 
products. 
2.5 Optochin sensitivity: 
All parent and mutant strains were tested for optochin sensitivity to confirm the 
purity of strains by plating colonies on blood agar and placing 5 μg optochin disc 
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(Oxoid, UK).  Plates were incubated overnight at 37 oC to confirm a zone of 
growth inhibition around the disc. 
2.6 Serotyping: 
Capsular serotype of parents and transformants were determined by the 
Quellung test with serotype specific typing sera (Statens Serum Institute, 
Denmark).  Equal amount of bacterial suspension was mixed with type specific 
antiserum (Statens Serum Institute, Denmark), incubated for 10 min and 
examined under the microscope using an oil immersion lens at 1000X for capsule 
swelling. Agglutination was also observed macroscopically. 
2.7 PCR amplification: 
PCR amplification was performed to amplify the Janus cassette and confirmation 
of correct placement of transformed DNA using 150 ng of genomic DNA in 50 μl 
mixture comprising of 10 μl buffer, 5 μl 2mM dNTPs and 100nM each primer with 
4.5 U of Taq DNA polymerase (Invitrogen, USA) or 5 μl buffer, 5 μl 2mM dNTPs 
and 100nM each primer with 0.5 U of Pfu DNA polymerase (Stratagene, USA).  
PCR reaction consisted of initial denaturation of 3 min at 95°C and 30 cycles 
with every step comprising of 30 sec at 95°C, 25 sec at 5°C less than annealing 
temperature of primers, and 1 min/1000 base pairs of estimated product length 
at 72°C and a final incubation at 72°C for 4 min. 
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Table 2.3. Primers used in this study.   
    
Primer Sequence 
 
Description Reference 
CPSF 5'-GACCGTCGCTTCCTAGTT-3'   Forward primer dexB to amplify Janus cassette This study 
 
CPSR4 5'-AGCCTTAGCAGTTGTCAAAT-3' Reverse  primer aliA to amplify Janus cassette This study 
TTM05 5'-AAGGTGAGGAGATTGGGATGA-3' Forward primer dexB to confirm Janus cassette placement (Trzcinski et al., 2003) 
TTM06 5'-TGTCGCAGCCTTAGCAGTTG-3' Reverse  primer aliA to confirm Janus cassette placement (Trzcinski et al., 2003) 
Cps2AR 5'-CTGCCAAGTAAGACGAACTC-3' Reverse primer wzg to confirm capsule placement This study 
 
CPS1rmlDF1 5'-TCAAGCCAGTAGATTCCAGT-3' Forward primer rmlD specific for serotype 1 and 2. This study 
Cps3wchEF 5'-TTTCCAGACATAAACCATCCATCCGA-3' Forward primer wchE specific for serotype 3   This study 
 
Cps8wzy   5'-AGCTTGGTCTATGTATGCG-3' Forward primer wzyE specific for serotype 8   This study 
 
Cps1A 5'-CGACCGTCGCTTCCTAGTTGTGGCTAAC-3' Forward primer dexB to confirm capsule placement Bentley et al., 2006 
Cps1B 5'-GTCTTGAGCTTTGACTGCCGCGTATTCT-3' Reverse  primer aliA to confirm capsule placement Bentley et al., 2006 
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2.8 Janus Intermediates: 
Capsule knock-out strains were constructed using the Janus technique as 
discussed in Section 2.1.2 (Sung et al., 2001).  These knock-outs could be 
selected for the acquisition of capsule genes from other strains on blood agar 
plates supplemented with streptomycin. 
2.8.1 Janus Intermediate in 403 and TIGR4: 
The Janus intermediate strain of 403 was a kind gift from Professor Marc Lipsitch 
of Harvard School of Public Health (U.S) and TIGR4 from Dr. Jeremy Brown of 
University College London (U.K). 
2.8.2 Construction of Janus Intermediate in D39: 
Unencapsulated D39 was constructed using Janus cassette from TIGR4j.  The 
cassette was amplified using primers CPSF and CPSR4 against dexB and aliA and 
was cleaned using PCR purification kit (Qiagen,UK).  Strain D39 was statically 
grown to OD600 0.1 at 37
oC in BHI containing 1mM CaCl2, incubated 15 min with 
100ng/ml csp-1 and was transformed with a gene conferring streptomycin 
resistance rpslR+.  Suspension was then incubated for 2 hrs before plating on to 
BAB plates supplemented with 300 µg/ml streptomycin (Sigma-Aldrich, UK).  
streptomycin resistant colonies were picked up and were replated on BAB plates 
supplemented with 300 µg/ml streptomycin (Sigma-Aldrich, UK) with an optochin 
disc (Mast Diagnostics, UK) to confirm purity and identity.  Streptomycin 
resistant strain D39S was statically grown to OD 0.1 at 37o in BHI containing 1mM 
CaCl2, incubated 15 min with csp-1 and was transformed with 1μg purified Janus 
cassette.  Suspension was incubated for another 2 hrs before plating on to BAB 
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agar plates supplemented with 500µg/ml kanamycin (Sigma-Aldrich, UK).  
Colonies were picked up and were re-confirmed by using two sets of primers, 
original primers CPSF, CPSR4 used for amplification of cassette and primers 
cps1A and cps1B in flanking sequence of cps locus.  Confirmed colonies were 
saved and purified PCR product from one of them was sent for sequencing to 
confirm insertion site of Janus cassette. 
2.9 Construction of cps transformants; 
Cps transformants were constructed in strains TIGR4j, 403j and D39j using 
genomic DNA from the following strains.  They are summarized in Table 2.4. 
Table 2.4. Capsule donor strains   
  
Strain Type of capsule  
D39 Serotype 2 
OXC141 Serotype 3 
TIGR4 Serotype 4 
ATCC6308 Serotype 8 
  
  
 
For each transformation genomic DNA from the donor strain was transformed 
into the capsule knock-out strains (Section 2.4) and 50 µl of the suspension was 
plated on to the streptomycin supplemented BAB plates.  For each capsular 
transformation, up to 24 morphologically different colonies were picked from 
the plates, incubated overnight and streaked on kanamycin and streptomycin 
plates simultaneously to confirm the loss of kanamycin resistance and 
redevelopment of streptomycin sensitivity.  The process is schematically 
summarized in Fig 2.4. 
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Figure 2.4. Schematic diagram explaining generation of capsule switch mutant. Capsule 
knock-out mutant (Kan
R
, Str
S
) is transformed with the genomic DNA from the donor strain 
that removes Janus cassette resulting in Kan
S
, Str
R 
phenotype that can be selected on 
streptomycin-supplemented BAB plates. 
 
Quellung reaction was performed to confirm the capsular type. DNA was purified 
from that mutant and used to retransform the unencapsulated janus strain into 
an encapsulated strain again. This back crossing was repeated thrice to construct 
three times backcross (3x back-cross) transformants (Fig 2.5).  Mutant strains 
constructed using the Janus technique are summarized in Table 2.2. 
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Figure 2.5. Flow-dagram showing process of back-crossing to produce 3x backcrossed 
mutant strains.  
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2.10 Characterization of mutant strains: 
2.10.1 Growth curves: 
To compare the effect of capsule switching on growth of the mutant strains, 
growth rates of parent, capsule switch and capsule donor strains in BHI (Sigma-
Alrdich, UK) were investigated and compared by constructing growth curves 
using three replicates.  Approximately 1 x 105  colony forming units/ml (cfu/ml) 
were taken in 20 ml BHI and growth rates were monitored by reading OD600 every 
two hrs for the first four hrs and every hour then onwards for up to 12 hrs.  
Blood agar plates were inoculated for calculation of viable counts.  Growth 
curves were plotted using these viable counts in GraphPad Prism 4 (GraphPad 
Software, USA). 
2.10.2  Sample preparation for electron microscopy: 
To compare the effect of capsule switching on capsular thickness, electron 
microscopy was performed at the EM facility at University of Glasgow with the 
help of Ms. Margaret Mullin and Dr. Lawrence Tetley.  The samples were 
prepared by Ms. Margaret Mullin using the following method. 
Bacteria were grown to OD600 0.4 and centrifuged at 2400 x g for 15 min.  Pallets 
were resuspended in 1ml PBS and washed thrice.  The samples were transported 
to the EM facility and were incubated in a solution of 2% paraformaldehyde 
(Sigma, UK) and 2.0% glutaraldehyde (Sigma, UK) in 0.15M cacodylate buffer 
containing 0.15% ruthenium red (Agar Sc, UK) and 0.0075% lysine (Sigma, UK) for 
30 min on ice.  Samples were washed with 0.15M sodium cacodylate and 
   58
incubated in 2% paraformaldehyde, 2.0% glutaldehyde containing 0.15% 
ruthenium red in cacodylate buffer for one and a half hour on ice. Following 
three washes with 0.15M sodium cacodylate for 5 mins, samples were fixed with 
1% osmium tetroxide and 0.15M sodium cacodylate for an hour on ice.  Samples 
were washed thrice with distilled water and were left in the dark in 0.5% uranyl 
acetate in distilled water for an hour and washed with distilled water twice for a 
minute.  Samples were dehydrated with ethanol according to the following 
scheme.  
0% Ethanol                   2x5mins 
50% Ethanol                  2x5mins 
70% Ethanol                  2x5mins 
90% Ethanol                  2x5mins 
Absolute Ethanol          4x5mins 
Dried Absolute Ethanol 4x5mins 
Dehydrated samples were then given four washes of five min each with 
propylene oxide and left on overnight incubation with propylene oxide/Epon812 
resin 1:1mix.  Samples were washed with Epon 812 resin several times the next 
day and were embedded in fresh Epon resin and polymerised at 60⁰C for up to 48 
hrs.  These specimens were ultrathin sectioned (60-70nm thickness) and were 
contrast stained in 2% methanolic uranyl acetate for 5 min and Reynolds lead 
citrate for another 5 min.  Images were captured by Ms. Margaret Mullin on a 
LEO912 AB transmission electron microscope (TEM).   
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2.10.3 Measurement of capsule thickness: 
Mean capsular thickness was calculated from measuring the completely extended 
capsular fibres at 3-7 points/bacterium in five bacteria. Measurements were 
taken using image processing software iTEM (Olympus Soft Imaging Solutions, 
Germany) on the areas where cell wall boundaries could be traced easily.  
2.10.4 Measurement of amount of capsule: 
To compare the effect of capsule switching on the amount of capsular 
polysaccharide,  amount of capsular polysaccharide was calculated with the help 
of semi-quantitative Stains-All assay using Stains-All stain (Sigma, UK) for 
detecting acidic polysaccharides (Hathaway et al., 2007; Hammerschmidt et al., 
2005).  Bacteria were cultured in BHI to OD600 0.3 and 0.6, 20μl was removed and 
diluted in PBS for plating and quantification.  Four ml culture was centrifuged at 
5000 x g for 10 min, washed twice with PBS and resuspended in 0.5 ml water.  
A solution was freshly prepared with 20 mg 1-ethyl-2 (3-(1-ethylnaphthho-(1,2-d) 
thiazolin-2-ylidene)-2 methylpropenyl) naphthho-(1,2-d) thiazolium bromide, 
60μl glacial acetic acid and 100 ml 50% formamide and 2ml was added to sample 
and OD640 was determined.  Two ml Stains-All solution was used as a blank. 
Values for 109 cfu were calculated from obtained readings. 
2.10.5 Transformation efficiency: 
To compare the effect of capsule switching on the transformability of 
pneumococci, transformation efficiency was calculated by transforming similar 
number of bacteria under similar growth conditions with 200ng plasmid 
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pVA838/ml and selecting for development of erythromycin resistance.  
Experiment was repeated five times and total colonies were used to calculate 
number of colonies/ng of plasmid DNA. 
2.10.6 Chain formation in selected strains: 
To study the effect of different capsules on bacterial chain formation, number of 
bacteria associating in particular types of chains was calculated.  For counting 
number of bacteria associated to form a particular type of chain, all bacteria in 
chains in phase were counted in ten fields at early, mid and late log phase.  
These chains were broadly classified in three groups short (2-4), medium length 
(5-10) and long chains (11+).  Since there was no major difference in three 
different growth phases except for increase in total bacterial count, only early 
log phase readings were considered for statistical analysis.    
2.11 Mouse infection studies 
2.11.1 Mice 
Animal experiments were performed in 6-8 weeks old out-bred MF1 mice 
obtained from Harlan Olac (UK).  Experiments were performed according to the 
UK Animals Act 1986 (Scientific Procedures Act) under Home Office project and 
personal license, approval was taken from the University of Glasgow Ethics 
Committee.  Mice were acclimatized for one week before the procedure and 
were housed at 20-22ºC with a 12h light/dark cycle.  Mice were challenged at 
16-18 weeks of age.  
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2.11.2 Preparation of standard inocula: 
Single colonies of S. pneumoniae serotype 4 strain TIGR4, serotype 3 strains Xen 
10 A66.1 and OXC141, and serotype 8 strain ATCC6308 were grown up to mid-log 
phase in BHI and I ml aliquots were stored in 10% glycerol at -80ºC.  After 24 hrs, 
viable counts were performed and 5x106 cfu/200µl were injected 
intraperitoneally (IP) into an MF1 mouse, which was sacrificed after 6 hrs under 
general anaesthesia by terminal exsanguination via cardiac puncture.  Blood was 
incubated overnight in 20 ml BHI at 37ºC and plated onto BAB plates to check 
sterility.   
To prepare standard inocula, a 1:50 dilution of overnight culture was grown at 
37ºC to an OD600nm 0.6, inoculated in pre-warmed BHI containing 15% fetal calf 
serum (FCS) and frozen at -80ºC in cryovials.  Cultures were checked for purity 
and cfu/ml in each culture was calculated using following method:  
After freezing for 24 hours, three vials for each strain were defrosted rapidly for 
2 min in a 37ºC water bath and were centrifuged for 5 min at 13000 x g at room 
temperature in a bench-top centrifuge. The supernatant was decanted and 
pellet was resuspended in 1ml PBS.  1:10 dilutions were made in sterile 
Dulbecco’s Phosphate Buffer Saline (DPBS) (Sigma-Aldrich, UK) in a round-
bottomed 96 well plate from 10-1 to 10-8.  Three spots of 20µl from each dilution 
were spotted onto BAB plates, which were divided into eight sectors and allowed 
to dry.  Plates were incubated overnight in a candle jar at 37ºC and sector where 
there were 10-70 colonies/20µl was used to calculate cfu/ml in following steps: 
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o The average is calculated in the first step: 
[(Spot 1) + (Spot 2) + (Spot 3)] /3 = average/60µl 
o Average/ml is calculated as:    
[average/60µl] x 50(cfu/ml) x dilution = average/ml 
2.11.3 Dose preparation of avirulent 403 strains: 
S. pneumoniae strain 403 was found to be avirulent in mice so glycerol stocks 
were used to immunize the mice.  Single colony was selected and grown up to 
mid-log phase in BHI and I ml aliquots were stored in 10% glycerol at -80ºC.  
After 24 hrs, viable counts were performed and cultures were streaked on BAB 
plates to check for purity and optochin sensitivity. Colony forming units/ml in 
each culture was calculated using previously described method.  
2.12 Vaccination of mice with 403 strains: 
2.12.1 Vaccination of mice with live 403 strains: 
Twelve week old MF1 mice were caged into group sizes of 10 and were bled from 
the lateral tail vein a day before immunization for obtaining baseline blood.  
Blood was then left overnight to clot at room temperature and was centrifuged 
the next morning at 13000 x g for 5 min. Serum was then stored in a fresh tube 
and was frozen at -80ºC.   
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For IN vaccination, mice were anaesthetised and vaccinated IN with 10µl across 
both nares either with sterile DPBS or 105 cfu of strain 403.  Three vaccinations 
were performed at fortnightly interval.  
For IP vaccination, mice were anaesthetized and vaccinated IP with 10µl into the 
peritoneal cavity either with sterile DPBS or 105 live 403 strains. Three 
vaccinations were performed at fortnightly intervals.  
Bleeds were taken and mice were left for a further fortnight before challenge 
with the virulent strains.   
2.12.2 Challenge of mice with virulent pneumococcal strains: 
Mice wer challenged with strains TIGR4, ATCC6308 and A66.1 Xen 10 to assess 
the protection provided by the vaccination.  Mice were also challenged with the 
capsule donor and capsule switch strains OXC141, D39, TIGR42, TIGR43, TIGR48, 
P1702 and D398 to assess the effect of capsule switching on the virulence of 
these strains.  Mice were inoculated and bled by Dr. Kirsty Ross, Dr. Carol 
McInally and Mr. Ryan Ritchie. 
Standard inocula were thawed and a dose was prepared right before challenging 
mice by diluting in sterile DPBS.  Viable counts were assessed just before and 
after the challenge and compared to ensure that number of viable inoculum 
counts remained the same during challenge and whether the correct dose was 
given. 
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2.12.2.1 Intranasal challenge: 
Mice were anaesthetized with 3.5% isofluorane/1.5% oxygen (1.5 litre/min) 
(Astra-Zeneca, UK) until loss of limb movement reflex.  Mice were challenged IN 
with required dose in 50µl of sterile DPBS and 25µl was administered to each 
nare.  Mice were then relocated to their cages and were left to recover in 
ventral position within their cage.  
2.12.2.2 Intraperitoneal challenge: 
IP challenge with the virulent pneumococcal strains was carried out by scuffing 
the mice at neck and administration of injection with the specific dose in 200µl 
of sterile DPBS into the peritoneal cavity.  
2.12.3 Imaging with bioluminescent strains: 
Imaging was performed by Dr. Kirsty Ross and Mr. Ryan Ritchie.  Mice challenged 
with bioluminescent strain Xen 35 A66.1 were anaesthetised and positioned 
within IVIS Spectrum (IVIS: Caliper Life Sciences, UK) imaging chamber inside 
masks with a constant flow of anaesthetic. Living Image® 3.1 software (Caliper 
Life Sciences, UK) was used for image acquisition.  Mice were exposed for five 
min before acquisition of initial bioluminescent images on large binning and field 
of view, which were kept consistent in all figures. Further images were taken 
with adjusted settings in case if there were saturated pixels in the regions of 
interest.  
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2.12.4 Retrieval of blood for viable counts from infected mice: 
After each challenge with the virulent strain, mice were bled from the tail vein 
at 6 hourly intervals post infection (hpi) to monitor development of bacteræmia 
and progression of infection. Blood samples were promptly diluted in sterile 
DPBS to prevent clotting.   
2.12.5 Plating of the blood for viable counts:   
Blood samples were immediately plated on BAB plates and counted the next day. 
For the purpose of statistical analysis, samples below detection limits were 
ascribed value just beneath the limits of detection, which depends upon the 
number of spots and the dilution factor. As 1 cfu from three spots of dilution 10-1 
equals 166.6 cfu/ml or log10 2.22, or 1 cfu from three spots of neat dilution 
equals 16.6 cfu/ml or log10 1.22 therefore the cfu/ml of blood is plotted as a log 
value with a detection limit of 2.2. 
2.12.6 Survival assessment and management of clinical 
symptoms during infection: 
For assessment of progression of disease, a clinical scoring system is utilized in 
our lab instead of taking death as end point.  It consists of monitoring for 
hunching, lethargy and piloerection.  On reaching a point where an animal 
doesn’t move when encouraged, it is considered moribund and is humanely 
culled using a Schedule 1 method.  Animals are also culled if they lose 20% of 
their body weight during the course of the infection. If an animal dies between 
the two readings, survival time is calculated as intermediate time between the 
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two time points, when animal was last scored and the time it was found dead to 
approximate time when animal became moribund.  
2.13 Western blots: 
TIGR4 whole cell lysate was prepared by growing bacteria to OD600 0.6 in a 30 ml 
culture and sonicating after 2x centrifugation and washing with PBS. Loading 
buffer was added to samples, and were incubated at 70⁰C for 10 min.  Precast 
gels (Invitrogen, UK) were used to run the samples. Running tank was filled with 
MES running buffer and 13 μl of sample + 2 μl of marker was added to the gel 
tank and was then run for 1 hr at 150V.  Gels were equilibrated in transfer buffer 
and run with 100 μl antioxidant at 100V for 1 hour to transfer to Hybond-C 
nitrocellulose membrane (Amersham Biosciences, UK). They were blocked 
overnight in 3% skimmed milk in 0.25mM Tris-NaCl (pH 7.4) with shaking 
overnight and then incubated for 2 hrs with shaking in 3% skimmed milk at 37ºC 
with 1:100 mouse sera.   Membranes were rinsed 3x in 0.25mM Tris-NaCl (pH 
7.4), incubated in 3% skimmed milk with 1:1000 HRP-linked secondary anti-
mouse IgG (Amersham Biosciences, UK) and washed 4x with 0.25mM Tris-NaCl 
and developed by placing in 4-Chloro-1- naphthol developing solution. Distilled 
water was used to stop the reaction.  
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2.14 Genome sequencing, microarrays and bioinformatic 
and statistical analysis: 
2.14.1 Complete genome sequencing: 
Whole genome sequencing of strain 403 was carried at The Sir Henry Wellcome 
Functional Genomics Facility, University of Glasgow by Dr. Pawel Herzyk and Ms. 
Julie Galbraith using Illumina® genome analyzer and paired end-sequencing 
method was used.  Using CLC Bio® Genomics Workbench, genomic alignments 
were performed by Dr. Andrea Mitchell between complete genome sequence of 
TIGR4 strain and consensus sequence, which was generated for strain 403.    
2.14.2 Microarray experiments: 
2.14.2.1 RNA extraction: 
Bacteria were grown in 15ml BHI at 37°C until an OD600 0.6 was reached.  Purity 
of culture was checked by aseptically streaking 10µl on to 5% blood agar and 
incubating overnight at 37°C.  Ten ml of culture was centrifuged at 5027 x g for 
5 min at room temperature in 15 ml centrifuge tubes.  The supernatant was 
discarded and pellet was frozen in liquid nitrogen immediately and stored at -
80°C.  For extraction, lysozyme TE buffer was prepared freshly using 10µl 1M 
Tris HCl (pH8.0) (Ambion/Applied  Biosystems,  UK ),  2µl  of  0.5M  EDTA  
(pH8.0)(Ambion/Applied Biosystems, United Kingdom) and 15mg of lysozyme  
(Sigma-Aldrich, UK)  in 1ml of nuclease free water (Ambion/Applied 
Biosystems,UK).  Two hundred µl of buffer (15 mg/ml) was added to the pellet 
and vortexed for 10 sec in a rotamixer (Hook and Tucker Instruments, UK) and 
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incubated at room temperature.  Samples were incubated for 15 min and 
vortexed for 10 sec every 2 min.  Extraction was carried out using a Qiagen 
RNeasy Mini Kit (Qiagen, UK) according to manufacturer’s protocol. Five µl of the 
extract was separated for quality assessment on Agilent 2100 bioanalyser 
(Agilent Technologies, UK).  An integrity number above 9 was set as an indicator 
of high enough quality.  Quantification was performed using Nanodrop ND-1000 
spectrophotometer (Agilent Technologies, UK).  Remaining RNA was stored at -
80°C  
2.14.2.2 Microarray analysis of RNA from Strain 403:  
Expression experiments on strain 403 were performed in triplicates by Dr. Jenny 
Herbert (different broth cultures grown to mid log phase) by hybridizing 403 RNA 
against RNA from TIGR4 grown to mid-log phase.  Reactions were performed as 
per manufacturer’s protocols.  One Cy3 and one Cy5 labeled cDNA sample (2-
10µg) was prepared for each microarray by incubating at 70°C for 10 min with 
1µl random primers (Invitrogen, UK) and made up to 11µl with nuclease free 
water (Ambion/ Applied Biosciences, UK).  Samples were snap cooled on ice and 
centrifuged.  Hundred mM dithiothritol (DTT) 2.5µl, 5xFirst strand buffer 
(Invitrogen, UK) 5µl, dNTPs (containing 5mM dATP, 5mM dGTP, 5mM dTTP  and 
2mM  dCTP) 2.3µl,  Cy3  or  Cy5  dCTP  (GE  Healthcare,  UK)  1.7µl  and 200U/µl 
SuperScript II (Invitrogen, UK) 2.5µl  were added to each sample from TIGR4 and 
403 and solution was then incubated for 10 min in dark at 25°C and then at 42°C 
for 90 min in a Techegene thermal cycler (Bibby Scientific, UK). 
Prehybridization  solution (20 x Standard Saline Citrate (SSC)  (Ambion/Applied  
Biosciences,  UK) 8.75 ml,  20%  SDS  (Ambion/Applied  Biosciences,  UK) 250µl, 
100mg/ml bovine serum albumin (Sigma-Aldrich, UK) 5ml  and sterile double 
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distilled water (to make up 50ml)  was preheated  to  65°C and samples were 
soaked in  a  Coplin  jar  (Fisher  Scientific,  UK)  for  20  min  and placed in a 
Techne Hybridizer HB-1D (Bibby Scientific, UK).   Prehybridized arrays were 
washed for 1 minute with 400ml double distilled water and then with 400ml 
propan-2-ol (VWR International, USA) for another minute. Each array was 
centrifuged for 5 min at 1200 x g then stored in a box.   
Labelled samples were combined into a Qiagen mini-elute purification column 
(Qiagen, UK) and eluted according to manufacturer’s protocol.  14.9 µl of 
Cy3/Cy5 labelled sample was combined with 4.6µl of 20xSSC and 3.5µl of 2% SDS 
and the solution was heated at 95°C for 2 min in a Techegene thermal cycler 
(Bibby Scientific, Uk).  Arrays were covered by lifter slips (Erie Scientific 
Company, USA), and DNA samples were pipetted under, and array slides were 
then carefully placed into hybridization cassette, sealed and then incubated in 
water in dark at 65oC for 20 hrs in  a Techne-Hybridiser HB-1D (Techne, USA). 
After hybridization was complete, slides were first washed with shaking in a pre-
heated (65oC) buffer solution (1xSSC buffer, 0.05% SDS,) for 2 min and then again 
with a second buffer solution (0.06xSSC buffer) for 4 min followed by 
centrifugation at 800 x g for 5 min.   
2.14.2.3 Normalization for analysis of RNA expression: 
The arrays were scanned with ScanArray Express ™ (Packard Biosciences Biochip 
Technologies, USA) and generated TIFF images were entered into Bluefuse 
(BlueGnome Ltd , UK) for Microarrays 3.5 © BlueGnome Ltd using Channel 1 for 
Cy3 labelled image and Channel 2 for Cy5 labelled image.  Gridmap files were 
obtained from Bacterial Microarray Group at St George’s (BUG@S). Unreliable 
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results with a confidence estimate < 0.1 due to poor hybridization were 
excluded.  
Normalization  was  performed  by  importing  the  Output_fused.xls  files  into  
Genespring  GX 7.3.1  (Agilent  Technologies,  USA)  for  triplicate samples.  Dye 
swap procedure was not used.  Data generated by Genespring GX 7.3.1(Agilent 
Technologies, USA) was statistically analyzed using ANOVA.  Gene lists were then 
imported into Microsoft Office Excel, (Microsoft, UK) for comparison. 
2.14.3 Bioinformatics and statistical analysis: 
All bioinformatics work including genome comparison and primer designs were 
performed using CLC Bio® Genomics Workbench.  Sequence searches were 
performed using search engines from Kyoto Encyclopedia for genes and genomes 
(KEGG) (http://www.genome.jp/kegg), National Center for Biotechnology 
Information (NCBI) (http://www.blast.ncbi.nlm.nih.gov/Blast.cgi) and The 
comprehensive microbial resource (CMR) (cmr.jcvi.org). 
All statistical analysis was performed in Graph Pad prism. (GraphPad Prism 4.0, 
USA). 
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3 Construction of capsular switch mutants:        
Pneumococcal capsule is an important virulence factor and is necessary for 
invasion and pathogenesis.  It protects pneumococcus from the host immune 
system by multiple mechanisms including evasion of opsonins, inhibition of 
complement activity, protection from phagocytosis and provides resistance from 
killing after phagocytosis (Peppoloni et al., 2010; Hyams et al., 2010a; Melin et 
al., 2010). It is electrostatically charged and helps them to avoid the mucosal 
clearance by electrostatic repulsion (Nelson et al., 2007).  It is a complex 
structure and is made up of multiple sugars bonded with each other to form a 
complete protective layer around the bacterial cell (Bentley et al., 2006).  
There are at least 93 known serotypes of pneumococcal capsule and it has been 
reported that pneumococci can switch between different serotypes under 
influence of environmental stress or therapeutic interventions (Golubchik et al., 
2012; Croucher et al., 2011; Brueggemann et al., 2007; Munoz et al., 1991; 
Coffey et al., 1991).  The above studies report natural capsular switching in a 
number of strains though enough data is not available to indicate whether 
capsular switching is a universal phenomenon or if only a few strains can switch 
capsules.  Many studies indicate that natural capsular switching events are not 
uncommon in the evolutionary history of pneumococcus.  A study analyzing 252 
isolates from Scotland reported frequent capsular switching by analyzing number 
of serotypes expressed by particular sequence types.  Many sequence types such 
as ST 311 (Serotypes 23, 23F, 3 and 9V), ST199 (Serotypes 15, 15B and 9A), ST66 
(Serotypes 9N, 9V), ST156 (Serotypes 14,9V and non-typable), ST113 (Serotypes 
11A, 18C and non-typable) were found to be expressing more than two 
serotypes, indicating capsular switching among these strains (Jefferies et al., 
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2004).  Another study in Finland, which analyzed 224 isolates from different 
cases in Finland also reported a number of sequence types such as  ST156 
(Serotypes 14,9V,19F), ST162 (9V,19F,14), ST199(15,19A,19F,35F) to be 
expressing more than two capsule types (Hanage et al., 2005). As many as nine 
different serotypes have been reported to be expressed by the multidrug 
resistant clone named Spain23F-1 including serotypes 6B, 9V, 14 19A, 19F, and 
23F, 3, 9N, and 15B. Another penicillin-resistant clone Spain 9V-3 was reported 
to be expressing serotypes 14, 9A,11 and 19 (Croucher et al., 2011; Porat et al., 
2006;  Mcgee et al., 2001).   A detailed study comprising of 240 isolates of 
Spanish 23F clone showed multiple capsule switching events, with one giving rise 
to whole sub-population of serotype 19A vaccine-escape mutants in the US 
(Croucher et al., 2011).  Similar findings have been reported in many other 
studies, which indicate that capsule switching is an important evolutionary 
phenomenon as it provides an important escape route from vaccines and other 
therapeutic interventions (Brueggemann et al., 2007; Sandgren et al., 2004;  
Porat et al., 2004; Ramirez & Tomasz, 1999; Nesin et al., 1998) as it can also be 
accompanied by acquisition of antibiotic resistance elements (Brueggemann et 
al., 2007) 
Analysis of the effects of capsule switching on pneumococcal biology in these 
naturally occurring mutants can be difficult and misleading due to the possibility 
of the presence of other unrelated genes as a result of acquisition of multiple 
genetic fragments.  To circumvent this issue, capsule switch mutants have been 
constructed, which remain isogenic except for the transformed capsule locus.  
These mutants have been used to study various aspects of pneumococcal 
biology.  Using the capsule switch mutants, it was reported by Battig and co-
workers that the pneumococcal capsule affects rate of growth in capsule switch 
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mutants (Battig et al., 2006; Sjostrom et al., 2006).  It has also been shown to 
affect pneumococcal virulence in a background-dependent manner by Kelly and 
co-workers (Kelly et al., 1994), while Sjostrom and co-workers showed that the 
capsular type is also related to colonization or invasion phenotype (Sjostrom et 
al., 2006).  
To study the capsular effects on pneumococcal biology, several studies have 
utilized capsule-switch mutants and reported various effects of capsule 
switching on the pneumococcal behaviour (Trzcinski et al., 2003; Kelly et al., 
1994), though data on virulence still remain deficient.  
To study role of capsule switching in pneumococcal virulence and other aspects 
of pneumococcal biology, mutants were constructed in three different 
backgrounds, the serotype 4 virulent strain TIGR4, serotype 2 virulent strain D39 
and the avirulent serotype 4 strain 403, expressing different capsule types.  
3.1 Janus intermediate strains: 
In this study capsule switch mutants were constructed using Janus technique 
(Sung et al., 2001), which has advantage of double selection over previously 
used techniques of capsule knock out and capsule replacement  (Pearce et al., 
2002). It is a bicistronic cassette, which allows selection for its acquisition as 
well as removal and contains kanamycin resistance gene aphIII and streptomycin 
sensitivity gene rpsL as discussed in Section 2.1.2.   
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The cassette was amplified and flanked with fragments of genes dexB and aliA, 
from S. pneumoniae strain R6, so that it can be used to knock out capsule locus 
(Trzcinski et al., 2003).  In this study the cassette was obtained from the Janus 
strain kindly provided by Professor Mark Lipsitch and was used to construct 
capsule-knock out mutant in serotype 2 strain D39.  The transformation removed 
the type 2 cps locus that is 20kb in size and contains 17 genes as shown in Fig 
3.1.   
 
  
Figure 3.1. Schematic diagram of capsular locus of serotype 2 strain D39, which was 
replaced by Janus cassette. It is 20kb in length and contains 18 genes.  Janus cassette, 
which was used to knock out capsule locus, was designed with flanking genes dexB and 
aliA. . Figure constructed using CLC Genomics workbench (CLC Bio, Denmark) 
 
 
Streptomycin resistant type 2 strain D39S was constructed from D39 and was 
transformed with Janus cassette to obtain unencapsulated mutant D39J.  The 
insertion of the cassette knocked out 20kb cps locus of D39S as schematically 
shown in Fig 3.2.   
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Figure  3.2.  Schematic diagram showing replacement of serotype 2 D39 capsule locus by 
Janus cassette.   
 
Other intermediate strains used for construction of capsule switching 403 Janus 
intermediate and TIGR4 Janus intermediate were kindly gifted by Professor Mark 
Lipsitch and Dr. Jeremy S. Brown respectively. 
3.2  Construction of capsule switch mutants 
Capsule switch mutants expressing serotype 2, 3 and 8 capsules were 
constructed in three different backgrounds.  These mutant strains and their 
intermediates constructed during the back crossing process are summarized in 
Tables 3.1, 3.2 and 3.3.    
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Table 3.1. Capsular switch mutants in TIGR4 background. 
 
Strains Description 
 
TIGR4
2
o TIGR4j derivative of kan-rpsL+ ::cps2 by transformation with D39 chromosomal DNA. Km
s
 Sm
r
. 
 
TIGR4
2
1x TIGR4j derivative of kan-rpsL+ ::cps2 by transformation with TIGR4
2
o chromosomal DNA. Km
s
 Sm
r
. 1x backcross transformant. 
 
TIGR4
2
 2x TIGR4j derivative of kan-rpsL+ ::cps2 by transformation with TIGR4
2
1x chromosomal DNA. Km
s
 Sm
r
. 2x backcross transformant. 
TIGR4
2
 3x TIGR4j derivative of kan-rpsL+ ::cps2 by transformation with TIGR4
2
2x chromosomal DNA. Km
s
 Sm
r
. 3x backcross transformant. 
TIGR4
3
o TIGR4j derivative of kan-rpsL+ ::cps3 by transformation with OXC141 chromosomal DNA. Km
s
 Sm
r
. 
 
TIGR4
3
1x TIGR4j derivative of kan-rpsL+ ::cps3 by transformation with TIGR4
3
o chromosomal DNA. Km
s
 Sm
r
. 1x backcross transformant. 
 
TIGR4
3
 2x TIGR4j derivative of kan-rpsL+ ::cps3 by transformation with TIGR4
3
1x chromosomal DNA. Km
s
 Sm
r
. 2x backcross transformant. 
TIGR4
3
 3x TIGR4j derivative of kan-rpsL+ ::cps3 by transformation with TIGR4
3
2x chromosomal DNA. Km
s
 Sm
r
. 3x backcross transformant. 
TIGR4
8
o TIGR4j derivative of kan-rpsL+ ::cps8 by transformation with ATCC6308 chromosomal DNA. Km
s
 Sm
r
. 
 
TIGR4
8
1x TIGR4j derivative of kan-rpsL+ ::cps8 by transformation with TIGR4
8
o chromosomal DNA. Km
s
 Sm
r
. 1x backcross transformant. 
 
TIGR4
8
 2x TIGR4j derivative of kan-rpsL+ ::cps8 by transformation with TIGR4
8
1x chromosomal DNA. Km
s
 Sm
r
. 2x backcross transformant. 
TIGR4
8
 3x TIGR4j derivative of kan-rpsL+ ::cps8 by transformation with TIGR4
8
2x chromosomal DNA. Km
s
 Sm
r
. 3x backcross transformant. 
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Table 3.2. Capsular switch mutants in D39 background. 
 Strains Description 
 
D39S D39 but Sm
r
 by transformation with streptomycin resistance cassette. Km
s
 Sm
r
 
D39j D39 but cps::kan-rpsL
+ 
Km
r
 Sm
s
 
D39
8
o D39j derivative of kan-rpsL+ ::cps8 by transformation with ATCC6308 chromosomal DNA. Km
s
 Sm
r
. 
 
D39
8
1x D39j derivative of kan-rpsL+ ::cps8 by transformation with D39
8
o chromosomal DNA. Km
s
 Sm
r
. 1x backcross transformant. 
 
D39
8
 2x D39j derivative of kan-rpsL+ ::cps8 by transformation with D39
8
1x chromosomal DNA. Km
s
 Sm
r
. 2x backcross transformant. 
D39
8
 3x D39j derivative of kan-rpsL+ ::cps8 by transformation with D39
8
2x chromosomal DNA. Km
s
 Sm
r
. 3x backcross transformant. 
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Table 3.3. Capsular switch mutants in 403 background. 
 Strains Description 
 
403
2
o 403j derivative of kan-rpsL+ ::cps2 by transformation with D39 chromosomal DNA. Km
s
 Sm
r
. 
 
403
2
1x 403j derivative of kan-rpsL+ ::cps2 by transformation with 403
2
ochromosomal DNA. Km
s
 Sm
r
. 1x backcross transformant. 
 
403
2
 2x 403j derivative of kan-rpsL+ ::cps2 by transformation with 403
2
1x chromosomal DNA. Km
s
 Sm
r
. 2x backcross transformant. 
403
2
 3x 403j derivative of kan-rpsL+ ::cps2 by transformation with 403
2
2x chromosomal DNA. Km
s
 Sm
r
. 3x backcross transformant. 
403
3
o 403j derivative of kan-rpsL+ ::cps3 by transformation with OXC141 chromosomal DNA. Km
s
 Sm
r
. 
 
403
3
1x 403j derivative of kan-rpsL+ ::cps3 by transformation with 403
3
o chromosomal DNA. Km
s
 Sm
r
. 1x backcross transformant. 
 
403
3
 2x 403j derivative of kan-rpsL+ ::cps3 by transformation with 403
3
1x chromosomal DNA. Km
s
 Sm
r
. 2x backcross transformant. 
403
3
 3x 403j derivative of kan-rpsL+ ::cps3 by transformation with 403
3
2x chromosomal DNA. Km
s
 Sm
r
. 3x backcross transformant. 
403
8
o 403j derivative of kan-rpsL+ ::cps8 by transformation with ATCC6308 chromosomal DNA. Km
s
 Sm
r
. 
 
403
8
1x 403j derivative of kan-rpsL+ ::cps8 by transformation with 403
8
o chromosomal DNA. Km
s
 Sm
r
. 1x backcross transformant. 
 
403
8
 2x 403j derivative of kan-rpsL+ ::cps8 by transformation with 403
8
1x chromosomal DNA. Km
s
 Sm
r
. 2x backcross transformant. 
403
8
 3x 403j derivative of kan-rpsL+ ::cps8 by transformation with 403
8
2x chromosomal DNA. Km
s
 Sm
r
. 3x backcross transformant. 
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The placement and the position of cps locus in mutants were confirmed in three 
steps. 
1. Redevelopment of kanamycin sensitivity with simultaneous reacquisition 
of streptomycin resistance. 
2. Quellung reaction and agglutination confirming the gain of particular 
capsule.  Agglutination is shown in Fig 3.3 
 
 
 
Figure 3.3. Agglutination reaction confirming presence of type 3 capsule in 403
3 
resulting 
from reaction with serotype 3 antiserum (Statens Serum Institute, Denmark). (A) Negative 
control showing 403
3
 in PBS. (B) Positive control showing serotype 3 mutant TIGR4
3
 mixed 
with antiserum. 
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Figure 3.3. Agglutination reaction confirming presence of type 3 capsule in 403
3 
resulting 
from reaction with serotype 3 antiserum (Statens Serum Institute, Denmark). (C) Test strain 
403
3 
mixed with antiserum.  Micrograph taken by Zeiss Acroscope Microscope at 40x. 
 
 
3.  PCR to confirm the presence and position of the cps locus were 
performed on each side, with one primer in the flanking region and other 
serotype specific primer within the capsule locus as shown in Figure 3.4 A 
and B (Schematic diagram in Section 2.1.2). 
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Figure 3.4. (A) Gel photo of PCR amplification for confirmation of transformation of serotype 
8 capsule in D39 showing a 2.5 kbp PCR fragment amplified with primers TTM05 and 
cps2AR confirming the position and placement of the left flank.  
Lane 1: 1 kb ladder 
Lane 2: PCR fragment from capsule donor strain ATCC6308 genomic DNA amplified with 
primer pairs TTM05 (dexB) and cps2AR (wzg). 
Lane 3: PCR fragment from recipient strain D39
8
 genomic DNA amplified with primer pairs 
TTM05 (dexB) and cps2AR (wzg) confirming identity of left flank in donor and recipient 
strains. 
Lane 4:  Positive control pneumolysin. 
Lane 5:  Negative control with no DNA. 
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Figure 3.4. (B) Gel photo of PCR amplification for confirmation of the transformation of type 
2 capsule in 403 showing approximately 2 kbp PCR fragment amplified with primers TTM06 
and rmlDF confirming position and placement of right flank along with confirmation of 
serotype.  
Lane 1: 1 kb ladder 
Lane 2: PCR fragment from capsule donor strain D39 genomic DNA amplified with primer 
pairs rmlDF (rmlD) present in serotype 2 capsule locus and TTM06 (aliA). 
Lane 3: PCR fragment from the recipient strain 403
2
 genomic DNA amplified with primer 
pairs rmlDF (rmlD) present in serotype 2 capsule locus and TTM06 (aliA). 
Lane 4:  Positive control pneumolysin 
Lane 5:  Negative control with no DNA. 
 
   
3.3 Capsule switch mutants:  
Capsular switch mutants were constructed in D39, TIGR4 and 403 to study 
effects of capsule switching on pneumococcal biology. 
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3.3.1 Type 2 capsule switch mutants: 
Type 2 capsule switch mutants were constructed in 403 and TIGR4 with genomic 
DNA extracted from D39.  The position of capsule was confirmed using primer 
sets as shown in Fig 3.5.    
 
  
Figure. 3.5. Schematic diagram of serotype 2 capsule locus.   The locus is approximately 
21kbp and consists of 17 genes.  Primers were designed to confirm presence and position 
of capsule along with the particular serotype.  
 
3.3.2 Type 3 capsule switch mutants: 
Type 3 capsule switch mutants were constructed in 403 and TIGR4 with genomic 
DNA extracted from OXC141.  These mutant forms large and mucoid colonies and 
could be identified with unaided eye (Fig 3.6). 
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Figure 3.6. Comparison of colony morphology 403,403
3 
and OXC141 grown on BAB plates 
supplemented with 5% Horse blood.   (A) 403
3 
(B) 403 (C) OXC141 
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Position of capsule was confirmed using primer sets as shown in Fig 3.7. 
 
Figure. 3.7. Schematic diagram of serotype 3 capsule locus.  The locus is 10 kbp and 
consists of 9 genes.  Primers were designed to confirm presence and position of capsule 
along with serotype 
 
3.3.3 TIGR4 type 8 capsular switch mutants: 
Type 8 capsule switch mutants were constructed in 403, TIGR4 and D39 using 
genomic DNA from serotype 8 strain ATCC6308.  These mutants also formed 
mucoid colonies and could be identified with unaided eye.  The capsule position 
was confirmed using serotype primer sets as shown in Fig 3.8.   
 
Figure 3.8. Schematic diagram of serotype 8 capsule locus.  The locus is 14 kbp and 
consists of 14 genes.  Primers were designed to confirm presence and position of capsule 
along with serotype. 
   
  
   86 
All type 8 mutants were observed to be forming longer chains as compared to 
parent strains as shown in Fig 3.9. 
 
Figure  3.9. Micrographs of strains associating in chains. (A) D39 diplococci (B) D39
8
 long 
chains (C) ATCC6308 long chains.  Micrograph taken with Zeiss Acroscope Microscope at 
40x. 
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These capsule switch mutants were used in a number of downstream 
experiments to study effect of capsule switching on various in vitro and in vivo 
pneumococcal characteristics.  
 
3.4 Discussion: 
Capsular switching has an important role in pneumococcal pathogenesis as it 
provides an opportunity for them to escape from effects of vaccines, which 
specifically target pneumococcal capsules.  Capsular switching events have been 
reported to occur in several studies as a result of environmental stresses 
(Croucher et al., 2011; Brueggemann et al., 2007). These events are among 
countless transformations, which occur in pneumococci and contribute towards 
their diversity.  Pneumococci may acquire other genes along with the capsule 
genes that may contribute to a particular phenotype (Croucher et al., 2011; 
Brueggemann et al., 2007).  Because of the possibility of the presence of 
multiple genetic fragments, analysis of capsule switching and its effects on 
pneumococcal biology in naturally occurring capsule switch mutants may be 
misleading, as otherwise otherwise isogenic mutants are required to study the 
effects of capsule switching.  These mutants were constructed with or without 
using Janus technique, within the same and different genetic backgrounds and 
their variation in growth, colonization and virulence was studied (Trzcinski et 
al., 2004; Kelly et al., 1994).  One of the studies reported that the type of 
capsule and genetic background both are important for pathogenesis and 
capsular switching may or not increase pathogenicity of the organism, though 
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the study was done in different genetic backgrounds (Kelly et al., 1994).  
Another study showed that type of capsule affects the rate of growth and 
capsule switch mutants could colonize mouse nasopharynx but did not describe 
the effects of capsule switching on virulence (Trzcinski et al., 2003).   
Available literature also shows that naturally occurring capsule switching is more 
frequently reported for certain sequence types while a lot of others show more 
stable populations (Hanage et al., 2005; Jefferies et al., 2004).  It is not clear 
whether capsule switching is only limited to certain clones or if it is a more 
widespread phenomenon.  There is a possibility that switching capsule to certain 
types could grossly affect phenotype and reduce virulence, which might limit its 
spread and further propagation in the population as correlation of capsule type 
with in vitro growth rate has been reported, which itself is related to property 
of the strains being carriage or invasive (Battig et al., 2006)  
To study these processes in detail capsular switch mutants were constructed in 
three different back grounds, which could be compared with one another for a 
number of in vivo and in vitro characteristics and possible use as a live 
attenuated vaccine.   
Though characterization of these mutants is discussed in the next chapter in 
detail some striking differences were observed in the mutants expressing 
different capsular types.  All the serotype 8 mutants, regardless of their genetic 
background were found to be associating in long chains of about 20 
pneumococci.  This behaviour was similar to the capsule donor strain ATCC6308, 
which tends to form long chains and is a highly virulent strain.  Long chains have 
been associated with certain mutations (Barendt et al., 2009) and have been 
reported to favour colonization (Rodriguez et al., 2012).  It has also been 
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reported that pneumococci and other streptococci form very long chains when 
they are grown in immune serum (Ekstedt & Stollerman, 1960) and shorter chains 
are more suitable for invasive phenotype (Dalia et al., 2012).  Though the chain 
length might have an association with the invasiveness of strains but the in vivo 
behaviour has not been reported in the literature. 
Another remarkable feature was noted in TIGR42, which formed colonies which 
resembled unencapsulated pneumococci.  There is a possibility that due to the 
difference in the biochemical structure of serotype 2 and serotype 4 capsules 
TIGR42 is unable to sythesize enough capsular polysaccharide. 
TIGR43 and 4033 were found to phenotypically similar to their capsule donor 
strains OXC141, as compare to the parent strains, which might be due to the 
simple structure of serotype 3 capsule and relatively short cps locus of only 
10kb.  There is a possibility that it can be easily incorporated in other serotypes 
but it has been reported to affect different serotype backgrounds differently as 
Kelly and co-workers reported it to be detrimental to the serotype 5 and 
serotype 6B strains while Nesin and co-workers observed it to be beneficial for 
serotype 23F as it increased the virulence of the recipient strain. 
The effect of capsule switching on pneumococcal biology can be found in the 
following chapter which also includes a detailed discussion on capsule switch 
mutants previously used in different experiments.   
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4 Effect of capsule on pneumococcal biology 
The capsule is an important virulence factor for pneumococci. It has at least 93 
serotypes, which are structurally different from each other (Calix & Nahm, 2010; 
Park et al., 2007; Bentley et al., 2006).  Pneumococci have the ability to switch 
their capsule, which is clinically important as it may result in failure of current 
pneumococcal vaccines that target the polysaccharide capsule.  The biological 
process of capsule switching is not understood very clearly as it is not known if 
capsule switching is a universal phenomenon or if it can occur only with certain 
serotypes and certain genetic backgrounds and whether all genetic backgrounds 
can express all types of capsules.  To study effects of capsule switching on 
pneumococcal biology, experiments were performed to observe effects of 
different capsules on same and different genetic backgrounds. 
4.1 Effect of capsule switching on pneumococcal growth:   
Pneumococcal growth in vitro, especially length of lag phase, has been observed 
to be associated not only with capsule serotype but also with the virulence of 
pneumococcal strains (Battig et al., 2006).  Capsule type has been reported to 
affect pneumococcal growth (Hathaway et al., 2012), while deletion of capsule 
genes have also been reported to extend duration of lag phase of growth in vitro 
(Battig & Muhlemann, 2007).  Capsule switch mutants were studied for effect of 
different capsules in isogenic backgrounds TIGR4 and 403 by using viable counts 
as indicator of growth and no differences were found in the duration of lag phase 
of parent strains and capsule switch mutants (Fig4.1).   
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Figure 4.1 Length of lag phase of capsule switch mutants measured by viable counts using 
three replicate experiments under identical conditions starting with 10
5 
cfu.  Red arrow 
marks the end of lag phase in growth curve. Growth curves plotted in Graph pad Prism 
(GraphPad Prism 4.0, USA). 
(A) Similar duration of lag phase in serotype 4 virulent strain TIGR4 and its capsule switch 
mutants. 
TIGR4
2
: Otherwise isogenic TIGR4 capsule switch mutant expressing serotype 2 capsule
 
TIGR4
3
: Otherwise isogenic TIGR4 capsule switch mutant expressing serotype 3 capsule 
TIGR4
8
: Otherwise isogenic TIGR4 capsule switch mutant expressing serotype 8 capsule 
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The statistical analysis of the slopes of growth curves also did not show any 
difference in the log phase of growth between capsule switch mutants and TIGR4 
as summarized in Table 4.1. 
Table 4.1.  Linear Regression analysis of the slope of the curve during the log phase of growth in 
TIGR4 and the capsule switch strains 
Strain Slope 
10
8
 
95% confidence 
interval 
10
8
 
P values versus 
TIGR4 
TIGR4 6.11 2.03-10.2  
TIGR4
2
 6.18 2.66-9.69 0.5216 
TIGR4
3
 5.94 2.34-9.55 0.8995 
TIGR4 
8
 7.08 4.93-9.22 0.4459 
 P1672 5.42 3.14-7.69 0.5932 
 
Analysis performed with GraphPad Prism 4.0, USA) 
TIGR4: Virulent type 4 strain 
TIGR4
2
: Otherwise isogenic TIGR4 capsule switch mutant expressing serotype 2 capsule.
 
TIGR4
3
: Otherwise isogenic TIGR4 capsule switch mutant expressing serotype 3 capsule. 
TIGR4
8
: Otherwise isogenic TIGR4 capsule switch mutant expressing serotype 8 capsule. 
P1672: Unencapsulated TIGR4   
 
The extension of lag phase with deletion of capsule, as has been reported for 
strain D39 (Battig & Muhlemann, 2007) was also not seen in case of capsule 
knock out strain of TIGR4 (P1672).  Comparison of un-encapsulated TIGR4 
retransformed with serotype 4 capsule (P1702) also did not show any difference 
in growth pattern of the two strains (Fig4.2). 
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Figure 4.2 Comparison of the length of lag phase of capsule in TIGR4, unencapsulated 
TIGR4 (P1672) and TIGR4 retransformed with serotype 4 capsule. Curves were plotted using 
viable counts. Red arrow shows end of lag phase.  Data were plotted in Graph Pad Prism. 
(GraphPad Prism 4.0, USA). 
 
4.2 Effect of capsule switching on capsule-thickness: 
TIGR4, D39 and their capsule switch mutants were studied under electron 
microscope Leo 912AB (Leo, USA) to observe structural details of capsules of 
parent strains and their capsule switch mutants. Electron micrographs are shown 
in Fig 4.3. 
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Figure 4.3. Transmission Electron micrographs showing capsule switch, capsule donor and 
unencapsulated strains obtained with electron microscope Leo 912AB (Leo, USA).  
(A) Serotype 4 virulent strain TIGR4.  
(B) Serotype 2 virulent strain D39   
(C) Serotype 3 virulent strain OXC141  
(D) Serotype 8 virulent strain ATCC6308 
(E)  TIGR4 retransformed with serotype 4 capsule P1702  
(F)TIGR4
2
: Otherwise isogenic TIGR4 capsule switch mutant expressing serotype 2 capsule.
 
(G) TIGR4
3
: Otherwise isogenic TIGR4 capsule switch mutant expressing serotype 3 
capsule.
 
(H) TIGR4
8
: Otherwise isogenic TIGR4 capsule switch mutant expressing serotype 8 
capsule.
 
(I)P1672:  Capsule knock out strain TIGR4. 
(J) D39j: Capsule knock out strain D39. 
(K) D39
8
: Otherwise isogenic D39 capsule switch mutant expressing serotype 8 capsule. 
 
TIGR4 strain retransformed with serotype 4 capsule (P1702) was used as positive 
control to see if switching capsule and replacing it back with same type of 
capsule has any effect on pneumococcal capsule formation, while capsule knock 
out strains from D39 and TIGR4 were used as negative controls.   
K 
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Mean capsular thickness was calculated from measuring completely extended 
capsular fibres at 3-7 points/bacterium in five bacteria. Measurements were 
taken using image processing software iTEM (Olympus Soft Imaging Solutions, 
Germany) on areas where cell wall boundaries could be traced easily. 
Measurements taken on TIGR4 and P1702 showed that thickness of type 4 
capsule was the same as P1702 and there was no significant difference between 
them (Fig 4.4). 
 
Figure 4.4. Comparison of measurements of capsule thickness in virulent type 4 strain 
TIGR4 and TIGR4 retransformed with serotype 4 capsule P1702. Data plotted as a bar graph.  
Bars represent the mean ± SEM.  Unpaired t-test showed (GraphPad Prism 4.0, USA) that 
there was no significant difference in capsular thickness in TIGR4 and P1702. (Number of 
measurements TIGR4=29, P1702= 25)    
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TIGR4 expressing serotype 2 capsule showed significantly reduced capsule, which 
was thinner than both capsule donor serotype 2 strain D39 and parent TIGR4.  It 
was also compared with capsule knock out strain P1672 to see whether capsule 
formation was taking place or not, which showed some capsule formation in 
TIGR42 (Fig 4.5). 
 
Figure 4.5. Comparison of the measurements of capsular thickness in serotype 4 virulent 
strain TIGR4, serotype 2 virulent strain D39, Capsule knock-out P1672 and otherwise 
isogenic TIGR4 expressing serotype 2 capsule TIGR4
2
. Data plotted as a bar graph.  Bars 
represent mean ± SEM.  Unpaired t-test showed (GraphPad Prism 4.0, USA) that TIGR4
2
 
capsule was significantly thinner than TIGR4 (p<.0001) and D39 (p<.0001) while was 
significantly thicker than the unencapsulated strain P1672 (p<.0003). (Number of 
measurements TIGR4=29, D39=14, P1672=19 TIGR4
2
=28)    
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TIGR4 expressing serotype 3 and serotype 8 capsules also formed reduced 
capsules which were thinner than both parent and capsule donors (Fig 4.6).   
 
 
 
 
 
 
 
Figure 4.6. (A) Comparison of measurements of capsular thickness in serotype 4 virulent 
strain TIGR4, capsule donor and otherwise isogenic mutant strains. Comparison of capsular 
thickness in TIGR4, serotype 3 virulent strain OXC141 and otherwise isogenic TIGR4 
expressing serotype 3 capsule TIGR4
3
. Unpaired t-test showed (GraphPad Prism 4.0, USA) 
significant difference (p<.0001) while comparing TIGR4
3
 with TIGR4 and TIGR4
3
 with 
OXC141. (Number of measurements TIGR4=29, TIGR4
3
=40, OXC141=11) 
 
 
 
 
 
 
  
   103 
 
 
 
 
 
 
 
Figure 4.6. (B) Comparison of measurements of capsular thickness in serotype 4 virulent 
strain TIGR4, capsule donor and otherwise isogenic mutant strains. Comparison of capsular 
thickness in TIGR4, serotype 8 virulent strain ATCC6308 and otherwise isogenic TIGR4 
expressing type 8 capsule TIGR4
8
.  Unpaired t-test (GraphPad Prism 4.0, USA) showed 
significant difference (p<.0001) while comparing TIGR4
8
 with TIGR4 and and TIGR4
8
 with 
ATCC6308. Data plotted as bar graphs.  Bars represent the mean ± SEM. (Number of 
measurements TIGR4=29, TIGR4
8
=40, ATCC6308=23) 
  
 
When type 8 capsule was expressed in a D39 background it was observed that 
thickness of serotype 8 capsule being expressed in serotype 2 background was 
same as compared with the capsule donor strain ATCC 6308 (Fig 4.7). 
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Figure 4.7. Comparison of measurements of capsular thickness in serotype 2 virulent strain 
D39, serotype 8 virulent strain ATCC6308 and otherwise isogenic D39 expressing serotype 8 
capsule D39
8
. Unpaired t-test showed (GraphPad Prism 4.0, USA) no significant difference 
between the capsular thickness of D39
8 
when compared with D39 and ATCC6308. Data 
plotted as bar graphs.  Bars represent the mean ± SEM.  (Number of measurements 
TIGR4=29, D39
8
=19, ATCC6308=23) 
 
  
   105 
On comparison of thickness of serotype 8 capsule in different backgrounds, it 
was observed that serotype 8 was thicker in D39 background as compared to 
TIGR4 background (Fig 4.8). 
 
Figure 4.8. Comparison of measurements of capsular thickness in otherwise isogenic TIGR4 
expressing serotype 8 capsule TIGR4
8
, otherwise isogenic D39 expressing serotype 8 
capsule D39
8
 and serotype 8 virulent strain ATCC6308.  In
 
D39
8
, the capsule is much thicker 
than TIGR4
8
.  Unpaired t-test showed (GraphPad Prism 4.0, USA) significant difference 
(p<.0001) between capsule thickness of D39
8 
when compared with TIGR4
8
.  Data plotted as 
bar graphs.  Bars represent the mean ± SEM.  (Number of measurements TIGR4
8
=40, 
D39
8
=19, ATCC6308=23) 
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4.3 Capsular polysaccharide in capsule switch strains: 
Semi-quantitative Stains-All Assay was performed with Stains-All (Sigma-Aldrich, 
UK) and relative amount of capsular polysaccharide was measured.  Calculated 
value for 109 cfu showed significant differences in capsule formation in different 
capsule switch strains.  
It was observed that there was no difference in TIGR4 and TIGR4 strain replaced 
with type 4 capsule (Fig 4.9).  
 
Figure 4.9. Comparison of measurements of capsular polysaccharide for 10
9 
cfu by Stains-
All Assay of virulent serotype 4 strain TIGR4 and TIGR4 replaced with serotype 4 capsule 
P1702 using 3 replicate experiments for each.  Unpaired t-test showed (GraphPad Prism 4.0, 
USA) no significant difference between the two strains. Data plotted as bar graphs.  Bars 
represent the mean ± SEM.   
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There was significant difference between TIGR4 and TIGR42 while no detectable 
difference was observed in TIGR4 and its mutants expressing serotype 3 and 
serotype 8 capsules (Fig 4.10). 
 
Figure 4.10. Comparison of measurements of capsular polysaccharide for 10
9 
cfu by Stains-
All Assay in TIGR4 and capsule switch strains. otherwise isogenic TIGR4 strain expressing 
serotype 2 capsule TIGR4
2
, otherwise isogenic TIGR4 strain expressing serotype 3 capsule 
TIGR4
3
 and otherwise isogenic TIGR4 strain expressing type 8 capsule TIGR4
8
 using 3 
replicate experiments for each.  Unpaired t-test (GraphPad Prism 4.0, USA) shows 
significant difference (p<.005) between TIGR4 and TIGR4
2
.  Data plotted as bar graphs.  Bars 
represent mean ± SEM. 
 
On comparison of D39 and D398 it was observed that amount of capsular 
polysaccharide was significantly higher in D398 as compared to parent strain D39 
(Fig 4.11). 
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Figure 4.11. Comparison of measurements of capsular polysaccharide for 10
9 
cfu by Stains-
All Assay of virulent serotype 2 strain D39 and otherwise isogenic D39 expressing serotype 
8 capsule D39
8
 using 3 replicate experiments for each.  Unpaired t-test (GraphPad Prism 4.0, 
USA) shows significant difference between the two strains (p<.0001). Data plotted as bar 
graphs.  Bars represent the mean ± SEM.   
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4.4 Chain formation: 
It has been known for a very long time that S. pneumoniae is most commonly 
found in short chains and pairs. This phenomenon of chain formation has been 
studied in Group A streptococci and pneumococci for about half a century in the 
past and certain factors were reported to be affecting their chain length 
including temperature and pH (Ekstedt & Stollerman, 1960). Some pneumococcal 
and other streptococcal mutants have also been reported to be forming longer 
chains (Locke et al., 2007; Sanches-Puelles et al., 1986; Tomasz, 1968).  It has 
also been reported that growth in the presence of immune serum results in 
increase in chain length in different streptococcal groups (Stewardson-Krieger et 
al., 1977;Ekstedt & Stollerman, 1960). Relationship of longer chains with 
pneumcococcal virulence have also been described recently and it was shown 
that smaller chains are associated with increased virulence (Dalia & Weiser, 
2011). In capsule switch mutants it was noted that mutants expressing type 8 
capsule in TIGR4 and other backgrounds formed longer chains than TIGR4 itself. 
This phenomenon was observed in all serotype 8 strains, regardless of their 
virulence potential (Fig 4.12). 
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Figure 4.12. Chain formation in virulent serotype 4 strain TIGR4 and its otherwise isogenic 
capsule switch mutant expressing serotype 8 capsule TIGR4
8
.  TIGR4 organizes in smaller 
chains as compared to TIGR4
8
. Unpaired t-test (GraphPad Prism 4.0, USA) shows (A)  The 
number of bacteria forming short chains is significantly higher in TIGR4 (p<.0001).  (B)  
Number of bacteria forming medium sized chains is significantly higher in TIGR4
8 
(p<.0013).   
 
 
 
 
A 
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Figure 4.12. Chain formation in virulent serotype 4 strain TIGR4 and its otherwise isogenic 
capsule switch mutant expressing serotype 8 capsule TIGR4
8
.  TIGR4 organizes in smaller 
chains as compared to TIGR4
8
. (C)  Number of bacteria associating in long chains is 
significantly higher in TIGR4
8 
(p<.0001). Data plotted as bar graphs.  Bars represent mean ± 
SEM. 
 
 
 
 
 
 
Similar behaviour was observed in D398 as D398 formed longer chains as 
compared to the parent strain D39, which tend to form short chains (Fig 4.13).  
4038  also showed the same behaviour (data not shown). 
 
 
 
C 
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Figure 4.13. Chain formation in serotype 2 virulent strain D39 and its capsule switch mutant 
expressing serotype 8 capsule D39
8
.  D39 organizes in smaller chains as compared to D39
8
. 
Unpaired t-test (GraphPad Prism 4.0, USA) shows (A)  Number of bacteria associating in 
short chains is significantly higher in D39 (p<.0001).  (B)  Number of bacteria associating in 
medium sized chains is significantly higher in D39
8 
(p<.0001).   
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Figure 4.13. Chain formation in serotype 2 virulent strain D39 and its capsule switch mutant 
expressing serotype 8 capsule D39
8
.  D39 organizes in smaller chains as compared to D39
8
. 
Unpaired t-test (GraphPad Prism 4.0, USA) shows (C) Number of bacteria associating in long 
chains is significantly higher in D39
8 
(p<.0001). Data plotted as bar graphs.  Bars represent  
mean ± SEM. 
 
 
On studying behaviour of parents it was observed that these strains 
phenotypically resemble serotype 8 strain ATCC6308, which formed longer chains 
as compared to shorter chains of D39 and TIGR4 (Fig 4.14). 
 
 
 
  
   114 
 
Figure 4.14.  Percentage of bacteria organizing in different types of chains in parent strains.  
(A,B) Serotype 4 virulent strain TIGR4 and seroype 2 virulent D39 organize in smaller chains 
(C) Serotype 8 virulent strain ATCC6308 associates in medium and longer chains. Data 
plotted as bar graphs.   
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4.5 Transformation Efficiency: 
Pneumococci are naturally transformable bacteria and this transformability plays 
an important role in spread of antibiotic resistance, capsular switching and 
transfer of other important pathogenic factors.  Development of competence is a 
complex phenomenon involving multiple factors (Johnsborg & Havarstein, 2009) 
and develops for only a very short period during in vitro growth (Claverys et al., 
2006).  Although effect of antibiotics and stress (Johnsborg & Havarstein, 2009; 
Prudhomme et al., 2006; Claverys et al., 2006) is known to effect competence of 
pneumococci but no data is available on effect of capsule type or thickness on it 
though it can be assumed that capsule type, its charge, its thickness or density 
may have effects on bacterial competence due to physical hindrance. 
To study effects of capsular type, TIGR4 and its capsule switch mutants were 
compared for transformation efficiency using plasmid pVA838 and selecting for 
erythromycin resistance.    
Since capsule switching experiments involve selection for mutants which have 
been transformable and have picked up capsule genes, there is a chance that 
subset of population selected after three back-crosses is the most competent 
one as competence varies among the bacteria (Chen & Morrison, 1987), this 
method may lead to bias in results if the comparisons are made with parent 
TIGR4 instead of P1702 (TIGR4 backcrossed with type 4 capsule).  
To confirm the above assumption transformation assays were performed in TIGR4 
and P1702 and they were found to differ significantly from each other (Fig 4.15). 
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Figure 4.15. Comparison of transformation efficiency between serotype 4 virulent strain 
TIGR4 and TIGR4 retransformed with serotype 4 capsule P1702.  Unpaired t-test (GraphPad 
Prism 4.0, USA) showed significant difference between the two strains (p<.0001). Data 
plotted as bar graphs.  Bars represent mean ± SEM.   
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To study effects of capsule on transformation efficiency all comparisons were 
performed with P1702 strain (Fig 4.16).  
 
 
Figure 4.16. Comparison of transformation efficiency between virulent serotype 4 strain 
TIGR4, TIGR4 retransformed with serotype 4 capsule P1702, otherwise isogenic TIGR4 
expressing serotype 2 capsule TIGR4
2
, otherwise isogenic TIGR4 expressing serotype 3 
capsule TIGR4
3
 and otherwise isogenic TIGR4 expressing type 8 capsule TIGR4
8
.  Unpaired 
t-test (GraphPad Prism 4.0, USA) shows significant difference between P1702 and other 
capsule switch strains. TIGR4
2
 is significantly more transformable than P1702 (p<.03).  
While TIGR4
3
 and TIGR4
8
 are significantly less transformable than P1702 (p<.0001). Data 
plotted as bar graphs.  Bars represent the mean ± SEM.   
 
Correlation studies (GraphPad Prism 4.0, USA) showed that transformation 
efficiency in capsule switch mutants was not correlated with capsule thickness 
(Pearson’s R2 0.07, p = 0.72) or amount of capsule associated polysaccharide 
(Pearson’s R2 0.27, p = .48). 
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4.6 Virulence: 
To study virulence of capsule switch strains and to compare it with their 
parents, parent and capsule donor strains were initially tested in mouse models 
of intraperitoneal infection.  Infection studies with 105 cfu showed marked 
differences between four strains.   Median survival time for mice infected with 
ATCC6308 was 13 hrs, TIGR4 was 21 hrs, OXC141 was 21 hrs and D39 was 23 hrs 
(Fig 4.17). 
 
 
 
 
Figure 4.17.  Virulence of capsule donor and parent strains. Kaplan-Meier curve showing 
survival of mice infected intraperitoneally with 10
5 
cfu virulent serotype  2 strain D39, 
virulent serotype 3 strain OXC141, virulent serotype 8 strain ATCC6308 and virulent 
serotype  4 strain TIGR4,  All data plotted as percentage survival as a staircase line with 
points for all observations against hrs post infection. Five mice used per strain. 
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To study whether capsule switching has any effect on virulence, low doses of 
TIGR4 and P1702 were compared against each other, which showed no 
difference in virulence of the two strains (Fig 4.18). 
  
 
 
 
Figure 4.18.  Virulence of serotype 4 virulent strain TIGR4 and TIGR4 retransformed with 
P1702. Kaplan-Meier curve showing survival of mice infected with 10
3 
cfu
 
TIGR4 and P1702 
intraperitoneally.  All data plotted as percentage survival as a staircase line with points for 
all observations against hrs post infection.  Survival analysis showed there was no 
significant difference in survival time between the two groups by log rank test. All data 
plotted as percentage survival as a staircase line with points for all observations against hrs 
post infection. Five mice used per strain. 
 
 
Mice infected with TIGR42 showed no sign of infection and survived till the end 
of experiment (Fig 4.19). 
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Figure 4.19.  Virulence of serotype 4 virulent strain TIGR4, otherwise isogenic TIGR4 
expressing serotype 2 capsule TIGR4
2
 and serotype 2 virulent strain D39. Kaplan-Meier 
curve showing survival of mice infected intraperitoneally with 10
5
 cfu.  All data plotted as 
percentage survival as a staircase line with points for all observations against hrs post 
infection.  Survival analysis showed there was a significant difference in survival time 
between the two groups by log rank test. Five mice used per strain. 
 
 
TIGR43 showed marked attenuation (p=.002) as compared to TIGR4 and capsule 
donor strain OXC141.  Median survival time in mice infected with TIGR43 was 37 
hrs as compared to 21 hrs in those infected with TIGR4 (Fig 4.20).  
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Figure 4.20.  Virulence of serotype 4 virulent strain TIGR4, virulent strain OXC141 and 
otherwise isogenic TIGR4 strain expressing serotype 3 capsule. Kaplan-Meier curve 
showing survival in mice infected with 10
5
 cfu intraperitoneally.  Survival curve in mice 
infected with TIGR4
3 
showed marked attenuation as compared to the capsule donor and the 
parent strain.  All data plotted as percentage survival as a staircase line with points for all 
observations against hrs post infection.  Survival analysis showed there was a significant 
difference in the survival time between the TIGR4 and TIGR4
3
 by log rank test (p=.002). Five 
mice used per strain. 
 
TIGR48 also showed marked attenuation (p=.002) as compared to TIGR4 and 
capsule donor strain ATCC6308.  Median survival time in mice infected with 
TIGR48 was 78 hrs as compared to 21 hrs in those infected with TIGR4 (Fig 4.21). 
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Figure 4.21.  Virulence of serotype 4 virulent strain TIGR4, serotype 8 virulent strain 
ATCC6308 and otherwise isogenic TIGR4 strain expressing serotype 8 capsule TIGR4
8.
 
Kaplan-Meier curve showing
 
survival of
 
in mice infected with 10
5 
cfu intraperitoneally. 
Survival curve of TIGR4
8 
showed marked attenuation as compared to capsule donor and 
parent strains.  All data plotted as percentage survival as a staircase line with points for all 
observations against hrs post infection.  Survival analysis showed there was a significant 
difference in the survival time between TIGR4 and TIGR4
8
 by log rank test (p=.002). Five 
mice used per strain. 
 
 
D398 expressing type 8 capsule in D39 background showed a markedly different 
behaviour than TIGR4 as D398 showed a very high virulence, which was similar to 
ATCC6308 as compared to D39 and mice infected with D398 showed same median 
survival time as those infected with ATCC6308 (13 hrs) as compared to those 
infected with D39 (23 hrs) (Fig 4.22).   
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Figure 4.22.  Virulence of serotype 2 virulent strain D39, serotype 8 virulent strain ATCC6308 
and otherwise isogenic D39 expressing serotype 8 capsule D39
8 
in mice infected with 10
5 
cfu 
intraperitoneally. Kaplan-Meier curve showing survival of D39
8 
showed marked increase in 
the virulence as compared to the parent strain D39.  All data plotted as percentage survival 
as a staircase line with points for all observations against hrs post infection.  Survival 
analysis showed there was a significant difference in the survival time between the mice 
infected with D39 and those with D39
8
 by log rank test (p=.002). Five mice used per strain. 
 
 
4.7 Adaptability of the capsule-switch strains: 
It is well-known that animal passage increases virulence of bacteria as passaged 
bacteria are generally used to infect animal models as standard inoculum 
(Saladino et al., 1997; Canvin et al., 1995).  Bacteria, while infecting animals, 
have been reported to differentially express their virulence factors including 
capsular genes (LeMessurier et al., 2006; Ogunniyi et al., 2002; Mahdi et al., 
2008). Pneumococcal capsule has also been reported to be differentially 
regulated during different stages of pathogenesis (Hammerschmidt et al., 2005) 
and highly encapsulated bacteria were found to be highly virulent (Kim & 
Weiser, 1998).   
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To test the adaptability of capsule switch strains, those recovered from animals 
were reused to infect a new set of animals to see if their virulence can reach the 
virulence-level of TIGR4 strains.  It was observed that there was significant 
increase in virulence of animal-passaged strains but they still remained less 
virulent than TIGR4 (Fig 4.23 and 4.24).   
 
Figure 4.23  Virulence of serotype 4 virulent strain TIGR4, animal passaged otherwise 
isogenic TIGR4 strain expressing type 3 capsule  TIGR4
3
A and otherwise isogenic TIGR4 
strain expressing serotype 3 capsule TIGR4
3
. Kaplan-Meier curve showing survival in mice 
infected with 10
5 
cfu intraperitoneally.  Survival curve of TIGR4
3
A showed marked increase 
in the virulence as compared to TIGR4
3
.  All data plotted as percentage survival as a 
staircase line with points for all observations against hrs post infection.  Survival analysis 
showed there was a significant difference in survival time between mice infected with 
TIGR4
3 
and TIGR4
3
A (p=.002) and those with TIGR4
 
and TIGR4
3
A (p=.002) by log rank test. 
Five mice used per strain. 
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Figure 4.24 Virulence of serotype 4 virulent strain TIGR4, animal passaged otherwise 
isogenic TIGR4 strain expressing serotype 8 capsule TIGR4
8
A and otherwise isogenic 
TIGR4 strain expressing type 8 capsule TIGR4
8
 in mice infected with 10
5 
cfu 
intraperitoneally.  Kaplan-Meier curve showing survival of TIGR4
8
A showed marked increase 
in virulence as compared to TIGR4
8
.  All data plotted as percentage survival as a staircase 
line with points for all observations against hrs post infection.  Survival analysis showed 
there was a significant difference in survival time between mice infected with TIGR4
8 
and 
TIGR4
8
A (p=.001) and those with TIGR4
 
and TIGR4
8
A (p=.002) by log rank test. Five mice 
used per strain. 
 
 
4.8 Discussion: 
Capsule switching is an important evolutionary process in pneumococci, which 
allows them to change and adapt according to environmental pressures.  In the 
current era of intercontinental travel, pneumococcal vaccines and widely 
available effective antibiotics, it has become an extremely important tool for 
them to spread globally as it not only allows them to escape from effects of 
natural immunity and vaccines but also helps in spread of drug-resistant strains 
across the globe.   
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Since different capsules have different chemical composition and sugars needed 
for their construction have to be supplied by the metabolic and transport 
machinery of the pneumococcus (Bentley et al., 2006), there is a possibility that 
pneumococci of all genetic backgrounds cannot express all types of capsular 
polysaccharides and it is only possible for certain types to accept and express 
few different capsular types. Capsule switching events are frequent and may 
occur as a response to environmental stresses (Golubchik et al., 2012; Croucher 
et al., 2011; Brueggemann et al., 2007) and are mainly facilitated by high 
homology of up-stream and downstream regions across the capsule, as the 
capsule locus is located between two genes called dexB and aliA (Bentley et 
al.,2006).  It is already known that there are gross differences in the genetic 
constitution of capsule locus and biochemical structure of capsular 
polysaccharide of different serotypes (Bentley et al., 2006). Many studies 
indicate that these differences may be related to their virulence, their 
interaction with the host and many in vitro and in vivo characteristics as the 
capsule is one of the major determinants of pneumococcal biology (Hyams et al., 
2010; Battig & Muhlemann, 2007; Sandgren et al., 2004; Sjostrom et al., 2006; 
Hausdorff et al., 2000a; Hausdorff et al., 2000b; Kelly et al., 1994).  Capsule 
switching has been reported more frequently in some specific genetic 
backgrounds, which have altered their capsule type more than once and have 
spread across the globe whereas in some serotypes switching has not been 
reported such as serotype 1 (Croucher et al., 2011; Coffey et al., 1998b; Munoz 
et al., 1991). 
All strains used in these experiments have been genome sequenced except 
ATCC6308, which will be sequenced by our lab in the near future.  They were 
chosen in order to maximize observations on pneumococcal diversity by selecting 
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strains of different virulence, having different in the size of capsule locus as all 
of them demonstrate differences in all these categories.  These differences can 
be summarized in Table 4.2: 
Table 4.2. Characteristics of Parent and capsule donor strains 
Strain Cps Locus size Median Survival Time of Mice infected with 10
5 
IP   
TIGR4  20.9 kbp 21 hrs 
D39 21.6 kbp 23 hrs 
OXC141 10.7 kbp 21 hrs 
ATCC6308. 14.4 kbp 13 hrs 
   
 
The biochemical structure of the capsular polysaccharide of these strains is also 
different and is summarized in Table 4.3.  
Table 4.3. Capsule constitution of parent and capsule donor strains 
Strain Capsule Constitution  
TIGR4   Galactose, N-Acetyl mannosamine, N- Acetyl 
fucosamine, N Acetyl galactosamine 
21 hrs 
D39    Glucuronic Acid, Glucose and Rhamnose 
23 hrs 
OXC141 
 
 
 
 
OXC141 
   Glucuronic Acid, Glucose 
ATCC6308.    Glucuronic Acid, Glucose, Galactose, 
  
 
A number of studies have previously used capsule switch strains and their 
findings have significantly contributed to understanding of biology of capsule 
switching. Kadioglu et al. (2002) and Abeyta et al. (2003) have used a D39 
mutant expressing type 3 capsule.  Kadioglu et al. (2002) used an otherwise 
isogenic D39 FP50 expressing serotype 3 capsule, which was PCR amplified from 
virulent strain A66 and inserted using homologous recombination with kanamycin 
cassette.  They reported that infectivity of strains was affected by both serotype 
and genetic background in a site-dependent manner as A66 and the mutant 
behaved similarly in nasopharynx, while the mutant was also cleared easily from 
lungs as compared to the wild type.  Capsule-switch mutant was also found to be 
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avirulent in case of intranasal infection (Kadioglu et al., 2002).  Abeyta et al. 
(2003)  used a D39 expressing serotype 3 capsule JD803, which was constructed 
by transforming D39 with serotype 3 genomic DNA from a strain containing 
erythromycin resistance marker inserted within capsule locus (Abeyta et al., 
2003). They reported that mutant showed increased deposition of C3b as 
compared to serotype 3 wild type strain, though it was less than D39 (Abeyta et 
al., 2003).  These findings are also supported by recent studies using multiple 
capsule switch strains of TIGR4 (Melin et al., 2010).  D39 expressing serotype 3 
mutant was also reported to be similar in virulence as compared to D39 in both 
intraperitoneal and intravenous infection (Kelly et al., 1994).  A similar type 5 
mutant expressing type 3 capsule was reported to be avirulent as compared to a 
type 6 mutant expressing type 3 capsule, whose virulence increased as compared 
to parent type 6 strain (Kelly et al., 1994).  Though it is difficult to compare 
these mutants as they were not isogenic though it can be inferred that both 
genetic background and capsule contribute towards virulence, and infectivity 
may be site-specific.  Two studies have also used spontaneously arising capsular 
switch strains.  Nesin et al. (1998) using naturally switched 23F strains 
expressing type 3 capsule reported that virulence was affected by capsule type 
as these mutants were lethal as compared to parent 23F which were non-lethal 
even at high doses using intraperitoneal route of infection.  Another study using 
a serotype 14 strain and its naturally switched mutant expressing type 9V 
capsule did not find any difference in virulence of the two strains using 
intranasal route of infection (Mizrachi Nebenzahl et al., 2004).   During this 
study, instead of using non-isogenic strains or naturally occurring capsular switch 
strains, mutant strains were constructed in isogenic background as described 
earlier (Trzcinski et al., 2003).  These strains can be considered more reliable as 
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the chances of genetic variation are less as compared to naturally occurring 
capsule switch strains, which might harbour other small mutations.  
In this study, using capsule switch mutants, the effect of capsule was studied on 
a number of biological properties of pneumococcus including growth, chain 
formation, transformability and virulence.   
Since capsule incurs a considerable metabolic cost, it was proposed earlier that 
the capsule effects pneumococcal growth in vitro. In contrast to previous 
research which indicates that unencapsulated strains grow slower than 
encapsulated strains (Battig & Muhlemann, 2007) capsule-switch strains may 
have growth deficiencies (Trzcinski et al., 2003) and more recently that growth 
is dependent on capsular type (Hathaway et al., 2012), our studies with TIGR4, 
TIGR4 capsule switch mutants and unencapsulated TIGR4 did not show any 
detectable growth deficit in our TIGR4, its capsule switch and unencapsulated 
mutant strains in BHI.  We also did not find any growth deficit in unencapsulated 
TIGR4 strain as compared to wild-type TIGR4. TIGR4, its capsule switch mutants 
and capsule knock-out Janus intermediate all had similar lag phase length, and 
similar curve in log phase of growth.  We also did not find any shortening in the 
lag phase in unencapsulated TIGR4 as has been reported for D39.  Our findings 
show that rate of pneumococcal growth in TIGR4 is independent of presence or 
absence of capsule or capsule type though it is a complex structure and has a 
long and complicated synthetic pathway. Our findings could be explained by 
difference of methodology in obtaining readings for plotting growth curves, as in 
our studies growth curves were plotted by taking a known number of colony 
forming units as starting inoculum and plotting curve using viable counts in 
contrast with other studies which used certain quantity from a subculture 
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containing unknown number of bacteria from overnight growth and plotted 
curves using optical density, which can be different for same number of bacteria 
and can vary with the degree of capsulation (Hathaway et al., 2012; Battig et 
al., 2006; Trzcinski et al., 2003)  
Electron microscopy and Stains-All Assay demonstrated differences in capsule 
formation in parents and capsule switch strains and it was observed that TIGR42 
had the thinnest capsule with the least amount of polysaccharide formation.  
TIGR43 and TIGR48 formed significantly less amount of capsule as compared to 
TIGR4 and their donor strains.  D398 demonstrated differences in formation of 
capsular polysaccharide as compared to TIGR48 and though capsule thickness of 
D39, D398 and ATCC6308 was similar, D398 formed much more capsular 
polysaccharide as compared to parent strain D39.  Formation of capsular 
polysaccharide seems to be related with both the genetic background and 
capsule constitution.  Decrease in formation of capsular polysaccharide could be 
explained on the basis of biochemical structure of capsules as TIGR4 capsular 
polysaccharide mainly contains acetylated amino sugars and does not have 
glucose, galactose, rhamnose and glucuronic acid as its constituents.  There is a 
possibility that an ample supply of some of these sugars cannot be maintained by 
TIGR4 sugar transport and synthesis mechanisms.   The above hypothesis is also 
supported by the fact that D39 made plenty of type 8 capsule, which contains 
galactose instead of rhamnose found in D39 capsule, which is a non-house 
keeping sugar and is uniquely found in type 2 capsule among our capsule switch 
strains.  It has a separate pathway of synthesis with genes rmlA, rmlC, rmlB and 
rmlD located within the type 2 capsule locus, which contains three rhamnose 
units as its structural constituents (Bentley et al., 2006).  These genes are also 
present in some other pnuemococci such as serogroup 6, serogroup 7, serogroup 
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17, serogroup 18 and serogroup 19 though they differ in number of repetitive 
rhamnose subunits.  There is a possibility that TIGR4, if spontaneously acquires 
one of these capsules may be unable to incorporate repetitive units of rhamnose 
in its capsular polysaccharide structure and may become attenuated due to 
insufficient capsule information, though TIGR4 capsule switch mutants 
expressing simpler capsular polysaccharide with just one rhamnose unit have 
been constructed and reported to be forming capsules with proper thickness 
(Hyams et al., 2010b). Simplified capsular polysaccharide structures are shown 
in Fig 4.25. 
.  
Figure 4.25. Schematic diagrams of capsular polysachharide structures showing constituent 
sugars (A) Serotype 2 capsule. (B) Serotype 3 capsule. (C) Serotype 4 capsule (D) Serotype 
8 capsule.  Redrawn with modification and simplification from Bentley et al. (2006).   
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It might also be inferred that capsule switching may be related to 
transformability as many pneumococci that are not transformable would not be 
able to accept and thus switch to newer capsule types.  There is a possibility 
that thickness, density, capsular charge or type of capsule also plays a role in 
the transformability of pneumococci as they might offer a physical or charge 
barrier to DNA molecules coming in contact with pneumococcus, though our 
studies did not establish a statistical correlation between capsular thickness or 
amount of capsule with transformability of our capsule switch mutants.  Since 
during construction of capsule-switch strains only those colonies are picked 
which have integrated the capsule genes, there was a chance that after three 
times back crossing, capsule switch strains might be the most transformable ones 
and might give a false value if compared with parent TIGR4 strains.  The 
comparison of TIGR4 and capsule switch strain expressing type 4 capsule showed 
significant difference in transformability of the two strains. To remove the bias 
all analyses were done by comparing capsule-switch strains with strain P1702, 
which showed TIGR42 to be significantly more transformable as compared to 
P1702, TIGR48 was comparatively less transformable while TIGR43 was the least 
transformable among capsule switch strains. Transformability might be related 
to biochemical constitution of capsule and there is a possibility that after 
acquiring certain capsules the population may become more transformable or 
less transformable depending upon the type of capsule. 
Chain formation is a characteristic feature of pneumococci and they tend to 
associate themselves in variable number of chains.  Significance of number of 
bacteria per chain is not clearly understood but it has been reported in the past 
that very long chains are associated with decreased virulence (Ekstedt & 
Stollerman, 1960).  More recently, Dalia and Weiser (2011) also showed that 
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decrease in length of chain is associated with increased virulence and allows 
evasion of complement, though host immune system responds by agglutinating 
antibodies to overcome this strategy (Dalia & Weiser, 2011). It has also been 
reported that some mutant strains show longer chains as compared to normal 
strains (Barendt et al., 2009; Sanches-Puelles et al., 1986).  The results showed 
that pneumococci expressing type 8 capsule tend to form longer chains, 
consisting of 12-30 pneumococci.  Relationship of chain-length with virulence 
could not be established as though D398 and ATCC6308 were highly virulent, 
TIGR48 was attenuated as compared to parent TIGR4 strain, though it showed 
adaptability and there is a possibility that it might reach to virulence of TIGR4 
with repeated animal passage or become more virulent.  There is a possibility 
that longer chains pose difficulty in phagocytosis and are associated with 
increased virulence contrary to the findings of Dalia and Weiser (2011), similar 
to the phenomenon observed in Mycobacterium tuberculosis (Hunter et al., 
2006). 
To study the effects of capsule switching parents and capsule switch strains were 
tested in intraperitoneal mouse model of infection.  Results showed that the 
process of capsule switching itself does not affect virulence as mice infected 
with TIGR4 and P1702 did not demonstrate any difference in virulence. Results 
also showed that different capsules have different effects on virulence of a given 
strain while same capsule can have different effects on strains of different 
genetic background.  These variations might be due to effects of  biochemical 
structure on complement deposition, which is vital for development of host 
immunity against the pneumococcus (Abeyta et al., 2003; Winkelstein, 1981).  
These complement proteins are organized in three pathways classical, 
alternative and mannose-binding  lectin  pathways, which  are serially activated 
  
   134 
to opsonize bacteria (Walport, 2001a; Walport, 2001b).  Activation of 
complement results in deposition of cleaved complement protein C3b on the 
surface of bacteria which can cause opsonophagocytosis  by interacting with 
complement receptors present on neutrophils (Lambris et al., 2008), resulting in 
death of bacteria within phagolysosome (Standish & Weiser, 2009).  Since the 
pneumococcal capsule resists opsonization by complement by multiple 
mechanisms including inhibition of IgG and C-reactive protein binding and 
reduction of degradation of surface bound C3b (Hyams et al., 2010a) variation in 
its thickness or density may completely uncover or partially expose the surface 
structures, which can then directly interact with the complement, resulting in 
subsequent phagocytosis.  It has also been shown that susceptibility to 
complement-mediated killing is serotype dependent (Hyams et al., 2010a) and 
resistance to complement-mediated lysis is more related to capsular serotype 
than genetic background (Melin et al., 2010) so a change in serotype might result 
in variation of virulence.  
It was also observed that passage of strains through animals significantly 
increased virulence of less virulent strains but it was still not comparable to 
TIGR4. Increase in the pneumococcal virulence with animal passage is a known 
phenomenon (Chiavolini et al., 2008), it is not clear yet whether this was due to 
change in expression of capsule genes, increased capsule formation or other 
changes in the pneumococcal biology.  An increase in capsular expression in vivo 
has been reported in several studies (Ogunniyi et al., 2002; Mahdi et al., 2008), 
thought others did not find any change in capsular expression in vivo in mouse 
models of infection (LeMessurier et al., 2006; Orihuela et al., 2004).   Since 
increase in expression of many virulence factors have been reported with 
exposure to animals in a number of studies (Mahdi et al., 2008; LeMessurier et 
  
   135 
al., 2006; Orihuela et al., 2004; Ogunniyi et al., 2002), there is a possibility that 
exposure to the animal environment might have allowed selection of those 
strains, which are able to adapt to the environment more readily and repeated 
passage through animals might render them equally or more virulent as TIGR4.  
It can be inferred that capsule switching is not a universal phenomenon and a 
successful capsule switch is only possible with suitable combination of genetic 
background and capsule type so there would be limitations in development 
vaccine escape mutants, which could possibly spread and cause treatment 
issues. 
Having compared effects of capsule switching on pneumococcal biology, the 
whole genome sequence of avirulent strain 403 was obtained and was compared 
with genome sequence of virulent TIGR4 strain to find genome-wide changes 
responsible for differences in virulence.  To study the differences in expression 
of different virulence factors, microarray experiments were performed, 
comparing 403 gene-expression with that of TIGR4. 
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5 Comparison of an avirulent strain 403 with 
virulent strain TIGR4 using whole genome 
sequencing and microarray. 
S. pneumoniae is an extremely diverse organism having a highly variable genomic 
content due to which different strains vary significantly in terms of virulence and 
other biological properties.  The highly transformable pneumococcal genome 
easily allows mutations, which may result in an increase or a decrease in 
pathogenicity of a particular strain.  The best way to understand the nature of 
these mutations and to study their effect is to compare the target strain with a 
standard strain in terms of genetic content, gene expression and other in vivo 
and in vitro characteristics.  This approach must involve the complete genome 
sequence as the first and foremost step as a complete, high quality genome 
sequence ensures smooth progress during all downstream work, and can explain 
phenotypic variation among the strains.  It also permits identification of genomic 
regions harboring mutations and enables in silico comparison of different 
genomes using BLAST (Basic Local Alignment Search Tool) or other software.  
Microbial genome sequence analysis has been an important approach to 
understanding the biology of different microorganisms since the complete 
genome of Haemophilus influenzae was published in July 1995 (Fleischmann et 
al., 1995).  It has been utilized for comparison of different streptococci 
including pneumococcus (Lanie et al., 2007) and other organisms (Ellison et al., 
2008; Howard et al., 2006) and has been a useful approach to identify 
pathogenic factors and to improve the understanding of the mechanism of 
microbial pathogenicity.  Identification of genetic differences between 
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pathogenic and non pathogenic strains allows definition of phylogenetic 
relationships between them and may help in identification of potential 
therapeutic targets for medical interventions, which has been the major goal of 
bacterial comparative genomics.  
Avirulent strain 403 is particularly interesting as it is derived from virulent strain 
TIGR4, which is opposite to what has been suggested in serogroup 6 strains that 
virulent pneumococcal strains tend to have evolved from carriage strains 
(Robinson et al., 2002).  In addition to this, since there are serotype specific and 
tissue specific virulence factors that are affected by transcriptional regulation, 
we also performed microarray experiments comparing 403 with TIGR4 to identify 
key genes responsible for altered phenotype in 403, which revealed more 
differences between the two strains and showed altogether 288 genes to be 
differentially expressed in 403 as compared to TIGR4 as summarized in Table 
5.5. 
403 and TIGR4 are both sequence type 205, serotype 4 strains , a serotype which 
is frequently implicated in cases of invasive pneumococcal disease (IPD) and 
have been also been observed to cause invasive disease in animal  models of 
pneumococcal infection (Sandgren et al., 2005; Sandgren et al., 2004).  Their 
characteristics are summarized in Table 5.1. 
 
 
 
 
  
   138 
 
 
 
This chapter compares 403 with TIGR4, and discusses the nature of 
spontaneously arising single nucleotide polymorphisms (SNPs) in 403.  In 
addition, relative transcription patterns determined by microarray analyses, and 
possible effects of these differences have been discussed.   
5.1 Comparison of virulence of 403 and TIGR4: 
Strain 403 was evaluated for its virulence potential in mouse model of sepsis and 
a group of MF1 mice were challenged intraperitoneally with 1 x 105 cfu, using 
the same quantity of virulent TIGR4 strain as control.  It was observed that not 
only were these strains were avirulent but also that they failed to produce any 
bacteraemia.  All the 403 challenged mice survived until the end of experiment 
as compared to their TIGR4 counterparts, which reached the end point by 30 hrs 
(Fig 5.1).  
Table 5.1. Comparison of TIGR4 and 403 
Strain Serotype MLST Type Virulence 
TIGR4 4 205 Virulent 
403 4 205 Avirulent 
G 
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Figure 5.1. Kaplan-Meier curve showing survival of MF1 mice challenged IP with 1 x10
5
 
cfu/200 µl with Streptococcus pneunomiae strains 403 and TIGR4.  All data plotted as 
percentage survival as a staircase line with points for all observations against hrs post 
infection.  Median survival time for TIGR4-challenged mice was 18 hrs as calculated by log 
rank test (GraphPad Prism 4.0, USA). Five mice were used in each group. 
 
 
5.2 Genomic comparison of 403 and TIGR4: 
Whole genome sequencing of strain 403 was carried out using Illumina® paired 
end-sequencing.  Genomic alignments were performed between complete 
genome sequence of TIGR4 strain and the consensus sequence, which was 
generated for strain 403, resulting in an almost complete sequence alignment 
with only few discrepancies, which are discussed in following sections.      
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Sequence alignments showed high homology shared by the two strains, without 
any remarkable chromosomal rearrangements. However, 35 single-nucleotide 
polymorphisms (SNPs) were identified in strain 403, some of which resulted in 
altered amino acid sequence in coding regions of annotated genome, while 6 
SNPs were present in intergenic regions. These SNPs affected several classes of 
genes, including biosynthetic pathways of several macromolecules, competence, 
DNA repair, cell division and fermentation.  It can be easily speculated that 
changes in structure or function of translated products might contribute towards 
the altered phenotype and pathogenicity of 403.   
22 Insertion-deletions and a 12 base pair deletion (1132424-36 of reference 
strain) were also found in 403, which are being analyzed in our lab as a separate 
project, and only possible effects of the SNPs will be discussed in this chapter. 
5.2.1 SNPs in intergenic region: 
On analysis of genome sequencing data, six out of thirty five SNPs were found in 
intergenic regions. These are summarized in Table 5.2.  
Most of the SNPs present in intragenic regions were not associated with any 
change in expression profile of surrounding genes.  SNP present at positions 
476404, 730678, 1622058 and 1622059 were not found to be affecting genes 
present upstream and downstream to them and only two SNPs at positions 
463629 and 463630 were associated with expression profile change of their 
surrounding genes as shown in Table 5.2. 
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Table 5.2. SNPs in the inrtragenic regions and genes upstream and downstream to the SNPs with expression profile change in two genes. 
Consensus Reference Reference Variation Upstream genes Downstream Genes 
463629 463630 G A Hypothetical protein (Sp0482)  1.25+ 
 
ABC transporter (Sp0483)  1.14- 
463630 463631 A G Hypothetical protein (Sp0482) 
 
ABC transporter (Sp0483) 
476404 476406 G T Na/Pi cotransporter II related protein (Sp496)  
 
 
 
Hypothetical protein (Sp0497) 
730678 730678 C T Petpidyl prolyl cis trans isomerase(Sp0771)   
 
Hypothetical protein (Sp0772) 
 
 
1622058 1622066 G A ABC transporter (Sp1717)  
 
Hypothetical protein (Sp1718) 
 
1622059 1622067 A G ABC transporter (Sp1717) 
 
Hypothetical protein   (Sp0718) 
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These two SNPs were found to be associated with altered expression profile of 
genes present upstream and downstream to them, hypothetical protein gene 
(Sp0482) located upstream to them was up regulated while the ABC transporter 
present downstream to them (Sp0483), was down regulated.  
5.2.2 Synonymous SNPs: 
Seven SNPs resulted in synonymous mutations and did not cause any change in 
the amino acid sequence of translation product.  Though variable effects of 
synonymous SNPs are not reported for bacteria but they have been shown to be 
associated with certain disease conditions in humans, (Chen et al., 2010; Ho et 
al., 2010) hence there remains a possibility of these SNPs may be associated 
with altered biology of 403 as some of them occur in genes vital for 
pneumococcal growth and pathogenesis including capsule biosynthesis, DNA 
replication and repair and competence as shown in Table 5.3. 
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1
   Gene annotation in TIGR4 
2
    Nucleotide in the reference genome TIGR4 
3
    Nucleotide in consensus sequence of 403  
4
    Amino acid change in 403 
5
    Position of the SNP in 403 consensus sequence 
6
    Position of the SNP in the reference sequence  
7    Expression profile change. 
 
Table 5.3. Synonymous SNPs in 403 and expression profile change in 403. 
Gene  TIGR4
1
 
**Anno
tation 
Reference
2
 Variation
3
 Amino Acid Change
4
 Consensus
5
 Reference
6
 Expression Profile change
6
 
Capsular polysaccharide 
biosynthesis protein, putative 
Sp0103 
 
C T - 106332 106332 - 
DNA polymerase IV Sp0458 T G - 431222 431223 - 
Gln-2 Sp2245 G A - 807984 807984 - 
glyA Sp1024 G T - 967258 967257 1.78+ 
RecN; DNA repair protein Sp1202 C T - 1135386 1135396 - 
Prolyl oligopeptidase family protein Sp1343 C G - 1267209 1267219 - 
ComF;competence protein 
ComF,putative 
Sp2207 G T - 2127991 2127997 - 
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Microarray analysis did not show any change in expression profile of these genes 
except glyA which codes for a serine hydroxymethyltransferase that is involved 
in multiple metabolic pathways such as glycine, serine and threonine 
metabolism, lysine degradation, methane metabolism and cyanoamino acid 
metabolism and is responsible for reversible interconversion of glycine and 
serine with tetrahydrofolate, which serves as one-carbon carrier.  Expression 
profile changes are summarized in Table 5.3. 
5.2.3 Non synonymous SNPs: 
The rest of the 22 mutations were found to be non synonymous and were 
associated with change in amino acid sequence of genes, though microarray 
showed only four of these genes to be differentially regulated in 403.   This 
finding does not rule out a malfunctioning translational product, which might 
contribute towards avirulence of 403.  Differentially regulated genes with SNPS 
are summarized below. 
1. Sp1161, which is putative acetoin dehydrogenase complex, E3 component, 
dihydrolipoamide dehydrogenase, was found to be upregulated along with 
Sp1162 and Sp1163 which are E1 and E2 components of same enzyme and 
are involved in multiple metabolic processes including metabolism of 
alanine, serine, threonine, pyruvate, glycine and aspartate, dergradation 
of valine, leucine and isoleucine, glycolysis and gluconeogenesis, 
regulation of NAD/NADH ratio and carbon storage (Xiao & Xu, 2007). 
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2. Sp1645 (relA) which codes for GTP pyrophosphokinase and involved in 
cellular adaptation to atypical conditions was also found to be 
upregulated.  It has been reported that relA mediates uptake and 
utilization of certain ions under nutritionally stressed condition and does 
not play much important role when nutrients are abundantly present.  It 
is known to be an important virulence factor which helps bacteria to 
adapt during disease progression (Kazmierczak et al., 2009). Since it is 
known to cause repression of rRNA synthesis and affect patterns of gene 
transcription, protein synthesis and enzyme activation (Wolz et al., 2010), 
there is a possibility that mutation causing amino acid change from valine 
to phenylalanine in relA product along with a 1.5 increase in expression 
might be the reason for generalized increase in aminoacid acquisition and 
decreased synthesis of ribosomal proteins in 403.   
3. Sp1003, which codes for conserved hypothetical protein and Sp0272, 
which is ribosomal protein S7 gene were found to be down regulated. 
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Table 5.4.  SNPs present in 403. 
Gene TIGR4 Annotation Reference Allele Var Reference Consensus Amino Acid Change 
Cell Envelope:       
Capsular polysaccharide biosynthesis protein Cps4E Sp0350 G A 324506 324505 Asp173Asn 
       
Cofactors, Prosthetic groups and Carrier Biosynthesis        
gor; Glutathione reductase Sp0784 A G 737108 737108 Cys382Arg 
       
Cell Division:       
Cell division protein FtsW, putative Sp1067 T G 1001704 1001704 Phe143Val 
       
Fermentation:       
Acetoin dehydrogenase complex, E3 component, 
dihydrolipoamide dehydrogenase,putative  
Sp1161 T G 1096817 1096817 Asn395Thr 
MATE efflux family protein Sp1164 C G 1101585 1101585 Arg405Pro 
MATE efflux family protein Sp1164 G C 1101586 1101586 Arg405Gly 
       
Carbohydrate and Energy Metabolism:       
lacD:Tagatose 1,6-diphosphate aldolase Sp1190 C G 1127020 1127021 Val300Leu 
lacD;Tagatose 1,6-diphosphate aldolase Sp1190 G C 1127021 1127022 Cys299Trp 
recP-1 Sp1615 G A 1517039 1517030 Ala173Val 
       
Degradation of proteins:       
Prolyl oligopeptidase family protein Sp1343 G C 1267220 1267210 Thr120Arg 
       
DNA metabolism:       
Type II DNA modification methyltransferase, putative Sp1431 G T 1350621 1350612 Glu291Stp 
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Gene TIGR4 Annotation Reference Allele Var Reference Consensus Amino Acid Change 
Adaptations to Atypical conditions:       
relA; GTP pyrophosphokinase Sp1645 C A 1543556 1543547 Val140Phe 
       
Transcription:       
rpoC; DNA-directed RNA polymerase subunit beta Sp1960 C T 1862985 1862977 Gly1113Glu 
       
DNA Interactions:       
bglG family transcriptional regulator Sp2131 G A 2042324 2042318 Thr647Ile 
       
Nucleoside/Nucleotide metabolism       
adk; Adenylate kinase Sp0231 C T 204679 204679 Ala40Val 
       
Transport       
ABC transporter, substrate-binding protein Sp0145 G C 146055 146055 Leu181Phe 
ABC transporter, ATP-binding protein Sp1918 G T 1828206 1828198 His218Gln 
Phosphate ABC transporter, ATP-binding protein, putative Sp1397 C A 1320529 1320520 Asp244Tyr 
       
Hypothetical proteins:       
Hypothetical protein Sp1003 G C 947167 947168 Val59Leu 
Hypothetical protein Sp1334 G T 1257186 1257176 Pro58Gln 
Hypothetical protein Sp1715 A G 1618223 1618214 Glu130Gly 
       
Ribosomal Proteins:       
30S ribosomal protein S7 Sp0272 A G 247805 247805 Lys90Glu 
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Other genes harboring SNPs having important biological functions are: 
1. Sp0350:  Also known as cps4E  encodes a glycosyl-phosphotransferase that 
transfers glucose-1-phosphate units to growing undecaprenyl phosphate 
glycolipid (Cartee et al., 2005).  It has been reported that disruption of 
this gene does not affect the viability of bacteria (Xayarath & Yother, 
2007;Hava & Camilli, 2002) though cps4E mutants were found to be 
capsule deficient but good biofilm formers. Capsule deficient mutants 
were also found to be good at biofilm production (Munoz-Elias et al., 
2008).  
2. Sp0231 or adk, which codes for an adenylate kinase and is required for 
proper maintenance and growth of cell, was reported among essential 
genes by allelic replacement mutagenesis (Song et al., 2005). 
3. SP1960 or rpoC, which is a DNA dependent RNA polymerase was also 
reported to be among essential genes by allelic replacement mutagenesis 
(Song et al., 2005).  
4. Sp1190 or lacD which codes for tagatose 1,6-diphosphate aldolase and is 
an important enzyme in galactose metabolic pathway, where it converts 
D-tagatose 1,6-bisphosphate  to glycerone phosphate  and D-
glyceraldehyde 3-phosphate.  Though lacD itself did not show decreased 
expression but a number of other genes related to galactose metabolism 
showed lesser levels of expression as compared to TIGR4.  
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All above genes have important biological functions and it can be predicted that 
functional disruption of any one of these genes alone or in combination might 
result in loss of pathogenicity as some of these mutations were also found to be 
affecting expression of genes that play important roles in pneumococcal 
metabolism, its regulation and virulence.   
A microarray analysis revealed even more difference between the two strains 
and showed altogether 288 genes to be differentially expressed in 403 as 
compared to TIGR4 as summarized in Table 5.5 and discussed below. 
5.3 Expression patterns in 403:  
5.3.1 Surface Structures and virulence factors: 
Pneumococcal surface is composed of three major components which include 
polysaccharide capsule, peptidoglycan cell wall and cell membrane.  These 
layers are also embedded with surface proteins which are very important for 
pneumococcal virulence and interaction with host cells and their expression 
levels can affect virulence of any strain.   In our microarray studies we observed 
altered expression levels of a number of genes related to surface structures in 
403 and most of these showed decreased expression levels.  Important surface 
related genes with altered expression levels are discussed below. 
1. strH is an exoglycosidase, which resists neutrophilic opsonophagocytic 
killing in the human body and act in conjugation with two other virulence 
factors, a neuraminidase NanA, and a beta-galactosidase BgaA (Dalia et 
al., 2010). BgaA did not show altered expression in 403, while NanA is 
known to be non-functional in TIGR4 due to a frame-shift mutation 
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(Pericone et al., 2002). It has been shown that they reduced deposition of 
C3 component of the complement on surface of pneumococci, which 
provides an escape route against phagocytic killing.  As pneumococcus 
encounters a number of glycoconjugates on host epithelial surface 
including membrane associate glycoproteins and mucin (Lodish et al., 
2000), and these glycosidases modify them to assist in colonization and 
subsequent invasion of cells (Burnaugh et al., 2008), a 1.5 fold decreased 
expression of strH along with absence of neuraminidase A might 
contribute towards attenuation of 403.   
2. pulA is another downregulated gene that codes for a putative pullulanase 
present on pneumococcal surface, which codes for a protein called SpuA.  
It was shown to play a role in binding to a number of complex 
carbohydrates including submaxillary mucin, asialofetuin  and fetuin and 
exhibiting strepadhesin activity in Group A streptococci (Hytonen et al., 
2003).  Pullulanase deficient mutants have also been observed to be 
deficient in cell adhesion (Hytonen et al., 2006). 
3. MurB and MurF are other two enzymes less expressed in 403, which are 
critical for cell wall synthesis and important drug targets.  Their 
decreased expression may be related to defects in cell wall synthesis 
(Smith, 2006; El Zoeiby et al., 2003).    
4. CpoA is a downregulated gene that encodes for a glycosyl transferase and 
mutations in cpoA have been reported to affect pneumococcal 
competence along with beta-lactam resistance (Grebe et al., 1997). 
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Some other genes coding for hypothetical proteins and proteins of unknown 
functions were also noted to have lower expression in 403 as compared to TIGR4, 
while only one notable gene Sp0378 coding for choline binding protein J involved 
in adherence, was found to be expressing highly in 403 as compared to TIGR4.  
Reduced expression of these genes may contribute towards lack of pathogenicity 
of 403 as proteins coded by these enzymes are vital for invasion of tissues and 
expression profile of surface factors favors a colonization phenotype as 
compared to an invasive one. 
5.3.2 Genes related to metabolic pathways: 
5.3.2.1 Carbohydrate metabolism 
Pneumococcus can metabolize a few sugars such as glucose, sucrose, raffinose, 
lactose, trehalose, inulin and maltose as sources of energy (Hava & Camilli, 
2002).  A number of genes coding for enzymes participating in galactose 
metabolism such as galM, glmS, galK, galT, aga, nagB and fructose metabolism 
such as fruB were down-regulated though genes coding for enzymes related to 
glucose metabolism were upregulated along with those coding for enzymes of 
gluconeogenesis such as acetoin dehydrogenase complex, which indicates 
preferential utilization of glucose over other resources in 403. 
Genes adhE and adh are iron and zinc containing alcohol dehydrogenases 
involved in anaerobic metabolism, which were observed to have lower 
expression levels in 403 as compared to TIGR4.   
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5.3.2.2 Amino acid and protein metabolism: 
Analysis of data over amino acid synthesis showed that genes coding for enzymes 
related to metabolism of basic amino acids including arginine and lysine were 
downregulated (argF, arcA and proC) though those related to synthesis of 
aromatic amino acids including phenylalanine, tyrosine and tryptophan 
biosynthesis (pheA, tyrA, aroC, trpA, trpB, trpC, trpD and , trpG) and 
hydrophobic amino acids were up-regulated.  Another important gene nspC 
coding for carboxynorspermidine decarboxylase was found to be down-regulated, 
which is known to participate in a number of metabolic processes including 1 
and 2 methylnaphthalene degradation, 3-chloroacrylic acid degradation, alkaloid 
biosynthesis, benzoate degradation, phenylpropanoid biosynthesis, purine 
metabolism, pyruvate, tryptophan and tyrosine metabolism. 
A number of ribosomal proteins were also observed to have decreased expression 
including rpsD, rpsJ, rplC, rplB, rpsN, rpmD, rpsG, rplM, rplA, rpsP, rplT,pepF, 
rpmA, rplL, rpsR , rpsB and tsf.  
5.3.2.3 Transport proteins: 
A number of transporters related to various metabolic pathways were found 
downregulated in 403 which include fruA (fructose specific), Sp1682 (Sugar ABC 
transporter, permease protein), Sp1683 (Sugar ABC transporter, sugar-binding 
protein), Sp0063  (PTS system, IID component), Sp1684 (PTS system, IIBC 
components),  rafF (Sugar ABC transporter, permease protein),   rafE (Sugar ABC 
transporter, sugar-binding protein),  malX (Maltose/maltodextrin ABC 
transporter, while choline transporters proWX and proV and genes related to 
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phosphate ABC transport system pstC, pstA, pstB and phoU were found to be 
expressing highly in 403. 
Differences in expression profiles of the two strains are summarized in Table 
5.5. 
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Table 5.5.  Differentially regulated genes in strain 403. 
 
 
 
Differentially regulated Genes in 403 Annotation in TIGR4 Expression in 403 Expression in TIGR4 Fold Change in 403 
Virulence determinants 
 
    
pulA; Putative alkaline amylopullulanase Sp0268 0.251 0.678 2.7- 
xseA; Exodeoxyribonuclease VII, large subunit Sp1207 0.767 0.987 1.29- 
nanA; Neuraminidase A, authentic frameshift Sp1693 0.279 0.953 3.42- 
     
     
Cell Envelope     
strH; Beta-N-acetylhexosaminidase Sp0057 0.715 1.073 1.5- 
Lipoprotein Sp0149 0.836 0.999 1.19- 
cps4G; Capsular polysaccharide biosynthesis protein cps4, 
Putative identification 
Sp0352 0.744 0.989 1.33- 
Membrane protein Sp0637 0.654 0.96 1.47- 
Conserved hypothetical proteins: Sp1851 0.251 0.727 2.9- 
cpoA; Glycosyl transferase CpoA Sp1075 0.852 0.986 1.16- 
murB;UDP-N-acetylenolpyruvoylglucosamine reductase Sp1390 0.762 1.025 1.35- 
murF;UDP-N-acetylmuramoylalanyl-D-glutamyl-2,6-
diaminopimelate--D-alanyl-D-alanyl ligase 
Sp1670 0.792 1.044 1.32- 
Cell wall surface anchor family protein Sp1992 0.639 1.033 1.62- 
     
Stress related     
General stress related protein 24, putative Sp1804 0.572 0.958 1.67- 
     
DNA repair, recombination and modification     
MutT/nudix family protein Sp0119 0.708 1.192 1.68- 
dnaG; DNA primase Sp1072 0.693 0.945 1.36- 
 
  155 
     
Differentially regulated Genes in 403 Annotation in TIGR4 Expression in 403 Expression in TIGR4 Fold Change in 403 
DNA repair, recombination and modification     
ligA; DNA ligase, NAD-dependent Sp1117 0.711 1.06 1.49- 
rexA;Exonuclease RexA Sp1152 0.904 1.053 1.16- 
MutT/nudix family protein Sp1669 0.849 1.014 1.19- 
cbf1; Cmp-binding-factor 1 Sp1980 0.699 1.017 1.45- 
     
Carbohydrate and Energy Metabolism     
galM; Aldose 1-epimerase Sp0066 0.576 0.992 1.72- 
glmS; Glucosamine--fructose-6-phosphate aminotransferase Sp0266 0.576 0.989 1.72- 
fruB; 1-phosphofructokinase, putative Sp0876 0.173 0.692 4- 
nagB; Glucosamine-6-phosphate isomerase Sp1415 0.552 0.931 1.69- 
npl; Putative N-acetylneuraminate lyase Sp1676 0.427 0.918 2.15- 
galK; Galactokinase Sp1853 0.311 0.757 2.43- 
galT; Galactose-1-phosphate uridylyltransferase Sp1852 0.291 0.669 2.3- 
Putative dextran glucosidase DexS Sp1883 0.164 0.616 3.76- 
aga; Galactose metabolism Sp1898 0.182 0.567 3.12- 
rpe; Ribulose-phosphate 3-epimerase Sp1983 0.773 0.97 1.25- 
adhE; Alcohol dehydrogenase, iron-containing Sp2026 0.148 0.764 5.16- 
adh; Alcohol dehydrogenase, zinc-containing Sp2055 0.376 0.944 2.51- 
malP; Glycogen phosphorylase family protein Sp2106 0.403 0.883 2.19- 
malQ; 4-alpha-glucanotransferase Sp2107 0.38 0.815 2.14- 
fcsK; Putative L-fuculose kinase fucK Sp2167 0.367 0.762 2.08- 
     
Aminoacid metabolism and Acquisition     
cad; Lysine decarboxylase Sp0916 0.447 0.938 2.1- 
speE; Spermidine synthase Sp0918 0.431 0.916 2.13- 
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Aminoacid metabolism and Acquisition     
proC; Pyrroline-5-carboxylate ,Amino acid biosynthesis: 
Glutamate family 
Sp0933 1.018 1.161 1.14- 
arcA; Arginine deiminase Sp2148 0.296 0.846 2.86- 
argF; Ornithine carbamoyltransferase Sp2150 0.415 0.853 2.06- 
     
     
     
Nucleoside/Nucleotide metabolism     
purF; Amidophosphoribosyltransferase Sp0046 0.546 0.934 1.71- 
purH: Phosphoribosylaminoimidazolecarboxamide 
formyltransferase/IMP cyclohydrolase 
Sp0050 0.542 1.049 1.94- 
pyrG; CTP synthase Sp0494 0.794 1.031 1.3- 
nspC; Carboxynorspermidine decarboxylase Sp0920 0.53 1.079 2.04- 
mtf; 5-methylthioadenosine/S-adenosylhomocysteine 
nucleosidase, 
Sp0991 0.905 1.032 1.14- 
tdk; Thymidine kinase Sp1018 0.935 1.104 1.18- 
udk ; Uridine kinase Sp1208 0.798 1.167 1.46- 
guaA Sp2072 0.167 1.074 6.43- 
carB; Carbamoyl-phosphate synthase, large subunit Sp1275 0.529 1.017 1.92- 
apt; Adenine phosphoribosyltransferase Sp1577 0.636 0.995 1.5- 
     
Cofactor, Prosthetic Group and Carrier  Metabolism     
ispA; Geranyltranstransferase Sp1205 0.819 1.075 1.31- 
mvaS; Hydroxymethylglutaryl-CoA synthase Sp1727 0.805 0.948 1.18- 
Thiamine pyrophosphokinase Sp 1982 0.778 1.001 1.29- 
     
Reguatory Functions:     
lacR; Lactose phosphotransferase system repressor Sp0875 0.169 0.647 3.83- 
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Differentially regulated Genes in 403 Annotation in TIGR4 Expression in 403 Expression in TIGR4 Fold Change in 403 
Reguatory Functions:     
Serine/threonine protein phosphatase Sp1201 0.745 0.922 1.24- 
Putative transcriptional repressor Sp1203 0.784 1.044 1.33- 
Putative fucose operon repressor Sp2168 0.487 0.932 1.91- 
     
Transcription     
rpoE; Putative DNA-directed RNA polymerase, delta subunit Sp0493 0.692 0.94 1.36- 
rnc; Ribonuclease III Sp1248 0.99 1.111 1.12- 
aspB; GTP-sensing transcriptional pleiotropic repressor CodY  Sp1584 0.618 1.055 1.71- 
     
     
Translation and Protein Synthesis     
rpsD; Ribosomal protein S4 Sp0085 0.648 1.047 1.62- 
trmU; 5-methylaminomethyl-2-thiouridylate-      
Methyltransferase Sp0118 0.834 1.011 1.21- 
rpsJ; Ribosomal protein S10  Sp0208 0.634 0.98 1.55- 
rplC;  Ribosomal protein L3 Sp0209 0.781 1.026 1.31- 
rplB; Ribosomal protein L2 Sp0212 0.754 1.084 1.44- 
rpsN ;Ribosomal protein S14  Sp0222 0.724 1.085 1.5- 
rpmD; Ribosomal protein L30  Sp0228 0.649 0.995 1.53- 
rpsG; Ribosomal protein S7 Sp0272 0.667 1.024 1.54- 
rplM; Ribosomal protein L13  Sp0294 0.704 1.023 1.45- 
RNA methyltransferase, TrmH family  Sp0486 0.622 1.124 1.81- 
rplA; Ribosomal protein L1 Sp0631 0.606 1.074 1.77- 
rpsP; Ribosomal protein S16 Sp0775 0.576 0.958 1.66- 
rplT; Ribosomal protein L20 Sp0961 0.615 0.97 1.58- 
pepF; Oligoendopeptidase F  Sp0979 0.74 1.044 1.41- 
     
  158 
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Translation and Protein Synthesis     
Protease maturation protein, putative Sp0981 0.936 1.104 1.18- 
Ribosomal large subunit pseudouridine synthase Sp1099 0.435 0.878 2.02- 
rpmA; Ribosomal protein L27 Sp1107 0.66 0.968 1.47- 
rplL; Ribosomal protein L7/L12 Sp1354 0.635 0.939 1.48- 
rpsR; Ribosomal protein S18  Sp1539 0.644 0.925 1.44- 
rplM; Ribosomal protein L13  Sp0294 0.704 1.023 1.45- 
rplA; Ribosomal protein L1 Sp0631 0.606 1.074 1.77- 
rpsP; Ribosomal protein S16 Sp0775 0.576 0.958 1.66- 
rplT; Ribosomal protein L20 Sp0961 0.615 0.97 1.58- 
pepF; Oligoendopeptidase F  Sp0979 0.74 1.044 1.41- 
Protease maturation protein, putative Sp0981 0.936 1.104 1.18- 
Ribosomal large subunit pseudouridine synthase Sp1099 0.435 0.878 2.02- 
rpmA; Ribosomal protein L27 Sp1107 0.66 0.968 1.47- 
rplL; Ribosomal protein L7/L12 Sp1354 0.635 0.939 1.48- 
rpsR; Ribosomal protein S18  Sp1539 0.644 0.925 1.44- 
ksgA; Dimethyladenosine transferase Sp1985 0.815 1.099 1.35- 
rpsB; Ribosomal protein S2  Sp2215 0.618 1.028 1.66- 
tsf; Translation elongation factor Ts  Sp2214 0.602 0.995 1.65- 
htrA; Serine protease Sp2239 0.844 1.077 1.28- 
     
Unknown functions     
GTP-binding protein Sp0004 0.754 0.998 1.32- 
Hypothetical protein Sp0099 0.561 0.941 1.68- 
Conserved hypothetical protein Sp0100 0.611 1.155 1.89- 
Hypothetical protein Sp0223 0.783 1.056 1.35- 
Hypothetical protein  Sp0270 0.757 1.029 1.36- 
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Differentially regulated genes in 403 Annotation in TIGR4 Expression in 403 Expression in TIGR4 Fold Change in 403 
Unknown functions     
Conserved hypothetical protein  Sp0409 0.25 1.004 4.02- 
Hypothetical protein Sp0703 0.402 0.974 2.42- 
Hypothetical protein Sp0704 0.472 0.968 2.05- 
Conserved hypothetical protein Sp0742 0.703 0.987 1.4- 
KH domain protein Sp0776 0.508 0.899 1.77- 
Conserved hypothetical protein Sp0783 0.63 1.108 1.76- 
Hydrolase, haloacid dehalogenase-like family Sp0805 0.677 0.985 1.45- 
Conserved hypothetical protein  Sp0919 0.488 0.975 2- 
Hypothetical protein  Sp0987 0.825 0.988 1.2- 
Conserved hypothetical protein Sp1003 0.605 1.031 1.7- 
Conserved hypothetical protein  Sp1004 0.362 0.912 2.52- 
Hypothetical protein  Sp1142 0.888 1.086 1.22- 
Conserved domain protein Sp1174 0.588 1.07 1.82- 
Conserved hypothetical protein Sp1384 0.787 0.986 1.25- 
Oxidoreductase, putative Sp1472 0.428 0.917 2.14- 
Hypothetical protein Sp1476 0.705 1.045 1.48- 
Hypothetical protein Sp1477 0.755 0.971 1.29- 
Conserved domain protein, authentic frameshift Sp1532 0.668 1.006 1.51- 
Conserved domain protein Sp1533 0.654 0.988 1.51- 
Isochorismatase family protein Sp1583 0.637 0.933 1.46- 
Conserved hypothetical protein Sp1685 0.428 0.893 2.09- 
Conserved hypothetical protein  Sp1801 0.687 1.23 1.79- 
Hypothetical protein  Sp1802 0.564 0.996 1.77- 
Hypothetical protein Sp2071 0.545 0.986 1.81- 
Hypothetical protein Sp2105 0.646 0.958 1.48- 
Hypothetical protein Sp2182 0.369 0.801 2.17- 
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Tranporters     
PTS system, IID component Sp0063 0.541 1.087 2.01- 
secY; Preprotein translocase, SecY subunit Sp0230 0.81 1.025 1.27- 
ABC transporter, ATP-binding protein Sp0483 0.884 1.012 1.14- 
Sodium:alanine symporter family protein  Sp0408 0.591 1.091 1.85- 
ABC transporter, ATP-binding protein Sp0707 0.462 0.93 2.01- 
Amino acid ABC transporter, ATP-binding protein Sp0709 0.491 0.889 1.81- 
fruA; PTS system, fructose specific IIABC components Sp0877 0.259 0.711 2.75- 
Amino acid permease family protein  Sp1001 0.591 0.884 1.5- 
Putative transporter, FNT family  Sp1215 0.406 0.92 2.27- 
uraA; uracil permease  Sp1286 0.486 1.138 2.34- 
Sugar ABC transporter, permease protein  Sp1682 0.32 0.783 2.45- 
Sugar ABC transporter, sugar-binding protein Sp1683 0.308 0.843 2.74- 
PTS system, IIBC components  Sp1684 0.305 0.837 2.74- 
ABC transporter, permease protein Sp1688 0.212 0.725 3.42- 
ABC transporter, permease protein Sp1689 0.337 0.718 2.13- 
ABC transporter, substrate-binding protein Sp1690 0.282 0.678 2.4- 
rafF; Sugar ABC transporter, permease protein Sp1896 0.255 0.599 2.35- 
rafE; Sugar ABC transporter, sugar-binding protein Sp1897 0.223 0.597 2.68- 
secE; Putative preprotein translocase, SecE subunit Sp2008 0.751 0.978 1.3- 
malX; Maltose/maltodextrin ABC transporter Sp2108 0.374 0.833 2.23- 
     
Transposase     
IS1167, transposase, degenerate Sp0572 0.687 0.941 1.37- 
IS66 family element, Orf3, degenerate, This gene has an N-
terminal truncation, and is interrupted by an RUP element. 
IRleft = deleted. IRright = GTAACCGCCCAATAACGAAG.  
Sp0644 0.751 0.98 1.3- 
Transposase Sp1064 0.329 0.871 2.65- 
Transposase  Sp1582 0.748 1.013 1.35- 
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Transposase     
Transposase, IS200 family  Sp1622 0.333 0.892 2.68- 
Transposase Sp1905 0.712 1.022 1.44- 
     
Signal Transduction     
hk07;putative sensor histidine kinase Sp0155 0.545 0.925 1.7- 
treP; Trehalose PTS system, IIABC components Sp1884 0.127 0.588 4.63- 
     
     
Upregulated Genes in 403     
Virulence     
Choline binding protein J  Sp0378 1.097 1.023 1.07+ 
Putative immunity protein Sp1988 1.308 1.035 1.26+ 
     
Membrane proteins     
Putative membrane protein  Sp0858 1.424 1.01 1.41+ 
Membrane protein Sp0859 1.488 1.086 1.37+ 
     
DNA repair, recombination and modification     
Putative type I restriction-modification system, S subunit, DNA 
metabolism: Restriction/modification 
Sp0505 2.165 1.002 2.16+ 
MutT/nudix family protein  Sp0794 1.487 0.96 1.55+ 
DNA polymerase III, epsilon subunit/ATP-dependent helicase 
DinG, DNA metabolism: DNA replication, recombination, and 
repair  
Sp0802 1.259 0.965 1.3+ 
Putative endonuclease Sp1251 1.873 0.981 1.91+ 
nth; endonuclease III  Sp1279 1.348 0.954 1.41+ 
     
Carbohydrate and Energy Metabolism     
PEP-utilizing enzymes family protein Sp0795 1.528 1.027 1.49+ 
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Carbohydrate and Energy Metabolism     
gapN; Glyceraldehyde-3-phosphate dehydrogenase  Sp1119 2.587 1.033 2.5+ 
Acetoin dehydrogenase complex, E3 component  Sp1161 1.668 1.006 1.66+ 
Acetoin dehydrogenase complex, E2 component Sp1162 1.52 0.958 1.59+ 
Putative acetoin dehydrogenase, E1 component  Sp1163 1.508 0.939 1.61+ 
 fer; Ferredoxin  Sp1605 1.507 1.021 1.48+ 
recP-2; Transketolase  Sp2030 1.488 0.939 1.58+ 
gpsA; Glycerol-3-phosphate dehydrogenase (NAD(P)+)  Sp2091 1.154 0.928 1.24+ 
     
Aminoacid biosynthesis and Acquisition     
IlvN; Acetolactate synthase, small subunit,Putative Sp0446 2.558 1.246 2.05+ 
Transulfuration enzyme family protein, authentic point 
mutation 
Sp1214 1.8 0.987 1.82+ 
leuB; 3-isopropylmalate dehydrogenase, authentic point 
mutation 
Sp1257 1.391 0.965 1.44+ 
glyA; Serine hydroxymethyltransferase Sp1024 1.9 1.067 1.78+ 
Integrase/recombinase, phage integrase family  Sp1159 1.279 0.995 1.29+ 
Putative chorismate mutase Sp1296 2.334 1.049 2.22+ 
pheA; Prephenate dehydratase  Sp1369 1.822 1.046 1.74+ 
aroA; 3-phosphoshikimate 1-carboxyvinyltransferase Sp1371 1.614 1.014 1.59+ 
tyrA; Chorismate synthase  Sp1373 1.471 1.09 1.35+ 
aroC; Chorismate synthase Sp1374 1.206 0.986 1.22+ 
lysA; Diaminopimelate decarboxylase  Sp1978 1.635 1.015 1.61+ 
trpA; Tryptophan synthase, alpha subunit Sp1811 2.731 0.965 2.83+ 
trpB; Tryptophan synthase, beta subunit  Sp1812 3.245 1.167 2.78+ 
trpC; Indole-3-glycerol phosphate synthase Sp1814 3.317 0.957 3.47+ 
trpD; Anthranilate phosphoribosyltransferase Sp1815 3.12 1.046 2.98+ 
trpG; Anthranilate synthase component II Sp1816 3.079 1.122 2.74+ 
asnA; Aspartate-ammonia ligase Sp1970 1.616 0.997 1.62+ 
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Nucleoside/Nucleotide metabolism     
Phosphorylase, Pnp/Udp family Sp0075 2.498 1.027 2.43+ 
Integrase/recombinase, phage integrase family Sp0506 1.494 0.964 1.55+ 
pyrC; Dihydroorotase, multifunctional complex type  Sp1167 1.27 1.039 1.22+ 
ung; Uracil-DNA glycosylase  Sp1169 1.394 1.039 1.34+ 
Putative type II restriction endonuclease Sp1222 1.164 1.045 1.11+ 
mutY; A/G-specific adenine glycosylase Sp1228 1.422 1.009 1.41+ 
relA; GTP pyrophosphokinase Sp1645 1.456 0.99 1.47+ 
aroF; Phospho-2-dehydro-3-deoxyheptonate aldolase  Sp1700 1.236 0.963 1.28+ 
     
Cofactor Metabolism     
 ribC; Riboflavin synthase, alpha subunit Sp0177 2.468 1.14 2.16+ 
pdxK; Phosphomethylpyrimidine kinase,putative  Sp1598 2.031 1.081 1.88+ 
5-formyltetrahydrofolate cyclo-ligase family protein Sp2095 1.695 1.017 1.67+ 
     
Fatty Acid Metabolism     
fabG; Oxidoreductase, short chain dehydrogenase/reductase 
family  
Sp0793 1.614 1.03 1.57+ 
     
Transcription     
Putative transcriptional regulator Sp0461 2.013 0.971 2.07+ 
Transcriptional regulator Sp1130 1.243 0.971 1.28+ 
PolyA polymerase family protein Sp1554 1.35 1.017 1.33+ 
     
Translation     
truA; tRNA pseudouridine synthase A Sp1599 2.057 1.065 1.93+ 
tyrS; tyrosyl-tRNA synthetase  Sp2100 1.534 1.09 1.41+ 
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Post translational protein alterations     
pepT; Peptidase t   Sp1008 2.048 0.947 2.16+ 
lplA; Lipoate-protein ligaseputative  Sp1160 1.841 1.002 1.84+ 
Serine/threonine protein kinase  Sp1732 1.213 0.975 1.24+ 
     
Unknown functions     
Conserved hypothetical proteins Sp0024 1.878 1.023 1.84+ 
Hypothetical protein Sp0133 1.219 1.098 1.1+ 
Conserved hypothetical protein  Sp0239 1.879 0.97 1.96+ 
Hypothetical protein Sp0448 1.98 1.005 1.97+ 
Hypothetical protein Sp0449 2.127 0.999 2.13+ 
Conserved hypothetical protein  Sp0482 1.278 1.019 1.25+ 
Conserved hypothetical protein Sp0785 1.527 1.067 1.43+ 
Hypothetical protein Sp0792 1.604 1.016 1.58+ 
Hypothetical protein Sp0901 1.348 0.998 1.35+ 
hemK;HemK protein Sp1021 1.722 1.039 1.66+ 
Sua5/YciO/YrdC family protein  Sp1022 1.867 1.018 1.83+ 
Acetyltransferase, GNAT family  Sp1023 1.824 1.042 1.75+ 
Hydrolase, haloacid dehalogenase-like family Sp1171 1.506 0.997 1.34+ 
Conserved domain protein Sp1175 1.276 1.077 1.18+ 
crcB protein Sp1294 1.895 0.984 1.93+ 
crcB2;crcB protein  Sp1295 2.211 1.11 1.99+ 
DHH subfamily 1 protein Sp1298 1.43 0.921 1.55+ 
 Amidohydrolase family protein  Sp1356 3.178 1.048 3.03+ 
 Psr protein  Sp1368 1.745 1.089 1.6+ 
Conserved hypothetical protein Sp1393 1.611 1.003 1.61+ 
Conserved hypothetical protein Sp1462 1.853 0.989 1.87+ 
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Unknown functions     
Acetyltransferase, GNAT family Sp1464 1.931 1.058 1.83+ 
Hypothetical protein Sp1465 1.791 0.948 1.9+ 
ATP-dependent RNA helicase, DEAD/DEAH box family Sp1483 1.195 0.997 1.2+ 
Hypothetical protein Sp1493 1.623 0.933 1.74+ 
Conserved hypothetical protein Sp1564 1.3 1.015 1.28+ 
Conserved hypothetical protein  Sp1565 1.454 1.091 1.33+ 
Rrf2 family protein Sp1636 1.194 0.971 1.23+ 
Metallo-beta-lactamase superfamily protein  Sp1646 1.489 0.984 1.51+ 
Hypothetical protein Sp1862 1.558 1.002 1.55+ 
Conserved hypothetical protein  Sp1922 1.493 1.016 1.47+ 
Hypothetical protein Sp1925 1.538 0.967 1.59+ 
Conserved hypothetical protein  Sp1967 1.163 0.937 1.24+ 
Hypothetical protein  Sp2004 2.669 1.17 2.28+ 
Hypothetical protein Sp2005 2.857 0.789 3.62+ 
Conserved hypothetical protein Sp2143 1.969 0.949 2.07+ 
SPFH domain/Band 7 family Sp2156 1.585 0.933 1.7+ 
     
Transport     
Xanthine/uracil permease family protein  Sp0287 1.567 1.053 1.49+ 
ABC transporter, ATP-binding protein Sp0720 1.326 1.049 1.26+ 
Potassium uptake protein, Trk family  Sp0480 1.249 0.943 1.32+ 
livH; Branched-chain amino acid ABC transporter Sp0750 1.577 1.008 1.56+ 
ABC transporter, ATP-binding protein Sp0786 1.296 0.956 1.36+ 
DNA primase, DNA metabolism: DNA replication, 
recombination, and repair 
Sp1071 1.907 1.038 1.84+ 
bta; Bacterocin transport accessory protein Sp1499 1.31 0.925 1.42+ 
ntpC; v-type sodium ATP synthase, subunit C  Sp1319 1.599 0.787 2.03+ 
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Transport     
ABC transporter, permease/ATP-binding protein Sp1357 3.205 1.093 2.93+ 
ABC transporter, permease/ATP-binding protein Sp1358 2.842 1.079 2.63+ 
aatB; Amino acid ABC transporter, amino acid-binding protein Sp1500 2.671 1.05 2.54+ 
Amino acid ABC transporter, ATP-binding protein Sp1501 2.813 1.065 2.64+ 
Amino acid ABC transporter, permease protein Sp1502 3.036 1.122 2.71+ 
Cation efflux family protein, Sp1552 1.479 1.071 1.38+ 
Oxalate:formate antiporter Sp1587 1.982 1.057 1.88+ 
Sodium/dicarboxylate symporter family protein, authentic 
frameshift  
Sp1753 1.401 1.06 1.32+ 
proWX: Choline transporter  Sp1860 1.697 0.967 1.75+ 
proV; Choline transporter  Sp1861 1.69 0.984 1.72+ 
amiC; Oligopeptide ABC transporter, permease protein AmiC Sp1890 1.164 1 1.164+ 
ABC transporter, ATP-binding protein  Sp2003 3.335 1.059 3.15+ 
ABC transporter, permease/ATP-binding protein Sp2073 1.86 1.002 1.86+ 
ABC transporter, permease/ATP-binding protein  Sp2075 1.747 1.013 1.72+ 
pstS; Phosphate ABC transporter, phosphate-binding protein Sp2084 3.742 1.086 3.45+ 
pstC; Phosphate ABC transporter, permease protein Sp2085 3.417 0.93 3.67+ 
pstA: Phosphate ABC transporter, permease protein  Sp2086 3.729 1.001 3.73+ 
pstB: Phosphate ABC transporter, ATP-binding protein Sp2087 3.589 0.867 4.14+ 
phoU; Phosphate transport system regulatory protein PhoU Sp2088 3.919 0.924 4.24+ 
     
Transposons     
IS66 family element, Orf2, interruption  Sp1313 1.314 1.017 1.29+ 
Putative IS1239, transposase, degenerate Sp1515 1.363 1.086 1.26+ 
Transposase OrfA Sp1927 1.161 0.909 1.28+ 
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Differentially regulated genes in 403 Annotation in TIGR4 Expression in 403 Expression in TIGR4 Fold Change in 403 
Transposons     
Transposase OrfB Sp1928 1.072 0.969 1.11+ 
Transposase, IS116/IS110/IS902 family, degenerate Sp2074 1.211 0.962 1.26+ 
IS1381, transposase OrfB Sp2079 1.095 0.931 1.18+ 
     
Signal Transduction     
DNA-binding response regulator Sp2000 2.227 0.999 2.23+ 
hk11; Putative sensor histidine kinase  Sp2001 2.881 1.216 2.37+ 
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5.4 Discussion 
S. pneumoniae is an organism which is found globally and continues to cause 
significant morbidity and mortality across the continents.  The ubiquitous nature 
of pneumococcal carriage and infections was only possible due to very high 
carriage rate in human population that results from high plasticity of 
pneumococcal genome and its capability to adapt to a number of environments 
which vary in terms of population dynamics, antibiotic use, vaccination coverage 
and competition with other colonizers.  This high plasticity of pneumococcal 
genome results in variation of pathogenicity of different strains and might result 
in a mutation, which can render a strain completely non-pathogenic.  The two 
strains can be compared in several ways but the most appropriate one is 
complete genome sequencing as it has the advantage of being extensive and it 
can identify minor differences in the two genomes with precision. 
403 is a strain, which was isolated in our lab and was found to be completely 
non-pathogenic in mouse models of sepsis.  Since the records suggested that this 
strain evolved from TIGR4, we decided to sequence it to get the complete 
genome sequence of this strain, which would provide a concrete basis for the 
future investigations and will ensure quality of downstream research work in the 
lab.   
Genome comparison of the two pneumococcal strains was not very complicated 
as both the strains have remarkable similarity. Complete assembly of 403 
sequences against TIGR4 revealed only a few differences between the two 
strains and only 35 SNPs were present in 403, which might be responsible for 
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phenotypic difference between the two strains.  Though six of these SNPs were 
in intergenic regions, and other seven mutations were synonymous and were not 
associated with any amino acid change, the rest of them were located in 
functionally important genes which could contribute towards decreased 
virulence of strain 403. 
Microarray analysis showed differential regulation of 288 genes, some of which 
are critical for pneumococcal virulence and have been reported as being 
essential for pneumococcal growth.  The list also includes a very large number of 
ABC transporters and proteins of unknown function, whose contribution in 403 
phenotype cannot be assessed.  
It was observed that a number of genes related to carbohydrate metabolism 
were differentially regulated in 403 and among sugars (glucose, sucrose, 
raffinose, lactose, trehalose, inulin, maltose and galactose)  utilized by 403 
(Hava & Camilli, 2002), genes related to fructose metabolism (fruB, glmS) and 
transport (fruA), galactose metabolism (galM, , galK, galT, aga, nagB), trehalose 
transport (treP), maltose/maltodextrin transport (MalX) and other sugar 
transporters(raff, rafE, Sp0063, Sp1682, Sp1683 and Sp1684) were down-
regulated though genes coding for enzymes related to glucose metabolism(gapN, 
gpsA and Sp0795) were upregulated along with those of gluconeogenesis such as 
acetoin dehydrogenase complex, which indicates preferential utilization of 
glucose over other resources in 403.  There is a possibility that downregulation 
of metabolism and transport of other sugars in 403 is due to preferred glucose 
utilization, which has a known suppressive effect upon the use of other sugars 
called carbon catabolite repression or CCR.   This repressive effect of glucose 
  170 
over other sugars has been known for more than half a century and was first 
described by Jacques Monod in 1942 (Gorke & Stulke, 2008).  It is defined as:  
“….a regulatory phenomenon by which the expression of functions for the use of 
secondary carbon sources and the activities of the corresponding enzymes are 
reduced in the presence of a preferred carbon source………. (Gorke & Stulke, 
2008).” 
Also known as “diauxie,” it has been observed in a number of organisms and 
studied in detail and has been extensively reviewed by Gorke and Stulke, and 
Duetcher in 2008 and Vinuselvi in 2012 (Vinuselvi et al., 2012; Deutscher, 2008; 
Gorke & Stulke, 2008).  In S. pneumoniae a gene CcpA related to CCR has been 
identified, which is known to affect expression of a number of virulence factors 
according to changes in nutrient availability.  CcpA expression was not altered in 
403, but the role of one or more genes coding for “proteins of unknown 
functions” causing the same effect cannot be excluded. 
Iron and zinc containing alcohol dehydrogenases adhE and adh were also 
observed to have lower levels of expression in 403 as compared to TIGR4, which 
may compromise the organism’s ability to effectively colonize and invade host 
tissues as it would need a fully functional anaerobic metabolism for adaptation 
to low-oxygen environments within the host since it relies heavily on 
fermentation and is a facultative anaerobe.  Gene adh was also reported to be 
among essential genes for pneumococcal virulence (Hava & Camilli, 2002). 
It was also observed that genes coding for enzymes related to metabolism of 
basic amino acids including arginine and lysine were downregulated (argF, arcA 
and proC) though those related to synthesis of aromatic amino acids including 
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phenylalanine, tyrosine and tryptophan biosynthesis (pheA, tyrA, aroC, trpA, 
trpB, trpC, trpD and , trpG) and hydrophobic amino acids were up-regulated.  
Decreased synthesis of arginine appears related to reduced production of 
spermidine (as indicated by decreased expression of speE, spermidine synthase), 
which is among polyamines and has an important role in cellular growth, 
proliferation and stabilization and maintenance of subcellular organelles, and 
membrane systems (Murray et al., 2003).  Another downregulated gene nspC 
coding for carboxynorspermidine decarboxylase might be an important 
contributor responsible for 403 phenotype as it participates in a number of 
metabolic processes including 1 and 2 methylnaphthalene degradation, 3-
chloroacrylic acid degradation, alkaloid biosynthesis, benzoate degradation, 
phenylpropanoid biosynthesis, purine metabolism, pyruvate, tryptophan and 
tyrosine metabolism. 
Decrease in expression of ribosomal proteins including rpsD, rpsJ, rplC, rplB, 
rpsN, rpmD, rpsG, rplM, rplA, rpsP, rplT,pepF, rpmA, rplL, rpsR , rpsB and tsf 
might be related to over-expression of relA/Sp1645 (Table 5.5) as it has been 
reported to have important role in E. coli and other gram-negative organisms, 
where it decreases RNA synthesis and ribosomal proteins, increases synthesis of 
amino acids, and alters transcription pattern (Dennis & Nomura, 1974).   Though 
its role in S. pneumoniae is not detrimental in presence of abundant nutrients 
but it is mainly required in nutritional stress (Kazmierczak et al., 2009), its up-
regulation along with decreased ribosomal protein expression indicates that 403 
probably grows under stressful conditions and there is a possibility that it is 
unable to adapt to eukaryotic host environment as adaption is not only required 
during nutritional scarcity and stress but is also required to develop a symbiotic 
relationship with the host, which is the first step towards invasion. 
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Among the transport proteins, genes related to phosphate ABC transport system 
pstS, pstC, pstA, pstB and phoU were found up-regulated.  It has been reported 
for gene pstS that its expression levels increase during infection and they are 
responsive to availability of phosphate (Orihuela et al., 2004).  More recently, 
the role of the pst sytem in phosphate transport was described in Streptococcus 
mutans and it was reported that this system is also important for biofilm 
formation and proper growth (Luz et al., 2012).   Genetic regulation of this 
system is complex and involves a regulon called Pho regulon that is under the 
influence of a two component regulatory system (Lamarche et al., 2008).  
Though reasons of up-regulation of the whole operon along with phoU, which is 
the repressor, cannot be explained on the basis of available literature, and are 
unclear, it can still be assumed that it has some contribution towards the 
phenotype of 403.   
Though exact reasons for altered biology of 403 remains unclear, the complete 
genome sequence and array data has provided the picture of an evolutionary 
point in the phylogenetic history of this organism.  There is a possibility that 
differences in sugar and protein metabolism and changes in surface proteins 
might lead towards a phenotype, which is unable invade the host body and cause 
disease. 
Strain 403 was also tested as a live attenuated vaccine to see if it was protective 
against challenge with the same as well as different serotypes. Since its 
complete genome sequence is known and its biological behaviour was studied in 
detail, it was thought that once it is proven immunogenic, it can be easily 
altered to increase immunogenicity and any changes in its behaviour could also 
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be predicted and analyzed on the basis of genome sequence and array data. It 
can also be made untransformable to prevent further changes in its genome. 
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6 Avirulent pneumococci as live cell vaccines       
Different types of vaccines have been utilized for more than two centuries 
against infectious diseases. They have been a major weapon against micro 
organisms and their use has significantly reduced morbidity and mortality 
associated with infectious diseases (Plotkin, 2005).  Different strategies being 
used for vaccination against infectious diseases include use of killed whole cell 
vaccine, live cell attenuated vaccines, toxoids, capsular polysaccharides, 
polysaccharides conjugated with proteins and recombinant proteins (Plotkin, 
2005).  Among these, polysaccharides and protein-conjugated polysaccharide 
vaccines have been major vaccination strategies against pneumococcal diseases.  
Due to the availability of these vaccines along with antibiotics as easier 
alternatives, other vaccination strategies were never given due importance in 
pneumococcal research until recently as the human efforts were mainly directed 
towards development of newer and better antibiotics and improvement of 
existing vaccines.  Because of certain limitations associated with these vaccines, 
the last few years have seen a surge in research directed towards development 
of alternative vaccine strategies (Barocchi et al., 2007), which include 
development of protein based vaccines (Swiatlo & Ware, 2003), use of whole-
cell killed vaccines (Malley & Anderson, 2012; Lu et al., 2010; Malley et al., 
2004; Malley et al., 2001) and live cell attenuated vaccines (Kim et al., 2012; 
Roche et al., 2007).  
A number of pneumococcal proteins have been tried in different formulations as 
it has been observed that protection provided by proteins would be serotype 
independent (Moffitt & Malley, 2011; Ogunniyi et al., 2007; Tai, 2006; Swiatlo & 
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Ware, 2003).  Whole cell killed vaccines and live attenuated vaccines have also 
been tried against pneumococcal diseases and both have provided promising 
results.  They simultaneously deliver many antigens, which induces immunity in 
vaccinated animals.  It was observed that when unencapsulated pneumococci 
were used intranasally as whole cell killed vaccine with cholera toxin as 
adjuvant, it was not only able to prevent nasopharyngeal colonization but also 
protected against pulmonary infection by capsulated pneumococci (Malley et al., 
2001). Similar vaccine in aluminium derived adjuvant, when given as injection 
induced both cell mediated and humoral immunity with a 30 fold higher antibody 
response as compared to the previous approach (Malley & Anderson, 2012). It 
has also been shown that this immunity was inducible in μ MT −/− mice that are 
incapable of producing antibodies, while mice lacking T lymphocytes or lacking 
CD4+ T cell responses (MHC II-deficient mice) were not protected (Malley et al., 
2005). On the other hand, live attenuated unencapsulated pneumococcal strains 
used as intranasal vaccine were shown to induce mucosal as well as systemic 
protection in mice, which was serotype independent and did not require any 
adjuvant (Roche et al., 2007).  It was also shown that this protection was 
antibody mediated and also required T cells as a significant increase was noted 
in the levels of IgG in serum and IgA in nasal washes of immunized mice.  This 
protection was not seen in μ MT −/− and MHC II-deficient mice (Roche et al., 
2007). 
Strain 403 was tested as live attenuated vaccine, as it is an avirulent derivative 
of TIGR4 and was noted to be able to colonize the mouse nasopharynx, though 
its virulence potential was not reported (Trzcinski et al., 2003).  It was found to 
be avirulent in a chinchilla model (Personal communication with Dr. Stephen 
Pelton). This strain was selected to be tested as live cell vaccine as it offers 
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advantage of simultaneous delivery of many immunogens including capsule, 
which could result in stimulating anticapsular antibodies along with cell 
mediated response to protein antigens.  Its longer presence in the nasopharynx 
could be translated into a more persistent immune response as it would also 
mean longer exposure to immunogens.  Capsule switch mutants of this strain can 
also allow simultaneous delivery of different types of capsules which can replace  
conjugated vaccine as a cheaper alternative and easy to prepare formulation.     
6.1 403 as live cell vaccine: 
Before using strain 403 as vaccine it was necessary to evaluate its virulence 
potential in animal models and establish if it is actually harmless to them.  MF1 
mice were challenged intraperitoneally with 1 x 105 cfu/50 μl, using the same 
quantity of virulent TIGR4 strain as control.  It was observed that not only was 
403 avirulent but it also failed to produce any bacteraemia. 
6.2 Safety of strain 403 as a live-attenuated vaccine:  
Strain 403 was also assessed for safety before it could be tested as live 
attenuated vaccine.  It was observed that mice inoculated with 403 lost some 
weight during the initial 12 hrs post-inoculation but recovered as compared to 
their counterparts as shown in Fig 6.1.   
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Figure 6.1. Post-inoculation weight loss in MF1 mice inoculated with 10
5
 cfu/200 μl strain 
403 IP, as compared to mice challenged with 10
5
 cfu/200 μl TIGR4 IP.   
A. Comparison of weight loss in both the groups during the first 12 hrs.  Loss in TIGR4 
infected group is more pronounced.   
B.  Weight loss in mice inoculated with 10
5
 cfu/200 μl 403 IP.  Mice recovered after 36 hrs as 
compared to their TIGR4 counterparts which did not survive beyond 30h.  Data is plotted as 
box and whiskers plot with the horizontal line in the box representing the median. Weight 
changes were compared by paired t-test (GraphPad Prism 4.0, USA). 
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Some temperature drop was also noticed in mice challenged with 403 during the 
first 12 hrs of challenge, though it was not statistically significant (Fig 6.2). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2. Post-inoculation temperature drop during the first 12 hrs in MF1 mice inoculated 
with 10
5
 cfu/200 μl strain 403 IP and mice challenged with 10
5
 cfu/200 μl TIGR4 IP. 
Temperature data is plotted as a box and whiskers plot with horizontal line in the box 
representing the median.  Changes within a group were compared by paired t-test 
(GraphPad Prism 4.0, USA).  Decrease in temperature was more pronounced in mice 
infected with TIGR4 as compared to their counterparts challenged with 403, which gradually 
recovered within 24 hrs.  
 
6.3 IP Vaccination with strain 403: 
Two groups of out-bred MF1 mice were used to assess potential of 403 strains as 
live-attenuated vaccine.  Mice were vaccinated intraperitoneally with either 5 x 
106 403 cfu/200µl re-suspended in PBS or PBS alone.  Booster doses were given 
on day 14 and day 28.  Mice were left for a month before they were challenged 
with TIGR4 strains. 
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On challenging IP with 105 cfu/200µl TIGR4 suspended in PBS, vaccinated mice 
survived significantly longer than their counterparts (p=0.0018) though only 20% 
of vaccinated mice survived till the end of the experiment. Development of 
symptoms was also slower in the vaccinated group (Fig 6.3).   
 
 
 
 
 
Figure 6.3. Survival curve of mice 3x vaccinated IP with 5 x 10
6 
cfu of strain 403/ 200μl PBS 
or PBS only and challenged with 1x10
5 
cfu/200 μl TIGR4 IP.  Mice vaccinated with 403 strains 
survived longer than control mice and 20% survived till end of experiment.  Median survival 
time for vaccinated mice was 42 hrs as compared to that of 18 hrs for control mice.  Survival 
analysis showed there was a significant difference in survival time between the two groups 
by log rank test (p=0.0018). All data plotted as percentage survival as a staircase line with 
points for all observations against hrs post infection. 
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Level of bacterial load in vaccinated mice was also different as compared to 
non-vaccinated group and former showed decreased bacteraemia as compared to 
the latter.  Levels of bacteraemia were significantly different at the 12 hour 
time point.  All the analyses were performed while all mice were alive unless 
stated otherwise. 
The first mouse from the control group was culled at 12 (hours post infection) 
hpi and the next two were sacrificed at 18 hpi after they reached moribund 
state.  There was significant difference in bacteraemia levels in the two groups 
at 6 and 12 hour time points (Fig 6.4-6.5).  A continuous drop in bacteraemia 
was observed in vaccinated group after a peak at 24 hrs, which reached the 
lowest level at 42 hrs, where mice had to be sacrificed because they had 
reached moribund state. 
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Figure. 6.4. Comparison of bacterial load during 6-18 hrs post-challenge with 1x10
5 
cfu/ 200 
μl TIGR4 IP in mice 3x vaccinated IP with 5 x 10
6 
cfu of strain 403/ 200μl PBS and control 
group given PBS only.  Groups were compared with Mann-Whitney test (GraphPad Prism 
4.0, USA).  Circles mark individual mice. Horizontal dotted line represents the limit for 
detection. Horizontal bar represents median. (A)  Bacteraemia count at 6 hpi.  There was 
significant difference between PBS control and vaccinated mice (p=-0079) (B) Bacteraemia 
count at 12 hpi.  There was a significant difference between PBS control and vaccinated 
mice (p=-0079) (C) Bacteraemia count at 18 hpi.  Statistical analysis was not performed for 
this time point as one of the control mice had been sacrificed at 12 hpi. 
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Mann Whitney’s test showed significant difference (p=.0079) in the bacterial 
load between the two groups at 6 and 12 hrs (GraphPad Prism 4.0, USA) as 
shown in Fig 6.5. 
 
Figure 6.5. Comparison of bacterial load at different time points in mice challenged with 
1x10
5 
cfu/ 200 μl TIGR4 IP in groups vaccinated IP with 5 x 10
6 
cfu of strain 403/ 200μl PBS 
and 200 μl PBS only.  Mann Whitney’s test showed significantly different bacterial load at 6 
and 12 hour time points (GraphPad Prism 4.0, USA).  Statistical analyses were not 
performed beyond 12 hrs.  First mouse in the control  group died at 12 hrs, while first 
mouse in the vaccinated group died at 42 hrs. Dotted line represents the limit for detection. 
 
On monitoring and scoring for hunching, lethargy and piloerection clinically, 
vaccinated mice showed delay in the appearance of symptoms as compared to 
the control group, and clinical scores were significantly different at 12 hour time 
point (Fig 6.6). 
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Figure 6.6. Clinical score comparison at 12 hour time point of control group inoculated IP 
with 200 μl PBS and mice 3x vaccinated with 5 x 10
6 
cfu of strain 403/ 200μl PBS and 
challenged with 1x10
5 
cfu/ 200 μl TIGR4 IP.  Data plotted as a bar graph.  Bars represent 
mean ± SEM.  Unpaired t-test showed (GraphPad Prism 4.0, USA) that here was a significant 
difference in clinical scores at 12 hour time point between the two groups.   
 
6.4 Vaccination develops reactivity in mouse sera: 
To confirm if mice developed serological reactivity against TIGR4 strain, western 
blots were performed using mouse sera as a source of primary antibodies against 
TIGR4 cell lysate (Fig 6.7).  
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Figure 6.7. Western blot using pre-immune and post-immune sera from vaccinated mice as 
source of primary antibodies against TIGR4 cell lysate.  10 µl of ladder and sample was 
loaded in lanes. Molecular weights of major bands are indicated with the help of arrows. 
Serum was used in 1/100 while secondary anti-mouse antibodies were used at 1:1000 
dilution.  
(A) Pre-immune Sera. 
Lane 1: Protein ladder. 
Lane 2: Positive control using TIGR4 lysate in a previously immunized mouse. 
Lane 3: Protein ladder 
Lane 4: Pre-immunization serum from Mouse M1 
Lane 5: Protein ladder 
Lane 6:  Pre-immunization serum from Mouse M2 
Lane 7: Protein ladder 
Lane 8: Pre-immunization serum from Mouse M3 
Lane 9: Protein ladder 
Lane 10: Pre-immunization serum from Mouse M4 
Lane 11: Protein ladder 
Lane 12: Pre-immunization serum from Mouse M5 
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Figure 6.7. Western blot using pre-immune and post-immune sera from vaccinated mice as 
source of primary antibodies against TIGR4 cell lysate.  10 µl of ladder and sample was 
loaded in lanes. Molecular weights of major bands are indicated with the help of arrows. 
Serum was used in 1/100 while secondary anti-mouse antibodies were used at 1:1000 
dilution.  
(B) Post immune sera.  
Lane 1: Protein ladder 
Lane 2: Post-immunization serum from Mouse M1 
Lane 3: Protein ladder 
Lane 4:  Post immunization serum Mouse M2 
Lane 5: Protein ladder 
Lane 6: Post immunization serum Mouse M3 
Lane 7: Protein ladder 
Lane 8: Post immunization serum Mouse M4 
Lane 9: Protein ladder 
Lane 10: Post immunization serum Mouse M5. 
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Western blot showed that antibodies had developed in mice after vaccination 
against TIGR4 proteins and serum after vaccination of mice was reactive against 
them.   
6.4.1.1 Mouse serum also reacts with the type 4 capsular antigens: 
Quellung reactions are an important tool to show if anticapsular antibodies had 
developed in vaccinated mice as they are considered important defence 
mechanism and help in providing protection against pneumococcal infection.  
Quellung reactions performed using sera from vaccinated mice were positive 
against TIGR4 as well as 403. 
Further experiments were performed to see effects of vaccine administration 
through IN route, effect of vaccination on challenge with lesser number of 
bacteria and protection against different serotypes  
6.4.2  Intraperitoneal immunization and low dose challenge: 
10 MF1 mice were divided into two groups, and were given PBS or vaccinated 3x 
with strain 403 as described previously in Section 1.3. 
Mice were challenged intraperitoneally with 5 x 103 cfu/ 200µl and were bled 6 
hourly and monitored for development of clinical symptoms during the course of 
the experiment.   
As compared to previous experiment, median survival time of both groups 
increased by thirty hrs.  There was not statistical difference between the two 
groups.  There was one survivor in the vaccinated group which was able to clear 
A 
C 
E 
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the infection after reaching a relatively high level of bacteraemia but two of the 
vaccinated mice had to be sacrificed earlier in experiment (Fig 6.8).     
 
 
 
Figure 6.8. Survival curve of mice challenged with 5 x 10
3 
cfu/ 200 μl TIGR4 IP in groups 3x 
vaccinated IP with 5 x 10
6 
cfu of strain 403/ 200μl PBS and 200 μl PBS only. Mice vaccinated 
with 403 strains survived longer than unvaccinated mice and 20% survived till the end of 
experiment though survival analysis did not show any statistically significant difference in 
survival time between the two groups.  Median survival time for vaccinated mice was 72 hrs 
as compared to 48 hrs for control mice (GraphPad Prism 4.0, USA). All data plotted as 
percentage survival as a staircase line with points for all observations against hrs post 
infection. Five mice used in each group.  
 
There was no statistical difference in the bacteraemia in the two groups.  In 
vaccinated mice, after a very high level of bacterial load of 108 cfu/ml at 24 
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hour time point, the count dropped back to 106 cfu/ml at 30 hrs though only 20% 
survived beyond 72 hrs (Fig 6.9). 
 
 
 
Figure 6.9.  Comparison of the bacterial load in mice challenged with 5 x10
3 
cfu/ 200 μl 
TIGR4 IP in groups 3x vaccinated IP with 5 x 10
6 
cfu of strain 403/ 200μl PBS and 200 μl PBS 
only. Graph shows no notable difference in bacterial load in two groups.  Dotted line 
represents limit for detection. 
 
 
Individual mouse-data is shown in Fig 6.10. 
 
 
  189 
 
 
 
 
Figure 6.10. Comparison of bacterial load during 6-36 hrs post-challenge with 5x10
3 
cfu/ 200 
μl TIGR4 IP in mice vaccinated 3x IP with 5 x 10
6 
cfu of strain 403/ 200μl PBS and control 
group given PBS only.  Groups were compared with Mann-Whitney test (GraphPad Prism 
4.0, USA).  Circles mark individual mice. Horizontal dotted line represents the limit for 
detection. Horizontal bar represents the median. (A)  Bacteraemia count at 6 hpi.  (B) 
Bacteraemia count at 12 hpi.  (C) Bacteraemia count at 18 hpi.  (D) Bacteraemia count at 24 
hpi.   
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Figure 6.10. Comparison of bacterial load during 6-36 hrs post-challenge with 5x10
3 
cfu/ 200 
μl TIGR4 IP in mice vaccinated 3x IP with 5 x 10
6 
cfu of strain 403/ 200μl PBS and control 
group given PBS only.  Groups were compared with Mann-Whitney test (GraphPad Prism 
4.0, USA).  (E) Bacteraemia count at 30 hpi.  (F) Bacteraemia count at 36 hpi.   
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Though both groups did not show much difference in levels of attained bacterial 
load there was significant difference in clinical symptoms between the two 
groups (p= 0.0317)( (GraphPad Prism 4.0, USA).  The vaccinated group lost less 
weight as compared to the control group though it was not statistically 
significant (Fig 6.11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11. Comparison of weight and clinical symptoms at 30 hrs time points in mice 
challenged with 5 x 10
3 
cfu/ 200 μl TIGR4 IP.  Vaccinated group was 3x inoculated IP with 5 x 
10
6 
cfu of strain 403/ 200μl in PBS and control group was given PBS only.  (A) Comparison 
of clinical scores.  Unpaired t-test showed significant difference in clinical symptoms 
(GraphPad Prism 4.0, USA).  Bars represent the mean ± SEM (B) Comparison of weight-loss. 
Weight changes are plotted as a box and whiskers plot with horizontal line in the box 
representing median.   
 
B A 
B 
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6.4.3 Intranasal Immunization of mice: 
Thirty MF1 mice were divided into two groups.  The first group was vaccinated 
intranasally with 5 x 107 cfu/10µl under general anaesthesia, while control group 
was given 10 µl PBS. Intranasal booster doses were given on day 14 and 28 and 
sample bleeds were taken before each vaccination and on day 42. 
6.4.3.1 Intranasal challenge of mice with TIGR4 shows weak trends: 
Five mice were taken from each group and were challenged intranasally with 
5x106 cfu TIGR4/50µl.  Twenty percent of vaccinated mice survived and cleared 
infection as compared to none surviving in the control group (Fig 6.12).    
             
Figure 6.12. Survival curve of mice challenged with 5x10
6 
cfu/ 50 μl TIGR4 IN. Vaccinated 
group was vaccinated IN with 5 x 10
7 
cfu of strain 403/ 10μl in PBS and control group was 
given 10 μl PBS only.  20% survival was seen in vaccinated group. All data plotted as 
percentage survival as a staircase line with points for all observations against hrs post 
infection.  Log rank test did not show any significant difference between the two groups.  
The median survival time for both the groups was 54 hrs. Five mice were used in each 
group. 
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There was no significant difference in levels of bacteraemia the two groups (Fig 
6.13). 
 
Figure 6.13. Bacteraemia during 36 hrs post IN infection in mice challenged with 5x10
6 
cfu/ 
50 μl TIGR4. Vaccinated group was 3x vaccinated IN with 5 x 10
7 
cfu of strain 403/ 10μl in 
PBS and control group was given 10 μl PBS only.  There was no significant difference in 
level of bacteraemia between the two groups. Five mice were used in each group. 
 
The first vaccinated mouse died at 45 hrs before any of control group mouse, 
though the last one to be culled at 72 hrs also belonged to vaccinated group.  
One of the mice from vaccinated group cleared infection and survived till the 
end of experiment. 
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6.4.3.2 Intranasal challenge of mice with A66: 
Five vaccinated and five control mice were challenged intranasally with 
bioluminescent serotype 3 strain A66.1 using 5 x 106 cfu/50 µl dose.  The results 
did not show any significant differences between the two groups.  There were no 
survivors in any group, though 40% mice from vaccinated group reached 96 hour 
time point as compared to 20% from the control group (Fig 
6.14).
 
Figure 6.14.  Survival curve of mice challenged with 5x10
6 
cfu/ 50 μl bioluminescent strain 
A66.1 IN.  Vaccinated group was 3x vaccinated IN with 5 x 10
7 
cfu of strain 403/ 10μl in PBS 
and control group was given 10 μl PBS only.  There was no significant difference in the two 
groups.  All data plotted as percentage survival as a staircase line with points for all 
observations against hrs post infection. . Five mice were used in each group. 
 
Group analysis did not show significant differences in bacteraemia in vaccinated 
group as compared to control group, on excluding vaccinated mouse M5 as it 
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showed exceptionally high bacteraemia levels, some difference could be seen in 
the two groups though it did not reach statistically significant level (Fig 6.15). 
 
Figure 6.15.  Bacteraemia and thoracic photon emission in mice challenged with 5x10
6 
cfu/ 
50 μl bioluminescent strain A66.1 IN. The vaccinated group was 3x vaccinated IN with 5 x 
10
7 
cfu of strain 403/ 10μl in PBS and control group was given 10 μl PBS only.  (A)  
Bacteraemia from 0-48 hrs in the two groups. (B) Bacteraemia from 0-48 hrs excluding 
outlier M5. (C) Thoracic photon emission from 0-48 hrs.  (D)  Thoracic photon emission from 
0-48 hrs excluding M5. Five mice used for each group. 
  
Bacteraemia results were consistent with images when compared with Thoracic 
Photon Emission recorded by the IVIS imaging system (IVIS: Caliper Life Sciences, 
UK), which is an optical imaging system for non-invasive monitoring of disease 
progression without killing the animals at each stage.  It records photon emission 
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from diseased animal and uses this data with 3D reconstruction of these images 
to localise source of bioluminescence, allowing visualisation of the spread of 
infection within the body of living animal (Fig 6.16).  
 
 
 
Figure 6.16.  IVIS images showing photon emission in mice challenged with 5x10
6 
cfu/ 50 μl 
bioluminescent strain A66.1 IN.  Vaccinated group was 3x vaccinated IN with 5 x 10
7 
cfu of 
strain 403/ 10μl in PBS and control group was given 10 μl PBS only.  Control mice are on left 
(M6-M10) and vaccinated mice on the right (M1-M5).  
(A) 0 hr time point. (B) 6 hr time point.  Infection developing in M5. 
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Figure 6.16.  IVIS images showing photon emission in mice challenged with 5x10
6 
cfu/ 50 μl 
bioluminescent strain A66.1 IN.  Vaccinated group was 3x vaccinated IN with 5 x 10
7 
cfu of 
strain 403/ 10μl in PBS and control group was given 10 μl PBS only.  Control mice are on left 
(M6-M10) and vaccinated mice on the right (M1-M5). (C) 12 hr time point.  Infection 
developed in M5. (D) 18 hr time point. Progression of infection in M5.   
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Figure 6.16.  IVIS images showing photon emission in mice challenged with 5x10
6 
cfu/ 50 μl 
bioluminescent strain A66.1 IN.  Vaccinated group was 3x vaccinated IN with 5 x 10
7 
cfu of 
strain 403/ 10μl in PBS and control group was given 10 μl PBS only.  Control mice are on left 
(M6-M10) and vaccinated mice on the right (M1-M5). (E) 24 hr time point. Infection has also 
appeared in M9. (F) 30 hr time point.  Infection has developed in several mice in both the 
groups.  
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Figure 6.16.  IVIS images showing photon emission in mice challenged with 5x10
6 
cfu/ 50 μl 
bioluminescent strain A66.1 IN.  Vaccinated group was 3x vaccinated IN with 5 x 10
7 
cfu of 
strain 403/ 10μl in PBS and control group was given 10 μl PBS only.  Control mice are on left 
(M6-M10) and vaccinated mice on the right (M1-M5). (G) 36 hr time point. (H) 42 hr time point.  
Infection can be seen particularly around the lung areas in heavily infected mice.  
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Figure 6.16.  IVIS images showing photon emission in mice challenged with 5x10
6 
cfu/ 50 μl 
bioluminescent strain A66.1 IN.  Vaccinated group was 3x vaccinated IN with 5 x 10
7 
cfu of 
strain 403/ 10μl in PBS and control group was given 10 μl PBS only.  Control mice are on left 
(M6-M10) and vaccinated mice on the right (M1-M5). (G) 36 hr time point. (I) 48 hr time point.  
Full blown infection in M5, M7, M9 and M10 
 
IVIS data did not show any significant difference in progression of infection in 
two groups.  
6.4.3.3 Intranasal challenge with ATCC6308: 
Both the groups were challenged with highly virulent type 8 strain ATCC6308 
using 5x 103 cfu/50 µl dose.  One of the unvaccinated mice (M7) did not develop 
any bacteraemia, so it was excluded from all analyses, while a vaccinated mouse 
(M4) developed very high bacteraemia and became sick before all the others.  
The analysis was performed with and without M4.  
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There were no survivors in any of the group, and there was no difference in 
survival.  
 
Figure 6.17. Survival curve of mice challenged IN with 5x10
3 
cfu/ 50 μl strain ATCC6308. 
Vaccinated group was 3x vaccinated IN with 5 x 10
7 
cfu of strain 403/ 10μl in PBS and 
control group was given 10 μl PBS only.  There was no difference in survival of two groups.  
All data plotted as percentage survival as a staircase line with points for all observations 
against hrs post infection. 
 
 
Initial group analysis showed that the level of bacteraemia was higher in 
vaccinated mice as compared to control mice.  On analyzing results by excluding 
outlying mouse M4, vaccinated mice showed to have developed lower level of 
bacteraemia as compared to controls (Fig6.18).    
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Figure 6.18. Bacterial load of mice challenged IN with 5x10
3 
cfu/ 50 μl strain ATCC6308. 
Vaccinated group was vaccinated IN with 5 x 10
7 
cfu of strain 403/ 10μl in PBS and control 
group was given 10 μl PBS only.  (A) Bacteraemia including vaccinated outlier M4. (B) 
Bacteraemia excluding vaccinated outlier M4.  
 
The analysis of bacteraemia at different time points was performed including 
and excluding outlier M4.  Though difference of level of bacteraemia did not 
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reach statistically significant levels there were clear trends of decreased 
bacteraemia in vaccinated group as compared to control group after exclusion of 
M4 (Fig 6.19). 
 
Figure 6.19. Comparison of bacterial load during 18-48 hrs post-challenge IN with 5x10
3 
cfu/ 
50 μl strain ATCC6308. The vaccinated group was 3x vaccinated IN with 5 x 10
7 
cfu of strain 
403/ 10μl in PBS and control group was given 3x 10 μl PBS only.  Groups were compared 
with Mann-Whitney test (GraphPad Prism 4.0, USA).  Circles mark individual mice. 
Horizontal dotted line represents the limit for detection. Horizontal bar represents the 
median. (A)  Bacteraemia count at 18 hpi.  (B)  Bacteraemia count at 18 hpi excluding M4 
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Figure 6.19. Comparison of bacterial load during 18-48 hrs post-challenge IN with 5x10
3 
cfu/ 
50 μl strain ATCC6308. The vaccinated group was 3x vaccinated IN with 5 x 10
7 
cfu of strain 
403/ 10μl in PBS and control group was given 3x 10 μl PBS only.  Groups were compared 
with Mann-Whitney test (GraphPad Prism 4.0, USA).  Circles mark individual mice. 
Horizontal dotted line represents the limit for detection. Horizontal bar represents the 
median. (E) Bacteraemia count at 30 hpi. (F) Bacteraemia count at 30 hpi excluding M4.  (G) 
Bacteraemia count at 36 hpi.  (H) Bacteraemia count at 36 hpi excluding M4. 
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Figure 6.19. Comparison of bacterial load during 18-48 hrs post-challenge IN with 5x10
3 
cfu/ 
50 μl strain ATCC6308. The vaccinated group was 3x vaccinated IN with 5 x 10
7 
cfu of strain 
403/ 10μl in PBS and control group was given 3x 10 μl PBS only.  Groups were compared 
with Mann-Whitney test (GraphPad Prism 4.0, USA).  Circles mark individual mice. 
Horizontal dotted line represents the limit for detection. Horizontal bar represents the 
median. (I) Bacteraemia count at 48 hpi. (J) Bacteraemia count at 48 hpi excluding M4 
 
 
Though data obtained from this experiment was spread but conclusion can still 
be drawn that IN vaccination with 403 was not effective in protecting against 
ATCC6308 challenge.  
In summary, intranasal vaccinations not only failed to provide complete 
protection against the same serotype which was used for vaccination but also 
there was almost no protection against serotypes other than one used to 
vaccinate mice, though weak trends of decreased bacteraemia were observed in 
some mice for homologous strain.  
6.5 Discussion: 
The quest for new vaccine targets is intense than ever as pneumococcal diseases 
are rising at an alarming rate.  The current vaccines, which use different types 
of pneumococcal capsular polysaccharide (CPS) and induce antibodies that are 
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serotype-specific, are capable of activating and fixing the complement and 
promote opsonisation and phagocytosis (Plotkin, 2008).  There have been 
consistent efforts for discovery of newer pneumococcal vaccines targeted 
against proteins that could act against all strains regardless of serotype.  
Whole cell killed vaccines have been used in a number of studies as it can induce 
immunity by delivering bulk of pneumococcal antigens and induce serotype 
independent immunity by humoral as well as cell mediated mechanism (Malley & 
Anderson, 2012).  The observation that intranasal whole cell killed vaccine 
containing unencapsulated pneumococci prevents colonization as well as 
pneumonia by capsulated pneumococci when administered with cholera toxin 
(Malley et al., 2001) and induces both cell mediated and humoral immunity 
when used with aluminium derived adjuvants (Malley & Anderson, 2012) makes 
whole cell killed vaccines a promising approach.  
Live attenuated unencapsulated pneumococcal strains used without adjuvant as 
intranasal vaccine have also been shown to induce mucosal as well as systemic 
serotype independent protection in mice (Roche et al., 2007).  This protection 
was also shown to involve both humoral and cell mediated immunity (Roche et 
al., 2007). 
As a combination of the above two approaches, we tested serotype 4 avirulent 
strain 403 intraperitoneally and than intranasally to observe the magnitude of 
protection in vaccinated mice.  The idea behind using live attenuated strain was 
to stimulate multiple immune mechanisms by delivering many immunogens at 
one time along with longer exposure as nasopharyngeal colonization would 
expose antigens other than capsule. Since the capsule gets down-regulated in 
the nasopharynx (Weiser et al., 1996; Weiser et al., 1994) there was a possibility 
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that other pneumococcal proteins will also get longer  exposure in nasopharynx 
along with the capsule, which could result in stimulation of both arms of immune 
system and induce capsule-specific antibodies as well as CD4+ cell mediated 
immunity.  Results of vaccination by intraperitoneal route showed only partial 
protection against homologous strain though there were significant differences 
in levels of bacteraemia, survival, weight and temperature losses, while 
heterologous strains were not tested.  On the other hand, intranasal vaccination 
and challenge with homologous strains showed trends of decreased bacteraemia 
though it did not reach statistically significant levels at most time points.  It also 
did not provide any protection against heterologous strains.         
It is quite clear that strain 403 on its own, if used as a vaccine, is not strongly 
immunogenic and is not able to provide complete protection against infection, 
especially through intranasal route.  The data obtained from these experiments 
is quite variable though some of its fluctuation can be attributed to use of out-
bred MF1 mice.  Another reason for variation in data could be route of 
administration as it might affect the efficacy of vaccine as differences in 
magnitude of immune response related to route of administration have been 
reported in the literature.  Hirabayashi and co-workers (1990) have reported 
superiority of intranasal route over other routes for hemagglutinin vaccine used 
in conjugation with cholera toxin against influenza A virus (Hirabayashi et al., 
1990), similar observations were reported by Tamura and co-workers (1992) 
while comparing intranasal vaccination route with subcutaneous route of 
vaccination for the same vaccine (Tamura et al., 1992).  Though Gai and co-
workers (2008) reported superiority of IP vaccination over IN route while 
vaccinating against SARS coronavirus with inactivated virus (Gai et al., 2008), 
Meitin et al. (1991) while vaccinating against H1N1 with inactivated H1N1 have 
  208 
also reported superiority of Intraperitoneal route (Meitin et al., 1991).  In case 
of pneumococcal vaccination, Malley and Anderson (2012) have reported that 
intraperitoneal immunization with whole cell killed vaccine administered with 
aluminium based adjuvants produced >30 fold superior antibody response as 
compared to the intranasal route (Malley & Anderson, 2012). These observations 
show that route of administration may affect efficacy of vaccine and an 
efficacious vaccine might become inefficient due to change in the site of 
delivery.    
Though strain 403 does not provide complete protection against pneumococcal 
infection as live attenuated vaccine but it was noted to have some effect 
through intraperitoneal route.  Immunized mice not only showed decreased 
bacteraemia levels but also survived significantly longer than control mice. It is 
tolerated well, and does not produce any bacteraemia on its own.  Moreover, 
sera from them were reactive against pneumococcal proteins ranging in size 
from 62-188 kd that might include pspA, pspC, IgA proteases, Srt, Pht and other 
proteins of unknown function, which are among surface associate proteins and 
have been reported to be involved in development of immunity in humans 
(Giefing et al., 2008).  It was also observed that sera from immunized mice were 
able to agglutinate serotype 4 pneumococci.  Considering the above facts, there 
is a possibility that 403, if combined with a suitable adjuvant can provide better 
protection than used alone as this approach have been shown to work with 
avirulent shigella strains as it was observed when avirulent shigella strains were 
given with cholera toxin and heat labile enterotoxin and their mutated versions, 
enhanced the immunogenicity of  live attenuated shigella strains was observed 
(Hartman et al., 1999). If immunogenic potential of 403 can be enhanced, it will 
prove to be a safe vaccine, which would be cost-effective, easy to produce and 
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administer. The strain 403 also offers and added advantage that its capsule-
switch mutants can be produced, (Some constructed and discussed in chapter 3), 
and used in the same way as a polysaccharide conjugate vaccine as a number of 
403 mutants expressing different capsular types can be administered together in 
live or killed form.  This can also help in dealing with vaccine escape 
phenomenon as in case of emergence of a vaccine escape serotype, 403 
expressing that particular serotype causing infections can be added to the 
regimen to produce protection for newly emerging serotype.  
Based on the information gathered from the work presented in this chapter, a 
number of experiments can be done to further investigate the potential of 403 
as live attenuated vaccine and enhance its immunogenicity.  Intraperitoneal 
immunizations can be performed by supplementing the vaccination mixture with 
appropriate quantity of suitable adjuvants to see if this could enhance 
immunogenicity of the vaccine.  In case of positive results, vaccination process 
can be repeated with capsule switch mutants to enhance options of vaccination.   
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7 Concluding thoughts and final discussion: 
The aim of this thesis was to study the effect of genetic variation on 
pneumococcal biology.  As a part of this project capsule switch mutants were 
constructed in three genetic backgrounds and were compared for effect of 
capsular switching on their biological characteristics. EM and capsule 
polysaccharide measurements showed differences in capsule formation in 
capsule switch mutants and it was seen that amount of capsular polysaccharide 
and capsular thickness was different in different mutants as compared to each 
other and with the parent, though expression of capsular genes could not be 
investigated due to time constraints. It was also observed that capsular 
switching is not always beneficial for the organism and it can actually decrease 
the virulence as the same capsule was observed to be having different effects on 
different genetic backgrounds.  This might be the reason that capsule switch 
mutants of only certain MLST types have been reported and switching of certain 
capsular serotypes (such as serotype 1) have not been observed.  Our findings 
also suggest that capsular switching might not be a universally favorable 
phenomenon despite high homology of the flanking regions (Bentley., 2006) and 
a successful capsule switch would only be possible if it is supported by a suitable 
genetic background.  This information can be considered encouraging as it can 
be assumed that vaccine escape phenomenon will have its limitations and only a 
few types of vaccine escape mutants will emerge in the future and magnitude of 
this problem will be smaller than it is generally thought.  These findings might 
influence future vaccine design as if the possible emergent vaccine escape 
mutants can be predicted in a population by studying the population dynamics 
and serotype distribution, it would be possible to alter the vaccine coverage to 
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cover the expected emerging serotypes and create herd immunity in the 
population. 
We observed that presence or absence of the capsule does not have an effect on 
any phase of the growth of TIGR4 and D39 strains in BHI, though it has major 
effects on transformability and tendency of pneumococci to associate in chains.  
Further investigations such as microarrays could reveal the effect of capsule 
switching on expression of genes elsewhere in the pneumococcal genome, which 
might increase our knowledge about the relationship of the capsule to the rest 
of the genome and the dynamics of capsule switching and explain the 
relationship of the capsule genes with the genetic background.  
The effect of chain formation on pneumococcal virulence needs to be studied in 
detail using animal models.  Our findings have shown that capsule type may 
result in formation of longer or shorter chains, but conclusions could not be 
drawn about the effects of chain length on bacterial virulence.  Further studies 
observing the chain formation in the infected animal might provide a conclusive 
answer. 
We studied the avirulent strain 403, which is a derivative of highly virulent and 
well-studied strain TIGR4 for investigation of genetic basis for its lack of 
virulence.  Both the strains were compared by whole genome sequencing and 
microarray analysis.  Genome analysis revealed only a few mutations in strain 
403, but microarray showed 288 genes to be expressed differently in this strain.  
Though exact reasons of the non-virulent nature of strain 403 remains unknown 
but it was observed that several genes related to key metabolic pathways had 
different expression profiles as compared to TIGR4.  There is a possibility that 
differences in expression of genes related to carbohydrate and protein 
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metabolism or transport systems in the two strains might be responsible for the 
non-virulent nature of 403.  Though there are limitations of microarray analysis 
and this approach requires further confirmation and validation of findings by RT-
PCR, it has documented the genes that can be further investigated. In addition, 
if the exact genetic cause of the avirulence of 403 can be found, it can serve as 
an interesting drug target. Any drug that can target a particular gene or its 
product, can result in the loss of virulence of highly virulent invasive strains and 
can serve as a treatment modality for the invasive pneumococcal disease.    
Strain 403 was also tested as a potential live attenuated vaccine as it was 
thought to function as a vehicle capable of delivering the complete set of 
pneumococcal antigens.  Since it can colonize the nasopharynx it was also 
thought that longer exposure will aid to the development of better immune 
response and would be able to induce serotype independent immunity by 
humoral as well as cell mediated mechanisms. It was further theorized that if 
403 could provide sufficient protection, its capsule switch mutants could also be 
used as a vaccine, combining several serotypes in a single dose, without 
conjugating to any adjuvant.  This approach could particularly be useful as it 
would only require the construction of capsule switch mutants of every serotype, 
their conversion to non-transformable forms by the knock-out of competence 
genes and administration according to the requirement of each population along 
with a suitable adjuvant. 
Though trial of 403 was not very successful as it failed to provide any protection 
through intranasal route but partial protection was observed through 
intraperitoneal route and significant differences were noted in levels of 
bacteraemia, survival, weight and temperature losses against the homologous 
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strain. There is still a possibility that 403 as a live attenuated vaccine can be 
improved by addition of a suitable adjuvant, which if successful, could provide a 
cheaper alternative for present vaccines.  It has the potential to serve as a 
comobination of live attenuated and whole cell killed vaccines as it would 
provide the antigen exposure for prolonged period of time resulting in the 
development of immunity which would be directed agasint the capsular 
polysaccharides as well as other proteins.  Another most important feature of 
the proposed vaccine is cost effectiveness, as once constructed and prepared, 
bacterial strains can be stored and supplied in unlimited quantity for unlimited 
period of time.  If immunogenicity can be improved, 403 along with its capsule 
switch mutants have the potential to become an easy to use and cost-effective 
vaccine, which can be easily produced in bulk and altered when needed.  
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